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“ Wenn der, der etwas notwendig braucht, dies ihm Notwendige findet,  
so ist es nicht der Zufall, der es ihm gibt, sondern er selbst,  
sein eigenes Verlangen und Müssen führt ihn hin.” 
 
    - Hermann Hesse, Demian - 
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ABSTRACT 
Bioreactors are commonly referred as apparatus comprising a homogeneous 
niche that support stable occurrence of biological processes to derive biological-
based products for consumption, medicinal or research purposes. Although 
similar principles are successfully applied in bone tissue engineering, the existing 
homogenous niche applied is insufficient for achieving bone-like constructs. In 
physiology, organogenesis and tissue repair processes require dynamic 
interactions among multiple cell types. In complementary with supporting 
parameters such as oxygen tension (pO2), growth factors, pH or mechanical 
stimulants, dynamic niches essential for naïve organs to attain functionalities are 
established. In this Ph.D. thesis, the dynamic niches needed for recapitulating 
bone development events in vitro; are derived and maintained in a previously 
described perfusion bioreactor prototype (Bone bioreactor). Additionally, three 
supporting parameters are implemented to increase the accuracy of biomimicry. 
These include: 1) oxygen tension (pO2), 2) pH of differentiation media, and         
3) implementing step-by-step differentiation regimes that applies specific 
differentiation medium at critical time points. Overall, the objective of this thesis is 
to establish an effective 3D in vitro platform that can recapitulate physiological 
congruent bone development events with hMSC. Hence, deriving engineered 
bone constructs with mechanical and physical properties similar to the native 
bone tissue.  
Firstly, the potential of a step-by-step differentiation approach (CMOM) to 
recapitulate endochondral ossification in the bone bioreactor is assessed. This is 
achieved by applying an acidic chondrogenic differentiation medium (CM) to 
mESC-laded collagen hydrogels (CM constructs) for 30 days, followed by a 
slightly basic osteogenic differentiation medium (OM) for another 30 days. 
Corresponding controls cultivated in CMCM or OMOM approaches for 60 days 
are used for comparison. Concurrently, a pO2 gradient is applied to elucidate the 
effects of pO2 on construct development and mESC differentiation. The 
pluripotent capacity of mESC is used to define the default osteochondral cell 
types supported by each differentiation approach. Further, the potential to derive 
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other cell types through different combinations of supporting parameters is also 
identified. Briefly, a hypoxic niche is shown to favor chondrogenesis, while an 
oxygenated niche is critical for initiating chondrocyte hypertrophy and 
osteogenesis. Interestingly, all the investigated differentiation approaches can be 
correlated to physiological developmental events. The development of CMCM 
constructs has resembled chronic acidosis and mineralisation is attenuated at 
the post-transcriptional level. Further, osteoclastogenesis is promoted after 
extended cultivation in the acidic medium. In contrast, the CMOM constructs 
have adopted similar mechanisms as endochondral ossification and the OMOM 
constructs are comparable to cranial bones derived from intramembranous 
ossification. 
Secondly, artificial extracellular matrix (aECM) scaffolds with tailored 
dimensions are derived through 3D-printing. Further, spinner flask bioreactors 
are used to establish a stable source of undifferentiated hMSC in large quantity. 
Together with an oxygenated niche and an effective differentiation regime 
identified in the mESC experiments, this chapter of my Ph.D. thesis aimed to 
develop a serial manufacturing process for synthesizing clinically applicable 
bone-like constructs with hMSC. Briefly, the hMSC have responded similarly as 
the mESC after cultivation in CMCM, CMOM and OMOM differentiation 
approaches for 60 days. This is true at the level of gene expression and status of 
construct mineralisation. Furthermore, immediate cultivation of hMSC in aECM 
scaffolds embedded with chondroitin sulfate A (CSA) in osteogenic differentiation 
medium (OMOM*) is shown to accelerate the mineralisation process. Taken 
together, the results have demonstrated the effectiveness of dynamic niches 
generated in the bone bioreactor to recapitulate physiological congruent bone 
development events in vitro. With this, structurally stable mineralised constructs 
are derived with both mESC and hMSC. Although the serial manufacturing 
process applied is not optimal, the working principle is feasible and can be 
further exploited for higher consistencies.  
Thirdly, an independent perfusion bioreactor prototype for blood vessel tissue 
engineering (vascular bioreactor) is constructed and investigated in parallel. This 
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is a proof-of-concept study to further explore the potential of integrating 
vasculatures within the bone bioreactor. Preliminary experiments are done in this 
thesis to establish naïve tubular constructs with human umbilical vein endothelial 
cells (HUVEC). The optimal approach for bio-functionalisation of scaffolds and 
HUVEC inoculation are identified. Briefly, tubular poly-ε-caprolactone (PCL) 
templates (length: 100 mm, ID: 4 mm) are synthesized through electrospinning 
and the elasticity is comparable to a medium-sized artery in vivo. Following bio-
functionalisation with rat-tail type I collagen (COL I), the PCL templates are 
cultivated in the vascular bioreactor with HUVEC. Active medium perfusion at   
2.5 mL/min is applied (continuously or intermittently) through the lumen of the 
PCL template for up to 10 days. Interestingly, intermittent medium perfusion is 
most effective for supporting HUVEC propagation and the cell distribution is 
relatively homogenous on the surface of the PCL template. 
In summary, the results presented in this thesis demonstrated the potential of 
recapitulating dynamic physiological congruent niches in perfusion bioreactors. 
These niches can also be easily manipulated to derive different cell types and is 
not limited to osteochondral lineages. Depending on the parameters applied, 
constructs with varying physical appearance and mechanical stiffness are 
derived. Although further optimisations are necessary to achieve engineered 
bone constructs with higher resemblance to the native bone tissue, the reported 
results in this thesis provided critical parameters that can be adopted in future 
experiments.  
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Highlights 
1. A preliminary prototype for vascular tissue engineering is developed and a 
primary tubular construct with HUVEC is derived. 
2. The dynamic cultivation niches derived in the bone bioreactor through 
interplay of pO2, medium pH and step-by-step differentiation regimes have 
recapitulated physiological congruent events such as: 1) endochondral 
ossification, 2) intramembranous ossification, and 3) impaired ossification 
mechanisms caused by chronic acidosis. 
3. The principles of step-by-step differentiation regime are transferable from 
mouse embryonic stem cells (mESC) to human bone marrow-derived 
mesenchymal stem cells (hMSC). 
4. Chondroitin sulfate A (CSA) is shown as a potent inducer for chondrogenesis, 
as well as a critical component that maintain the structural integrity of 
engineered bone constructs. 
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INTRODUCTION AND MOTIVATIONS 
According to the Global Burden of Disease study from 2016 (GBD 2016), 
musculoskeletal (MSK) disorder is ranked the second highest contributor to long-
term disability and economical burden (1). Among the different types of MSK 
disorder, age-related long bone degeneration and trauma-inflicted long bone 
fractures have the highest incidence. Further, the degenerative disorders are 
most prevalent in older population aged 65 years and higher; while trauma-
inflicted fractures prevail among the younger population aged 19–25 years (1). 
With reduced mobility over the long recuperation period (months–years) required 
by patients, the loss of capability to work and extended consumption of social 
supports will incur a major socioeconomic burden. Even though multiple 
treatment options with either autologous bone grafts or artificial implants are 
available, the treatment outcomes offered are neither optimum nor permanent. 
Furthermore, the risks for complications are relatively high and secondary 
surgical interventions are often required (2). For these reasons, clinicians and 
researchers have turned to bone tissue engineering for solutions. 
Despite successes in deriving various osteoconductive or osteoinductive 
engineered constructs, their potential for bone healing and regeneration in vivo 
still fall short against existing approaches in clinics (3,4). Generally, most 
engineered bone constructs do not share similar anatomical or mechanical 
properties as the native bone tissues and are often associated to lesser 
osseointegration (4). Furthermore, constructs composed of biological polymers 
are often resorbed before they can stabilise and integrate with the native tissue 
to complete the regeneration process. In this thesis, it is proposed that the 
leading cause is the differences between in vitro and in vivo niches. Unlike the 
dynamic physiological niche, in vitro cultivation conditions are typically 
homogenous but are inconsistent between different set of experiments. For 
example, bone/stem cells are typically inoculated on engineered constructs; 
followed by cultivation in oxygenated osteogenic differentiation medium to initiate 
bone-building activities. The engineered constructs are subsequently assessed 
based on the quantity of osteogenic cell-types present and the calcium 
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concentration accumulated in the construct. However, this does not comply with 
the long bone developmental events in vivo, which require dynamic interactions 
among multiple cell types to support continual remodeling and turnover 
processes. Furthermore, the niches will vary with growth and maturation to 
derive different tissue types in the long bone. For example, oxygenated niche 
brought about by vascular infiltration will enhance osteogenesis and bone 
building activities. On the contrary, an avascularised hypoxic niche will support 
chondrogenesis and is essential for deriving the hyaline cartilage model during 
early long bone formation (endochondral ossification), as well as formation of the 
articular cartilage. Additionally, the lack vasculatures also impaired the potential 
of in vitro cultures to support large tissue structures. 
 Although it is challenging to recapitulate physiological bone development in 
vitro, it is not impossible. Inspired by recent breakthroughs that derived functional 
multi-cellular organoids from embryoid bodies through step-by-step differentiation 
regimes (5–8), similar principles are applied in this thesis. Engineered constructs 
are cultivated in a customised perfusion bioreactor (bone bioreactor), with a 
controlled oxygen tension (pO2) gradient. The potential to derive large 
engineered bone constructs that are clinically applicable is investigated. In this 
thesis, the following aims and hypothesis are designed to further improve the 
existing technical incompetency to recapitulate physiology congruent 
environment in vitro.  
Aims and Hypotheses 
Aims:  
1) To develop and establish a perfusion bioreactor prototype (vascular 
bioreactor) that will support vasculogenesis in vitro.  
2) To characterise and establish the specificity of dynamic niches generated in 
the bone bioreactor with mouse embryonic stem cells (mESC). 
3) To mimic and recapitulate bone development events in bone bioreactor; so 
as to generate bone-like engineered constructs with human bone marrow-
derived mesenchymal stem cells (hMSC). 
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4) To develop a conceptual manufacturing process that derives tailored bone 
constructs that are applicable for either generic bone regeneration or 
personalised medicine. 
Hypotheses 
1) A naïve blood vessel can be achieved by cultivating human umbilical vein 
endothelial cells (HUVEC) on biofunctionalised poly-ε-caprolactone (PCL) 
tubular template. Further, fluid shear stress generated in the vascular 
bioreactor will enhance cell seeding procedures and the overall quality of 
naïve blood vessel. 
2) The path of stem cell differentiation can be specified by applying specific 
differentiation medium in a step-wise manner at critical time points. In turn, 
bone development events will be recapitulated accurately and sequentially in 
vitro. Since bone development is a conserved event, the differentiation 
approaches applied should be applicable for both mESC and hMSC; with little 
modifications necessary. 
3) Dynamic interplay of pO2, medium pH and defined aECM scaffolds will further 
improve the accuracy of recapitulation in the bone bioreactor. 
4) The physiological congruity of engineered constructs to native bone tissues 
can be further improved by: 1) up-scaling hMSC expansion in spinner flasks, 
so that similar quantity of cells present in the native tissues can be applied on 
the engineered scaffolds, and 2) consistent and rapid production of tailored 
scaffolds through 3D-printing. 
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CHAPTER 1: Research Background 
1.1 Medical implications: Critical bone defects 
Large bone defects caused by chronic inflammation, trauma or tumours, often 
require surgical interventions (9–11). Autografts, allografts or synthetic implants 
are commonly applied in grafting and reconstruction procedures. However, the 
existing treatments have a variety of drawbacks that limit treatment outcomes in 
patients. Autografts are often associated with limited availability and post-surgical 
donor-site morbidity, such as neurovascular injury, infection, persisting pain and 
local fractures. Even with extra precautions, further medical complications from 
iliac crest-derived autograft for example, can still occur at an incidence up to 30% 
(12,13).  
For allografts, these implants frequently pose significant risks of disease 
transmission (14) or triggering adverse graft-versus-host immunological 
complications. Even with successful transplantation, patients are typically 
required to stay on long term immunosuppressive therapies. Consequently, the 
patients become more susceptible to infections, post-transplant malignancy or 
other chronic conditions such as liver and renal failure (15). Although the burden 
caused by shortages in donors is relieved through effective bone banking 
programmes in the European Union, it remained challenging to provide sufficient 
allografts for clinical use (16). This is often caused by the lack of young healthy 
donors and the deteriorated quality of allografts retrieved from older donors. 
Consequently, many donated allografts are not usable and have to be discarded 
(16,17).  
Besides biological bone grafts, artificial materials such as titanium, ceramic or 
polymer-based implants are also used in clinic (18–20). However, these 
materials are often vulnerable to fatigue over time and do not integrate well with 
the native tissue. Furthermore, biofilms formation on these implants at the initial 
recovery stage remains a major setback for these artificial implants (21,22). 
Consequently, the patients are prescribed with large dosages of antibiotics and 
secondary surgical interventions are often inevitable (21,22). These procedures 
will not only cause the patients to be more susceptible to build-up of antibiotic-
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resistant bacteria, the treatment outcome after revision surgeries are also less 
desirable. Other than the biological impacts, these implants are usually available 
in standard dimensions. They lack flexibility for further alterations during 
surgeries, and often could not accommodate patient-specific injuries. As a result, 
the efficacy for patient recovery is will vary and is less predictable. However, this 
is undesirable, especially with an increasing trend for younger patients between 
the age of 18 to 45 years requiring bone and joint replacement (23–27); 
accompanied with increasing average life expectancy up to 88 years of age 
(28,29). The tendency for implant fatigue will increase and the variable efficacy of 
recovery in individual patients will mean that subsequent surgical interventions or 
revisions will be necessary at later stage in life. This will not only affect the 
overall quality of life, but will also incur a huge socio-economic burden; caused 
by increasingly enormous medical expenses that the healthcare system has to 
tolerate (30–33). Hence, better means of deriving customizable off-the-shelf 
biological bone grafts will be the most ideal and effective solution to the 
difficulties described above, as well as achieving the best treatment outcome for 
individual patient. 
1.2 Bone development and repair processes in physiology 
During fetal skeletal development, two distinct processes are involved in 
skeleton development: 1) intramembranous ossification and 2) endochondral 
ossification (34–36). Intramembranous ossification occurs primarily at the skull 
and clavicles, which do not require the formation of an initial cartilage template. 
The process begins immediately from mesenchymal condensation, followed by 
osteogenesis to derive bone-building osteoblasts that initiate ossification (37).   
In contrast, endochondral ossification involves a cartilaginous intermediate and 
occurs primarily during long bone formation and growth (38). Briefly, the 
mesenchyme forms a hyaline cartilage model composed of primary chondrocytes 
and mesenchymal stem cells. The chondrocytes continues to proliferate and 
deposit matrix into the hyaline cartilage model to facilitate growth in size. 
Concurrently, calcification of cartilage model will occur and when mass transfer 
becomes limited, chondrocyte hypertrophy is initiated. The empty spaces are 
 
Research Background 
6 | P a g e  
 
then infiltrated by blood vessels, followed by osteoblasts to initiate the 
ossification process through osteoid deposition. Simultaneously, 
osteoclastogenesis is initiated and remodeling by osteoclasts will occur to form 
the medullary cavity, in which the bone marrow will later reside. Cyclic bone 
building activities by the osteoblasts / osteocytes, and remodeling by osteoclasts 
will occur throughout bone development as illustrated in Figure 1 (39). Other 
than its critical role during neo-natal bone development, endochondral 
ossification is also critical for healing of post-natal long bone defects and 
fractures (36,40). Since endochondral ossification marks the initiation of long 
bone formation and healing, it is logical to recapitulate the physiological niches 
that support these processes in vitro. These physiological congruent artificial 
niches should overcome the current challenges in bone tissue engineering and 
Figure 1: Processes of endochondral ossification during fetal bone 
development (39). 1) The process begins with a hyaline cartilage model composed 
of chondrocytes and mesenchymal stem cells. 2) Initial calcification of cartilage 
model is carried out by osteoblasts/osteocytes that lead to bone collar and 
periosteum formation. At the primary ossification center, chondrocytes undergo 
hypertrophy as vascular infiltration begins. 3) At this point, osteoclasts formation is 
initiated to facilitate remodeling and allow further vascular infiltration. 4) The 
remodeling and resorption activities by osteoclasts continue, as the vascular network 
becomes more elaborated to form the medullary cavity. Concurrently, mineralisation 
of periosteum is orchestrated by osteoblasts/osteocytes to form compact bone shaft 
with increased mechanical strength. 5) Mineralisation and remodeling processes 
continue post-natal, which support further growth and homeostatic activities in the 
long bone. 
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derive large three-dimensional (3D) biological bone grafts in vitro. In turn, bone 
grafts with comparable mechanical and physical properties as the native bone 
tissue can be derived to improve existing treatment outcome; especially for the 
younger patients.  
1.3 The potential of bioreactors for bone tissue engineering 
Generally, bioreactors are specialised apparatus that contains an optimum 
artificial environment for a specific biological process. It will promote the 
biological process to occur at a predictable, stable manner and produce the 
desired product at high yield. Although with a long history of application in large-
scale bacteria cultivation in biologics production, bioreactors are only applied in 
tissue engineering over last two decades. Unlike conventional cell culturing 
vessels that provide two-dimensional (2D) or semi-three-dimensional (semi-3D) 
niches, bioreactors provide engineered constructs with a stable 3D niche for 
growth and development (Figure 2). Using the 3D settings available in 
bioreactors, an increasing number of research groups have dedicated their work 
on recapitulating physiological congruent environment in biomimetic bioreactors, 
so as to derive larger tissue- or organ- constructs in vitro (41). Specifically in 
bone tissue engineering, the technology has advanced from simple cultivation of 
cylindrical constructs in spinner flask to deriving tailored bone grafts in perfusion 
bioreactor shown in Figure 3 (42,43).  
Other than providing a stable 3D environment to support propagation, 
additional parameters are applied. This is done to improve the overall quality of 
engineered constructs and achieving higher degree of resemblance to the native 
bone tissue. In most literatures, continuous medium perfusion is applied directly 
through engineered constructs to enhance the depth of penetration and the 
homogeneity of mass transfer. Thus supporting larger and thicker constructs 
within a bioreactor (43–46). Further, cell seeding procedures are also improved 
by perfusing cells through porous scaffolds and the tendency for cell aggregation 
is reduced. Consequently, the cells are seeded homogeneously within the 
constructs and this is shown to enhance construct development in vitro (45,46). 
Furthermore, fluid shear stress is also generated along with the perfusing 
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medium and it is an effective mechanical stimulant for osteogenesis and 
construct mineralisation (47–50). More importantly, the major advantage of 
bioreactors over conventional cell culturing vessels is their potential for 
automation. Additional sensors can be integrated to monitor carbon dioxide (CO2) 
and oxygen (O2) level, medium pH and metabolites concentrations (glucose, 
glutamine, lactic acid ammonia) in real-time (51,52). With these capabilities, a 
defined optimum niche for cultivation can be maintained at stable state over 
extended time. In turn, the best possible outcome for construct development in 
vitro is ensured. Moreover, maintenance procedures can also be accomplished 
in the least labor-intensive manner and operate round the clock through 
integration of computer algorithms and robotics.  
 
 
  
Figure 2: Illustrations of 2D, semi-3D and 3D cultivation environment. The 
arrows represent the potential exposures of cultivated cells or engineered constructs 
to mass transfer. Typically, conventional cell culture vessels support a 2D niche. The 
mode of mass transfer can only occur via passive diffusion at the air-liquid interface, 
while the cells are attached at the bottom. In a semi-3D environment, the cells are 
embedded within hydrogels or scaffolds and mass transfer also occurs via passive 
diffusion. Cell necrosis at the inner volume is a common problem, especially in large 
constructs, due reduced efficacy of the passive diffusion mechanism with increasing 
construct thickness. In a 3D environment, cell-laded scaffolds are typically cultivated 
in suspension and mass transfer is enhanced by applying medium perfusion or 
constant stirring. Unlike the semi-3D environment, penetration of nutrients and 
oxygen through the scaffold is enhanced and necrosis is prevented. 
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Despite extensive amount of work already done in this field of study, there 
remain some major hurdles to overcome. Currently, the existing bioreactors are 
designed to establish and maintain a homogenous cultivation niche. Although 
they are favorable for basic researches such as: 1) identifying critical factors for 
tissue development, or 2) studying the effects of biological and chemical 
stimulants; such homogenous niche is generally unfavorable for bone tissue 
engineering. Consequently, existing engineered biological constructs often lack 
mechanical and physical resemblance to the native bone tissue and their 
potential for clinical applications are limited. Described in Figure 1, bone 
development requires synergistic interactions among multiple cell types. These 
include:  
1)   the osteochondral progenitor cells to produce chondrocytes, osteoblasts 
and osteocytes to regulate bone building or homeostatic activities; 
2)  the hematopoietic stem cells for osteoclastogenesis and blood vessel 
formation that are necessary for bone remodeling and enhancing mass 
transfer; 
3)   the mesenchymal stem cells that provide a stable pool of progenitor cells 
to support further growth and maturation. 
Figure 3: Examples of bioreactors applied in bone tissue engineering. (left) The 
technology started with simple cultivation in spinner flask, as described by Sikavitsas 
et.al. (42). Mass transfer is enhanced by constant stirring at 30–50 rpm and the fluid 
shear stress has also enhanced cell proliferation and construct mineralisation. (right) 
The technology has recently advanced to derive tailored bone grafts and direct 
medium perfusion is applied at higher precisions to enhance cell seeding and 
construct development as shown by Grayson et.al. (43). 
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Furthermore, the importance of recapitulating developmental processes in 
vitro should also be emphasized. As shown in physiology, direct occurrence of 
osteogenesis during intramembranous ossification will derive compact and thin 
cranial bones or the clavicle bones. In contrast, endochondral ossification that 
begins with an initial cartilage intermediate; followed by ossification, will derive 
long bones that are more robust in their mechanical and structural properties. 
Despite such importance, they are often not adopted in research. This is 
commonly due to the technical challenges met in cell culture, since a controlled 
dynamic niche has to be derived, in order to support different cell types 
simultaneously in vitro. Hence, next-generation bioreactors with capabilities to 
recapitulate the dynamic physiological niches in vitro would be critical for further 
advancements in bone tissue engineering. 
1.4 A preliminary bioreactor prototype with controlled pO2 gradient 
As part of a proof-of-concept study that was completed in my Master´s thesis, 
a perfusion bioreactor prototype (bone bioreactor) was developed (Figure 4) and 
the procedures to set up the bioreactor are published (53). The novel 3D 
cultivation platform is further characterised and exploited in this Ph.D. thesis to 
derive a dynamic niche that will support and recapitulate bone development 
events in vitro. Briefly, oxygen tension (pO2) is a critical determinant factor for 
cell fate and cell propagation. For example in long bone development, the 
hyaline cartilage model is generally exposed to a hypoxic environment at the 
early stage of development. With subsequent infiltration of blood vessels at the 
primary ossification centre, an oxygenated environment is derived and bone 
building activities by osteoblasts are initiated. Furthermore, the lack of 
vasculatures at the ends of the long bone will cause the site to remain hypoxic 
and chondrocytes residing in this region will mature to form the articular cartilage 
(Figure 1). With the emphasis to recapitulate physiological congruent niches in 
this Ph.D. thesis, the ability to control pO2 is critical for success and is inevitable. 
Based on the preliminary experiments completed in my Master thesis, a medium 
perfusion rate at   5.5 mL/min will achieve a stable pO2 gradient in the perfusion 
bioreactor. In contrast, a homogenous hypoxic niche is derived when the 
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medium is perfused at 1.5 mL/min. A more detailed description on the 
specifications of the bioreactor can be found in Chapter 3.1.3 of this thesis. 
Based on this study, the first step to derive a dynamic cultivation niche in vitro 
was taken and the pO2 can be controlled simply by adjusting the medium 
perfusion rate. Building on top of this platform, additional parameters are 
included in this Ph.D. thesis to achieve higher degree of biomimicry and a 
mathematical model was built to elucidate the mechanisms that eventually lead 
to the pO2 gradient. 
 
Figure 4: The perfusion 
bioreactor prototype. This 
bioreactor was developed as a 
proof-of-concept in my Master´s 
thesis completed at University 
of Calgary. By perfusing cell 
culture medium through the 
bioreactor at 5.5 mL/min, a pO2 
gradient was established. 
Based on this unique feature, 
additional parameters are 
included in this Ph.D. thesis to 
recapitulate bone development 
events in vitro.  
1.5 mESC versus hMSC 
Embryonic stem cells (ESC) are derived from the inner mass of a blastocyst. 
They are characterised by their capacity for self-renewal and differentiating into 
different cell types from all three germ layers (54,55). Compared to matured 
somatic cells, ESC and their differentiated derivatives possess higher 
proliferative and regenerative potential for healing of bone defects and fractures. 
Since large quantity of cells and multiple cell types are required to attain higher 
degree of biomimicry, the plasticity and capacity for self-renewal makes ESC an 
ideal candidate for bone tissue engineering applications. Using the unique 
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properties of ESC, they are more likely to succeed and achieve better 
regenerative efficacy in patients. The high cellular turnover rate at the site of 
injury will quickly replace lost cells and accelerates the healing process. However, 
it is essential to develop defined and specific differentiation protocols to achieve 
terminal differentiation of ESC. Otherwise, teratoma formation will occur and 
potentially become carcinogenic in vivo (55).  
Although ESC are attractive cell source for bone tissue engineering, the 
efficacy of human ESC (hESC) for applications in regenerative medicine remain 
ambiguous and debatable. This is mainly due to the developmental stage of 
embryos that hESC are often isolated from. Unlike the mouse ESC (mESC) that 
are isolated from blastocysts, hESC are typically isolated from much mature 
embryos at the trophoblast stage, due to accessibility and ethical issues (54,56). 
Hence, most of the existing sources for hESC used in laboratory 
experimentations are often comprised of heterogeneous stem cell populations. 
Unlike the naïve ESC with pluripotent capacity, the cell fate of these hESC are 
specified and are primed to differentiate into progenitor cells of a specific germ-
layer (56,57). Further, the differences between naïve ESC and primed ESC are 
subtle and is distinguishable only at the epigenetic level. Therefore, it is 
technically challenging to separate and isolate naïve hESC through existing cell 
sorting techniques. Consequently, hESC-laded engineered constructs possess a 
higher tendency for cellular heterogeneity, and are also susceptible to huge 
variability between different donors. Furthermore, it is also challenging to alter 
and manipulate the differentiation pathway of primed ESC. This is undesirable as 
it is a major causal factor for subsequent teratoma formation (57). 
In order to reduce the risk of uncontrolled teratoma formation in engineered 
constructs, tissue-derived mesenchymal stem cells become a more attractive 
source for stem cells and are increasing applied in osteochondral tissue 
engineering. Unlike the pluripotent ESC that can differentiate into cells from all 
three germ layers, the MSC are a pool of stem cells with multipotent capacity and 
are primed to become cell lineages for connective tissues only (58–60). 
Therefore, the differentiation pathway of MSC is easier to manipulate and is 
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more specific than hESC. Furthermore, MSC can be isolated from multiple 
sources such as adipose tissue (61,62), bone marrow (62,63) or hair follicles (64). 
Most importantly, autologous hMSC can also be isolated directly from the patient. 
This will mean that engineered osteochondral constructs generated from patient-
derived MSC will inherit the biological advantages of autografts, yet they can be 
customised to fulfill personalised medicine. However, it should also be noted that 
the proliferative and self-renewal capacity and potency of MSC to differentiate is 
age-dependent and will deteriorate with increasing age. Nonetheless, human 
MSC are more ethically accepted than human ESC and their specificity for 
deriving osteochondral tissues has made these stem cells a preferred choice for 
this thesis. 
Using the unique advantages of each stem cell, more thorough 
characterisations of the bone bioreactor are accomplished and tailored 
mineralised constructs containing human cells are derived at the end of this 
thesis. Briefly, mESC are used to characterise the potential of generated niches 
in the bone bioreactor to recapitulate bone development events. Since mESC 
are at the primitive and unprimed state, assessments on the specificity of applied 
parameters to derive osteochondral cell types will be most accurate. Furthermore, 
the parameters that will derive cell types of other origins; such as the 
hematopoietic lineages, can also be elucidated with mESC and will contribute 
significantly to future investigations aimed to derive more complex physiological 
congruent niches in vitro. After defining the effects of different parameters on 
construct development and mESC differentiation, hMSC are cultivated in similar 
set of conditions. This is done to gain exclusive insights on the effectiveness and 
transferability of these parameters on different stem cells, as well as their 
accuracy to recapitulate bone development in vitro. 
1.6 Step-by-step differentiation regimes and their design rationales 
1.6.1 Differentiation regimes for mESC 
A step-by-step differentiation regime (CMOM) is formulated to recapitulate the 
early processes of endochondral ossification in the bone bioreactor. This is 
achieved by inducing mESC to undergo chondrogenesis in the first 30 days with 
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an acidic chondrogenic differentiation medium (CM, pH 6.9 ± 0.15), followed by 
another 30 days of cultivation in a slightly basic osteogenic differentiation 
medium (OM, pH 7.6 ± 0.15). As shown in previous work (53), chondroitin sulfate 
A (CSA) is a potent inducer for chondrogenesis, especially in complementary 
with hypoxic niches generated in the bioreactor. However, key gene markers for 
hypertrophic chondrocytes (Col Xa) and mature osteoblasts (Sp7) were not 
detected, despite mineralised end-products being achieved after 50 days. While 
this may be due to the single time point analysis, some studies have suggested 
otherwise. Alternatively, extended cultivation in the acidic CM medium (65) or the 
higher concentration of dexamethasone (dex); with 10-6 M applied in previous 
work (66,67), can also attenuate Col Xa and Sp7 expression. Based on these 
observations, the differentiation approach is modified to include a slightly basic 
OM medium, with significantly lower concentration of dex (10-9 M); to enforce 
osteogenesis at the later stage of cultivation.  
Although the potential for mESC-derived chondrocytes to undergo 
hypertrophy and transit to osteogenesis was demonstrated by Hegert et. al. (68), 
this was validated in embryoid bodies at a micrometre scale setting. In this thesis, 
similar work principle is applied on engineered constructs at centimetre scale and 
the step-by-step CMOM differentiation approach is used to support the transition 
from chondrogenesis to osteogenesis. Interestingly, such differentiation 
approach is rarely practiced in bone tissue engineering, even though the 
transition process is critical for long bone development. Hence, the effects of the 
differentiation approach on development of bone construct are largely unknown 
and the results from this thesis will bring greater insights to the field of bone 
tissue engineering. In order to further enforce the specificity of each 
differentiation medium, the pH and composites of cell culture media are adjusted 
to simulate the physiological conditions. The design rationales are as follows:  
CMOM: In the first 30 days of cultivation, an acidic chondrogenic medium is 
applied with CSA to initiate chondrogenesis. It mimics the native environment of 
early endochondral ossification, brought about by local metabolic acidosis and 
lack of vascular infiltrations. This is further supported by multiple studies that 
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have demonstrated the inhibition of osteoblast formation in acidic environment, 
thus reducing mineralisation and enforcing chondrogenesis (69,70). 
Subsequently, a slightly basic OM medium is applied on the constructs to initiate 
chondrocyte hypertrophy and osteogenesis. CSA is included in the OM medium 
from Day 30–45; to ensure smoother transition from chondrogenesis to 
osteogenesis. On Day 45, CSA is removed from the OM medium to enforce 
osteogenesis. 
CMCM: Continual cultivation of constructs in acidic chondrogenic medium is 
implemented to determine the efficacy of CMOM protocol to support 
chondrogenic-osteogenic transition, and elucidate the effects of extended 
cultivation in the acidic CM medium on construct development. 
OMOM: The slightly basic OM medium is applied in the first 30 days, since 
alkalosis is known to enhance osteoprogenitors and osteoblasts formation 
(71,72). Subsequently, the DMEM basal medium is substituted with a neutral α-
MEM medium and the constructs are cultivated in this new medium for another 
30 days (73,74). The neutral medium is commonly applied to enhance 
mineralisation, and will provide additional source of calcium ions, phosphate ions 
and vitamins that are essential for mineralisation and hydroxyapatite 
crystallisation (74–76).  
Additionally, the mESC are at primitive state when the experiment begins and 
the mESC require higher glucose concentration for stable propagation. Hence, 
the mESC-laded constructs are cultivated in hgDMEM from Day 1–15 to support 
the metabolic needs. Once the mESC are primed to undergo either 
chondrogenesis or osteogenesis after 15 days, the hgDMEM basal medium is 
replaced with acidic DMEM:F12 medium to support chondrogenesis or the 
slightly basic DMEM medium to support osteogenesis (Figure 5).  
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1.6.2 Differentiation regimes for hMSC 
Similar to the mESC experiments, CMCM, CMOM and OMOM differentiation 
regimes are applied to the hMSC, but with slight modifications. Unlike the mESC, 
hMSC are primed to undergo adipogenesis, chondrogenesis or osteogenesis. 
Hence, hMSC can also propagate in the same basal medium as their 
differentiated derivatives and the acidic or slightly basic basal media are applied 
directly to respective hMSC-laded constructs at the beginning to initiate 
chondrogenesis/osteogenesis.  
Other than the three differentiation regimes investigated in the mESC 
experiments, an additional OMOM* setup is included. This is done to elucidate 
the effects of CSA on hMSC differentiation and construct development; under the 
influence of the OMOM regime (Figure 6). This is a more relevant comparison for 
Figure 5: Differentiation regimes applied on mESC-laded hydrogels. Variable 
differentiation media are applied step-by-step over 60 days. This is done with an aim 
to generate different osteochondral lineages sequentially. CMOM will recapitulate 
similar processes of endochondral ossification. CMCM and OMOM are 
corresponding controls for extended chondrogenesis and osteogenesis respectively. 
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the OMOM constructs, as some previous studies have shown sulfated 
glycosaminoglycan derivatives being a potent enhancer for osteogenesis and 
mineralisation; both in vitro and in vivo (77–81). With the results derived from this 
set of experiments, greater insights on the optimum differentiation regime to 
achieve mineralised bone constructs with hMSC will be attained. This is 
beneficial for subsequent experiments aimed to improve the physiological 
resemblance of engineered bone constructs to the native bone tissue. 
 
1.7 Gene expressions for endochondral ossification 
After formulating the step-by-step differentiation regime and corresponding 
controls, their accuracy and efficacy to recapitulate physiological bone 
development events in vitro will require authentication. A rapid analytical 
approach to characterise these constructs is through real-time quantitative 
Figure 6: Differentiation regimes applied on hMSC-laded aECM scaffolds. The 
entire cultivation will take 60 days to complete and the expected cell types after 
application of designated differentiation media are described in the flow chart. Unlike 
the mESC experiments, structured collagen-based scaffolds are derived through 
freeze-drying and the differentiation media are applied immediately to the hMSC-
laded constructs. 
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polymerase chain reaction (qPCR). This technique enables rapid screening of 
gene expression in each construct and the developmental status is determined 
based on the tabulated trend (Table 1). Described in Chapter 1.2, endochondral 
ossification is critical for regulating both long bone development and fracture 
healing. To recapitulate the process in vitro, multiple osteochondral cell lineages 
have to be derived from a single stem cell source and in specific sequence. This 
is elaborated in Figure 7 that describes the developmental sequence and major 
cell types present at each stage (82). The representative gene markers are 
highlighted with a red box. Generally, the cell types being analysed in this Ph.D. 
thesis are divided into four major categories and are summarised in Table 1 with 
gene markers that define each cell type. Since the process of bone development 
is conserved among different species, the gene markers listed in Table 1 are 
applicable to both mESC and hMSC. Nonetheless, it should be noted that gene 
sequences of some markers for differentiated cell types are not conserved 
between the mouse model and human. These include ALP, Osteoclacin, Sp7, 
Mepe, Dmp1, Sost and Trap5b. Hence, the primer sequences for these gene 
markers are not interchangeable and have to be designed separately. 
Table 1: Categories of stem cell-derived cell types investigated in this thesis and 
their corresponding gene markers. 
Cell types Gene markers 
Embryonic stem cells 
Mesenchymal stem cells 
Oct3/4, Sox2 
Sox2, CD90 
Chondrogenic 
Naïve chondrocytes 
Mature chondrocytes 
Hypertrophic chondrocytes 
 
Sox9 
Sox9, Col IIa 
Col Xa 
Osteogenic 
Progenitors 
Osteoblasts 
Osteocytes 
 
Sox2, Runx2, ALP 
Osteocalcin, Sp7, Col Ia 
Col Ia, Mepe, Dmp1, Sost 
Osteoclasts TRAP5b 
 
 
 
Figure 7: Long bone development: the process of cartilage formation and endochondral ossification with expression of 
specific gene markers over the course of development. The described developmental process is accurate for both mouse and 
human. Based on the gene profiling with quantitative real-time polymerase chain reaction (qPCR), the developmental status of 
bone constructs investigated can be elucidated. 
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1.8 Additional parameters to enhance the in vitro niches  
1.8.1 Up-scaling hMSC expansion in spinner flask 
Bone development is a multifactorial process and the potential for naïve 
tissue to mature and attain gain-of-function is not limited to the cell types present. 
The quantity of stem cells and their differentiated derivatives available to support 
continual growth over the course of bone development is equally important. In 
physiological conditions, it is estimated that approximately 70 × 106 cells are 
needed to form 1 cm3 of new bone (83,84). Despite the importance of cell 
quantity in bone development, significantly lesser cells are typically applied in 
laboratory settings. Firstly, existing in vitro cell culturing vessels are not 
competent at supporting such high cell density and inadequate mass transfer will 
induce necrosis. However, the bone bioreactor applied in this thesis is used to 
overcome this limitation and active medium perfusion is applied to enhance mass 
transfer. Secondly, it is rather labour-intensive and unreliable to derive such an 
amount of cells with conventional cell culture vessels, as the procedures for 
hMSC expansion can take up to two months; especially when the donor hMSC 
are limited. With considerations that the multipotency for hMSC will deteriorate 
with extended cultivation period and after each passage phase, it is most ideal to 
derive a large quantity of undifferentiated hMSC within a single passage phase. 
To do so, an extremely large quantity of hMSC can be used to start the 
expansion procedure. However, this will either incur rather high financial burden 
on the research project or introduce heterogeneity. Firstly, commercially 
available hMSC (Lonza) are typically available in 0.75 x 106 aliquots, which can 
only be expanded for 5–6 passage phases and each aliquot cost approximately 
1200 €. Hence, this is neither cost-effective nor a sustainable approach for both 
in vitro experimentations and clinical applications. Secondly, primary hMSC 
isolated directly from patient bone marrow aspirates are generally 20-30 x 106. 
Although the hMSC from several patients can be pooled together to attain the 
cell number required for effective tissue engineering, this will introduce 
heterogeneity and compromise the quality of engineered constructs. Therefore, it 
becomes a common practice in the field to inoculate lesser hMSC (1–10%) on 
 
Research Background 
21 | P a g e  
 
the initial engineered constructs and the remaining cell number is slowly 
achieved by inducing hMSC and their differentiated derivatives to proliferate. In 
relation to this thesis, similar compromise is also made and 3 x 106 hMSC are 
inoculated on a 0.75 cm3 artificial extracellular matrix (aECM) scaffold. However, 
each set of experiments will still require a total of 26 specimens to attain 
conclusive results (2 controls, 12 bioreactor cultures and 12 corresponding static 
cultures). At least 80 x 106 hMSC are required for each set of experiments from a 
single donor. Hence, a more proficient method for hMSC expansion has to be 
developed.  
For this purpose, 250 mL dimpled-bottom spinner flasks from NDS 
Technologies are used for up-scaling hMSC expansion in vitro. Since hMSC are 
anchorage-dependent cells, gelatin-coated microcarrier beads (Cultispher®-S) 
are used to facilitate cell attachment. Further, these macro-porous beads with 
increased surface area will allow more hMSC to adhere and increase the yield of 
hMSC. Generally, the hMSC expansion protocol is based on previous studies 
established by partners at University of Calgary (85,86). However, further 
optimisations are to meet the requirement for this thesis and are described 
further in Chapter 3.1.2.  
1.8.2 Engineering vascular structures in vitro 
During endochondral ossification, vascular infiltration is a critical step that 
drives further maturation of the hyaline cartilage model to proceed with 
ossification and long bone formation (Figure 1). The increase in mass transfer 
will enhance osteogenesis and bone-building activities by the osteoblasts, while 
monocytes that are introduced through vascular infiltration will differentiate into 
osteoclasts and initiate the bone remodeling mechanisms. To-date, multiple 
literatures have also demonstrated the synergistic effect of endothelial cells and 
osteoblasts co-cultures; to enhance ossification of engineered constructs in vitro. 
Additionally, small capillary network is also established in these constructs     
(87–89). However, the co-culture approach is not applicable for this thesis as the 
initial hyaline cartilage model with chondrocytes is avascular. Moreover, the 
small capillary network will not be sustainable in the bone bioreactor, as it is not 
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connected to a major vasculature. Hence, further infiltration of hematopoietic 
stem cells to support turnover of endothelial cells will not occur. Eventually, the 
pre-seeded endothelial cells will undergo senescence and apoptosis and the 
small capillary network in the construct will disintegrate. To overcome this, a 
large vascular template should be implemented in the bone bioreactor instead, 
and angiogenesis can be initiated at later stage through supplementation of 
growth factors and cytokines; such as ANG, VEGF, FGF, TNF-α and TGF-β. 
However, competent in vitro cultivation platforms that can support large 
vascular constructs are lacking in this field of research and the asynchronous 
development of blood vessel and bone tissue makes direct implementation in the 
existing bone bioreactor an impossible task. Hence, a stand-alone perfusion 
bioreactor for vascular tissue engineering has to be developed in this thesis. 
Although many studies have attempted to engineer artificial vascular structures 
in vitro, more focus are placed on deriving small tubular structures that are only 
composed of either endothelial cells or mesenchymal stem cells (90–93). These 
constructs resemble only the small capillaries (Figure 8A) and do not fulfill the 
research aim of this thesis. One of the major hurdles for achieving physiological 
congruent large blood vessels in vitro is the limited capability of conventional cell 
culturing vessels to support active medium perfusion. Secondly, the existing 
cultivation medium and approaches are insufficient to support a stable construct 
containing all three major cell types (endothelium, smooth muscle and 
connective tissue). Furthermore, these cells have to be arranged in distinctive 
layers; in order to attain similar structural stability and functions as the blood 
vessels in vivo. Thirdly and most importantly, the sources for these cells are 
limited and are commonly isolated from donated aortic endothelial (HAEC), 
coronary (HCAEC), iliac artery (HIAEC) endothelial cells or umbilical vein 
(HUVEC). Moreover, the capacity of these cells for self-renewal is also limited. 
The primary cells will typically undergo senescence and apoptosis after just a 
few passage phases of cell expansion in vitro. Although stem cells are a 
potential source, the differentiation approaches for each cells type are not the 
same (94,95). Hence, establishing a direct co-culture through this approach is 
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also technically challenging. As shown in Figure 8A, the inner-most endothelium 
lining (Tunica intima) is composed of a single layer of endothelial cells and is 
constantly exposed to fluid shear stress. It functions as a primary barrier that 
controls the permeability of biological materials into and out of the blood stream, 
as well as initiating angiogenesis (formation of new blood vessels). The middle 
layer (Tunica media) is an elastic smooth muscle cell layer that controls 
vasoconstriction or vasodilation and affecting the volume of blood flowing 
through. The outer-most layer (Tunica externa) is a connective tissue layer that 
maintains the structural integrity of a blood vessel and keeping it in position 
within the tissue (96).  
 
Thus in this thesis, a bioreactor prototype (vascular bioreactor) is developed 
to recapitulate the physiological niche in vitro. For preliminary investigations, a 
tubular poly-ε-caprolactone template coated with rat-tail type I collagen (COL I) is 
Figure 8: The anatomy of blood vessel in vivo and the proposed large vascular 
template derived in this thesis. A) The illustration describes the different cells 
layers in the artery and vein with the composites of each layer. (Illustration adopted 
with permission from Pearson Education). B) The tubular template applied in this 
thesis to mimic physiological conditions and establish a proof-of-concept. 
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inoculated with HUVEC and medium is perfused through the lumen to support 
cell propagation (Figure 8B). Although this tubular construct does not provide 
immediate solutions to the current challenges in vascular tissue engineering, a 
3D cultivation platform is derived and the specifications are described in Chapter 
2.2.1. Further cell culture experiments are also designed to elucidate the optimal 
fluid flow dynamics and cultivation conditions that are essential for deriving large 
blood vessels in vitro. Based on these results, the vascular bioreactor and 
tubular template can be used as a fundamental building block for future 
investigations to synthesize vascular structures in vitro. One possibility is through 
the layer-by-layer approach as described in Chapter 5.1. 
1.9 Bone tissue engineering for generic or personalised medicine 
Other than deriving bone-like engineered constructs by recapitulating bone 
development in vitro, it is also the research focus of this thesis to transfer these 
constructs from bench-to-bedside. To do this, a stringent manufacturing regime 
that ensures consistent production of bone constructs has to be considered and 
developed. In this thesis, a conceptual workflow that integrates multiple 
technologies to produce either generic or personalised bone constructs is 
proposed and investigated (Figure 9). Regarding the choice of technologies, they 
are selected based on their relevance to the objectives of this thesis and their 
potential to be coupled with robotics in the future.  
Briefly, the regime begins with the isolation of autologous human 
mesenchymal stem cells (hMSC) from the patient (Step 1). The hMSC can be 
derived from adipose tissue, bone marrow or hair follicles, as discussed in 
Chapter 1.5. Using the scaled-up hMSC expansion approach with spinner flasks, 
stable undifferentiated hMSC are derived in large quantity and within a short 
timeframe of 2–3 weeks (Step 2A). This will provide the quantity of hMSC 
required to attain physiologically congruent bone constructs in vitro. Concurrently, 
biological scaffolds are generated through existing 3D-printing technologies 
(Step 2B). In terms of clinical applicability, 3D-printers can be used to produce 
artificial bone grafts of two forms: 1) Personalised, and 2) Generic off-the-shelf 
bone grafts. For personalised medicine, the information retrieved from            
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µCT-imaging are used to derive tailored bone graft that matches the specific 
injury of individual patient (97,98). Additionally, a cocktail of antibiotics, anti-
inflammatory agents, growth factors or osteoinductive factors can also be 
formulated based on the medical history and embedded within the printed 
material to further enhance the healing process. For generic applications, 
standard molds are printed and used to cast tailored scaffolds. The cast and 
mold approach will facilitate consistent and rapid production of these scaffolds in 
large quantities. Furthermore, allogenic hMSC can potentially be applied on 
these scaffolds to derive off-the-shelf bone constructs. Engineered bone 
constructs derived from each approach can be applied; based on the patient 
profile and the type of bone defects. For example, the personalised constructs 
are more applicable to patients with impaired mechanisms for healing; such as 
diabetes and osteoporosis. In contrast, off-the-shelf generic bone constructs are 
more favoured for trauma-inflicted bone defects, as they will be readily available 
to the patients and shorter healing period can be achieved. Shown in Step 3 and 
4, tailored scaffolds with high density of hMSC are cultivated in the bone 
bioreactor for 2–4 months with the optimum differentiation regime identified in 
this thesis. The engineered constructs are subsequently implanted back into the 
patient for treatment and completing the conceptual cycle aimed to achieve 
better patient outcome (Step 5). Within the scope of this thesis, Step 1--4 of the 
proposed concept are investigated. Further, the cast and mold approach is 
applied to produce consistent aECM scaffolds for all experiments. Most efforts 
are made to identify the optimum combination of parameters that will recapitulate 
bone development events in vitro and to derive bone-like constructs with 
enhanced clinical potentials. 
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Figure 9: The concept of bone tissue engineering for generic or personalised 
medicine. (1) Starting from the patient, homologous hMSC are isolate and (2A) 
rapidly expanded in spinner flasks to achieve the number of cells required to build a 
physiological congruent bone construct. (2B) Simultaneously, tailored 3D scaffold 
can be printed. (3) Once all the building blocks are derived, they can be put together 
and cultivated in the bone bioreactor. (4) After about 2 to 4 months, the engineered 
bone construct with homologous hMSC will be ready and be implanted back into the 
patient for treatment purposes (5). Since homologous stem cells retrieved directly 
from the patient to derive the bone construct, effects of immunological rejection will 
be negated and enable better healing of large bone defects. Alternatively, allogenic 
hMSC can also be applied to derive off-the-shelf bone grafts. 
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CHAPTER 2: Materials and Methods 
2.1  List of materials and reagents 
2.1.1  Materials for constructing and setting up the bioreactors 
2.1.1a  Vascular bioreactor 
Materials 
Specifications, 
Catalogue number 
Manufacturer 
O-ring ethylene propylene 
diene monomer rubber 
(EPDM70), sulphur-cured 
9.19 x 2.62 mm 
18.64 x 3.53 mm 
 
 
#OR9.19-2.62 
#OR18.64-3.53 
 
Hansa-Flex 
Polycarbonate rods and 
plates * 
- 
Purchased by supporting 
Mechanical Engineer, Mr. 
Holger Sack, from the 
Faculty of Mechanical 
Engineering, TU Dresden 
Stainless steel rod, 
grade 316, OD: 6 mm 
- Mr. Holger Sack 
*Refer to Appendix 1 for the blueprint and assembly plan. These parts are made 
by Mr. Dirk Schmidt (Großer Beleg Student), supervised by Mr. Holger Sack. 
2.1.1b  Bone bioreactor 
Materials 
Specifications, 
Catalogue number 
Manufacturer 
Disposable 3 mL slip tip 
(Luer) syringe (Inlet/Outlet 
tubing attachment) 
#4020-000V0 Heike-Sass-Wolf 
Hose clamps, stainless stain 
grade 316,  
hex head, range: 21–44 mm 
#66020 BREEZE, USA 
Kitchen silicone, transparent #206110532 OBI GmbH 
Polypropylene (PP) caps - 
Retail purchase made in 
Singapore 
Polypropylene (PP) pipe 
OD: 38.1 mm, ID: 31.8 mm, 
wall: 3.18 mm 
- 
Retail purchase made in 
Singapore 
Sealing tape, 
Polytetrafluoroethylene 
(PTFE) 
- 
TURBO, Retail purchase 
made in Singapore 
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Stainless stain rod grade 
316, customized through 
lathe cutting (channel and 
platform mold) 
- 
Retail purchased and 
custom-made in 
Singapore 
Tygon® S50/L medical 
tubing, OD: 31.8 mm,         
ID: 25.4 mm, wall: 3.18 mm 
#AAX00062 Saint Gobain 
2.1.1c  Common accessories for both bioreactors 
Materials 
Specifications, 
Catalogue number 
Manufacturer 
75 cm2 cell culture flask with 
PS w/HDPE cap (medium 
reservoir) 
#83.3911.002 Sarstedt 
ISMATEC® high precision 
multichannel peristaltic 
pump, 12-channels 
#IPC12, ISM932 Ismatec 
Polypropylene straight 
tubing connectors 
#229-0713 VWR 
Tygon® LMT-55 peristaltic 
pump tubing, color code: 
purple/white ID: 2.79 mm 
#SC0024 Saint-Gobain  
Tygon® ND100-65 medical 
tubing, OD: 6.35 mm,        
ID: 3.18 mm, Wall: 1.59 mm 
#ADF00007 Saint-Gobain 
2.1.1d  Spinner flask for up-scaling hMSC expansion 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Acrylic rod, diameter:           
6 mm, for impeller extension 
- 
Retail purchase made in 
Singapore 
Spinner flask, dimpled 
bottom, fixed, 250 mL,      
GL-70 center neck, GL-32 
side arms, overall diameter x 
height: 85 mm x 145 mm  
#7702-04 NDS Technologies, Inc 
Sigmacote®  
(for pre-conditioning of 
glasswares and prevent the 
beads from sticking) 
#SL2 Sigma Aldrich 
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2.1.2  Materials and reagents for synthesizing the scaffolds 
2.1.2a  Vascular bioreactor, poly-ε-caprolactone (PCL) tubing 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Chloroform #22707.320 VWR 
Methanol #20.847.320 VWR 
Poly-ε-caprolactone (PCL) - Innovent, Jena 
Poly-vinyl-chloride (PVC) 
adapter 
Peristaltic pump tubing, 
color code: purple/white    
ID: 2.79 mm 
#SC0024 
 
Tygon® LMT-55 
 
Instant adhesive - UHU 
Bio-functionalisation 
rat tail COL I #354236 Corning 
Phosphate buffer (60 mM): 
Sodium phosphate  dibasic 
(Na2HPO4) 
Potassium phosphate 
monobasic (KH2PO4) 
 
#S0876 
 
#5655 
 
Sigma Aldrich 
 
Sigma Aldrich 
Poly-L-lysine,            
30,000– 70,000 kDa 
#P9155 Sigma Aldrich 
Porcine gelatin #L7230 Biochrom GmbH, Berlin 
Sulfated hyaluronic acid 
(sHya1), DSs 1.4 
#KS910 Innovent, Jena 
Sulfated hyaluronic acid 
(sHya3), DSs 3.5 
#KS814 Innovent, Jena 
2.1.2b  Hydrogels for mESC experiments 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Acetic acid ≥ 99% #A6283 Sigma Aldrich 
Antibiotic-Antimycotic    
(Anti-Anti, 100x) 
#15240062 
Gibco, Thermo Fisher 
Scientific 
ß-glycerophosphate (ß-GP), 
24% H2O  
#G9422 Sigma Aldrich 
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Chondroitin sulfate A (CSA), 
sodium salt from bovine 
trachea 
#C9819 Sigma Aldrich 
Rat-tail COL I  #354236 Corning 
hgDMEM; powder #T043-01 Biochrom GmbH, Berlin 
DMEM with 1.0 g/L glucose, 
liquid  
#F0415 
 
Biochrom GmbH, Berlin 
FBS #S0415, Lot: 740B Biochrom GmbH, Berlin 
MEM Non-essential amino 
acid (NEAA, 100x) 
#11140076 
Gibco, Thermo Fisher 
Scientific 
Ultra Pure water (1 L)  #L0020 Biochrom GmbH, Berlin 
2.1.2c  artificial Extracellular Matrix (aECM) scaffold for hMSC 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Printing molds with 3D-Printer 
Crystal clear red polylactic 
acid (PLA) filament 
#PL37008 3dk, Berlin 
Platinum cured silicone #SF33 Silikonfabrik, Germany 
aECM scaffold 
25 % glutaraldehyde  #3778.1 Roth GmbH 
Acetic acid ≥99% #A6283 Sigma Aldrich 
CSA, sodium salt from 
bovine trachea 
#C9819 Sigma Aldrich 
Rat-tail COL I #354236 Corning 
Potassium phosphate 
monobasic (KH2PO4) 
#5655 Sigma Aldrich 
Sodium phosphate dibasic 
≥99% (Na2HPO4) 
#S0876 Sigma Aldrich 
Ultra Pure water (1 L)  #L0020 Biochrom GmbH, Berlin 
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2.1.3  Consumables for cell culture 
2.1.3a  Vascular bioreactor: Cultivation and expansion medium for HUVEC  
*To be added separately before use, not included in the product purchased 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Endothelial cell growth 
medium (Ready-to-use) 
1% Penicillin-Streptomycin 
(Pen-Strep)* 
#C-22010 
 
#A2213 
PromoCell 
 
Biochrom GmbH, Berlin 
2.1.3b  Bone bioreactor: Characterisation with mESC 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
For mESC maintenance and expansion 
Dulbecco's Modified Eagle 
Medium high glucose 
(hgDMEM), powder 
- Sodium pyruvate 
+ 4.5 g/L D-glucose 
+ 4 mM L-glutamine 
+ 2.2 g/L NaHCO3 * 
+ 1 L Ultra Pure water* 
#T043-10 Biochrom GmbH, Berlin 
2-mecaptoethanol #M3148 Sigma Aldrich 
Anti-Anti, 100x #15240062 
Gibco, Thermo Fisher 
Scientific 
FBS #S0415, Lot: 740B Biochrom GmbH, Berlin 
Gelatin(porcine,10 mg/mL) #L7230 Biochrom GmbH, Berlin 
MEM-NEAA, 100x #11140076 
Gibco, Thermo Fisher 
Scientific 
Mitomycin-C #M4287 Sigma Aldrich 
Recombinant mouse 
leukemia inhibitory factor 
(LIF) 
#PMC9484 
Gibco, Thermo Fisher 
Scientific 
Sodium bicarbonate 
(NaHCO3) 
#S5761 Sigma Aldrich 
Trypsin/EDTA 
(0.5%/0.25%), diluted in 
Ultra Pure water * 
# L-2153 Biochrom GmbH, Berlin 
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Ultra Pure water (1 L) #L0020 Biochrom GmbH, Berlin 
Differentiation media applied in bone bioreactor 
hgDMEM, powder 
- Sodium pyruvate  
+ 4.5 g/L D-glucose 
+ 4 mM L-glutamine 
+ 3.7 g/L NaHCO3 * 
+ 1 L Ultra Pure water * 
 
DMEM:F12 (1:1), powder 
- Sodium pyruvate 
+ 15 mM HEPES 
+ 2.5 mM L-glutamine 
+ 1.125 g/L NaHCO3 * 
+ 1 L Ultra Pure water * 
 
DMEM, 500 mL 
- Sodium pyruvate 
+ 1.0 g/L D-glucose 
+ 3.7 g/L NaHCO3 
+ 2 mM L-glutamine * 
 
α-MEM, 500 mL 
- Sodium pyruvate 
- Nucleosides 
+ 2.0 g/L NaHCO3 
+ 2 mM L-glutamine * 
#T043-10 
 
 
 
 
 
#42400010 
 
 
 
 
#F0415 
 
 
 
 
#F0925 
Biochrom GmbH, Berlin 
 
 
 
 
 
Gibco, Thermo Fisher 
Scientific 
 
 
 
Biochrom GmbH, Berlin 
 
 
 
 
Biochrom GmbH, Berlin 
β-GP, 24% H2O #G9422 Sigma Aldrich 
CSA, sodium salt from 
bovine trachea 
#C9819 Sigma Aldrich 
Dex #D8893 Sigma Aldrich 
L (+)-ascorbic acid #33034 Riedel-de Haën 
L-glutamine (200 mM) #K0283 Biochrom GmbH, Berlin 
MycoZapTM prophylactic #VZA-2031 Lonza 
Agarose bedding and coating on cultivation platform 
mouse type IV collagen 
(COL IV) 
#354233 Corning 
UltraPureTM agarose #16500 
Invitrogen, Thermo 
Fisher Scientific 
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2.1.3c  Up-scaling hMSC expansion in spinner flasks 
*To be added separately before use, not included in the product purchased 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
CultiSpher®-S  #M9043 Sigma Aldrich 
Dulbecco's phosphate-
buffered saline (DPBS) 
without Ca2+ and Mg2+ 
#L1835 
Biochrom GmbH, Berlin 
 
Dulbecco's Modified Eagle 
Medium (DMEM), 500 mL 
- Sodium pyruvate 
+ 1.0 g/L D-glucose 
+ 3.7 g/L NaHCO3 
+ 2 mM L-glutamine* 
#F0415 
 
Biochrom GmbH, Berlin 
 
FalconTM Cell Strainer       
(70 µm), for 50 mL conical 
tubes 
#08-771-2 Corning 
FBS #S0415, Lot: 740B Biochrom GmbH, Berlin 
Trypsin/EDTA 
(0.5%/0.25%), diluted in 
Ultra Pure water * 
# L2153 Biochrom GmbH, Berlin 
2.1.3d  Bone bioreactor: Bone tissue engineering with hMSC 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
DMEM, 500 mL 
- Sodium pyruvate 
+ 1.0 g/L D-glucose 
+ 3.7 g/L NaHCO3 
+ 2 mM L-glutamine* 
 
DMEM:F12 (1:1), powder 
- Sodium pyruvate 
+ 15 mM HEPES 
+ 2.5 mM L-glutamine 
+ 1.125 g/L NaHCO3 
+ 1 L Ultra Pure water 
 
 
   
#F0415 
 
 
 
 
 
 
#42400010 
 
 
 
 
 
 
 
   
 
Biochrom GmbH, Berlin 
 
 
 
 
 
 
Gibco, Thermo Fisher 
Scientific 
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α-MEM, 500 mL 
- Sodium pyruvate 
- Nucleosides 
+ 2.0 g/L NaHCO3 
+ 2 mM L-glutamine 
 
#F0925 
 
Biochrom GmbH, Berlin 
β-GP, 24% H2O  #G9422 Sigma Aldrich 
CSA, sodium salt from 
bovine trachea 
#C9819 Sigma Aldrich 
Dex #D8893 Sigma Aldrich 
FBS #S0415, Lot: 740B Biochrom GmbH, Berlin 
L (+)-ascorbic acid #33034 Riedel-de Haën 
L-glutamine (200 mM) #K0283 Biochrom GmbH, Berlin 
MEM-NEAA, 100x #11140076 
Gibco, Thermo Fisher 
Scientific 
Pen-Strep #A2213 Biochrom GmbH, Berlin 
Sodium bicarbonate 
(NaHCO3) 
#S5761 Sigma Aldrich 
2.1.4  Consumables and reagents for analytics 
2.1.4a  Characterising HUVEC-laded PCL tubing 
Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Immunofluorescence (IF) 
DAPI (4′,6-diamidino-2-
phenylindole) , 350 nm 
#D1306 
Invitrogen, Thermo 
Fisher Scienctific 
DPBS with Ca2+ and Mg2+ #14040 
Invitrogen, Thermo 
Fisher Scientific 
MTT assay 
3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium 
bromide (MTT) 
#M5655 
 
Sigma Aldrich 
 
Acetic acid, ReagentPlus®, ≥ 
99% 
#472301 Sigma Aldrich 
Dimethyl sulfoxide (DMSO) 
ACS reagent, ≥ 99.9% 
 
#A6283 Sigma Aldrich 
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Sodium dodecyl sulfate 
(SDS), Ultra Pure 
#2326.2 Roth GmbH 
2.1.4b  Bone bioreactor: mESC-laded hydrogel constructs 
Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Immunofluorescence (IF) staining 
Bovine serum albumin 
(BSA), lyophilized 
powder   > 96% 
#A2153 Sigma Aldrich 
DAPI, 350 nm #D1306 
Invitrogen, Thermo Fisher 
Scientific 
DPBS with Ca2+ and Mg2+ #14040 
Invitrogen, Thermo Fisher 
Scientific 
Glycerol #3783.1 Roth GmbH 
MiniPAP pen #00-8877 
Invitrogen, Thermo Fisher 
Scientific 
Triton X-100 #T8787 Sigma Aldrich 
Antibodies for IF 
OCT-3/4 (H-134) rabbit 
polyclonal IgG 
#SC-9081 Santa Cruz 
SOX9 (H-90) rabbit    
polyclonal IgG 
#SC-20095 Santa Cruz 
COL IIA1 (H-300) rabbit 
polyclonal IgG 
#SC-28887 Santa Cruz 
SP7 (M-15) goat         
polyclonal IgG 
#SC-22538 Santa Cruz 
AlexaFluor 488, goat-Anti-
Rabbit (H+L) 
#A11034 
Invitrogen, Thermo Fisher 
Scientific 
AlexaFluor 488, donkey-
Anti-Goat (H+L) 
#A11055 
Invitrogen, Thermo Fisher 
Scientific 
real-time qPCR kits 
High capacity cDNA reverse 
transcription reaction mix  
#4368814 
Applied Biosystem, 
Thermo Fisher Scientific 
Taqman® universal PCR 
master mix 
 
#4304437 Applied Biosystem, 
Thermo Fisher Scientific 
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Mouse primers (Validated TaqMan® Probes) 
Housekeeping gene / 18S Mm02601777_g1 
Applied Biosystem, 
Thermo Fisher Scientific 
ESC / Pou5f1 (Oct3/4) Mm03053917_g1 
Progenitors / Sox2 Mm00488369_s1 
Primary chondrocytes / Sox9 Mm00448840_m1 
Mature chondrocytes /  
Col IIa 
Mm01309565_m1 
Hypertrophic chondrocytes / 
Col Xa 
Mm00487041_m1 
Osteoblast / Runx2 Mm00501584_m1 
Osteoblast / Col Ia Mm00801666_g1 
Osteoblast / Sp7 Mm00504574_m1 
Osteoclast / Trap5b Mm00475698_m1 
Osteocyte / Dmp1 Mm01208363_m1 
Mineralised osteocytes / 
Sost 
Mm00470479_m1 
2.1.4c  Bone bioreactor: hMSC-laded aECM constructs 
Reagents 
Specifications, 
Catalogue number 
Manufacturer 
Characterising the aECM scaffolds 
1,9-Dimethyl-methylene blue 
zinc chloride double salt 
(DMMB) 
#341088 Sigma Aldrich 
Absolute ethanol #20821.321 VWR 
Calcium chloride (CaCl) #7653 Sigma Aldrich 
Collagenase A #C1639 Sigma Aldrich 
Fluoraldehyde™ 
o-phthaldialdehyde reagent 
solution (OPA) 
#26025 Thermo Fisher Scientific 
Papain from papaya latex #P4762 Sigma Aldrich 
Sodium formate #247596 Sigma Aldrich 
TES #T1375 Sigma Aldrich 
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DNA isolation and quantification 
Ethylenediaminetetraacetic 
acid trisodium salt hydrate 
≥95% (EDTA) 
#ED3SS Sigma Aldrich 
Quant-iT™ PicoGreen ®  
dsDNA Assay Kit 
#P11496 Thermo Fisher Scientific 
Sodium citrate tribasic #S/3320/53 Fisher Scientific 
Sodium hydroxide ≥99% #9356.1 Roth GmbH 
Trizma® base #T6066 Sigma Aldrich 
real-time qPCR kits 
AffinityScript qPCR cDNA 
synthesis kit 
#600559 
Agilent 
Technologies 
Brilliant II SYBR ® green 
QPCR master mix with low 
ROX 
#600830 
Agilent 
Technologies 
qPCR primer sequences ( Human primer sequences (from previous literature 
or designed with Primer 3 program.) 
Lineage Gene Primer sequence 5´- 3´ 
forward (F), reverse (R) 
size 
(bp) 
Optimal 
anneal 
temp (°C) 
MSC CD90 
F - agagctgcttctgtctggtt 
R - gctctcactctccatcaggt 
101 58 
Progenitors Sox2 
F - aagtactggcgaaccatctc 
R - attaccaacggtgtcaacct 
121 56 
Primary 
chondrocyte 
Sox9 
F - gaaagagaggaccaaccaga 
R - cttggaaatttgggtacgag 
134 56 
Mature 
chondrocyte 
Col IIa 
F - ggatgggcagaggtataatg 
R - acagattatgtcgtcgcaga 
100 56 
Hypertrophic 
chondrocyte 
Col Xa 
F - attatgacccaaggactgga 
R - caggggtgccattcttatac 
120 56 
Primary 
osteoblast 
Runx2 
F - acccaagcagaatttagcag 
R - cctacaaaggtgggtttgag 
85 56 
osteoblast Col Ia 
F - agactggcaacctcaagaag 
R - acagtgacgctgtaggtgaa 
97 58 
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Osteoblast ALP 
F - acagacaagaagcccttcac 
R - tggagacattctctcgttca 
85 56 
Mature 
osteoblast 
Osterix 
(Sp7) 
F - cctacccatctgactttgct 
R - tctagctgcccactatttcc 
133 57 
Osteocyte Dmp-1 
F - agcatcctgctcatgttccttt 
R - gagccaaatgacccttccatt 
106 58 
Osteocyte Mepe 
F - cgagttttctgtgtgggactactc 
R - cttagttttctcagtctgtggttgaaat 
81 60 
Osteocyte  Sost 
F - agagtaccccgagcctcc 
R - agctgtactcggacacgtctttg 
116 60 
Housekeeping 36B4  
F - acggacaggattgacagatt 
R - gccagagtctcgttcgttat 
118 56 
Housekeeping β-Actin 
F - agcaggagtatgacgagtcc 
R - gttttctgcgcaagttaggt 
114 59 
2.1.4d  Common analytics materials and reagents 
Materials / Reagents 
Specifications, 
Catalogue number 
Manufacturer 
RNA isolation 
2-propanol, anhydrous, 
99.5% 
#278475 Sigma Aldrich 
Absolute ethanol #20821.321 VWR 
Chloroform #22707.320 VWR 
Nuclease-free water #AM9938 Ambion 
TRIzol® #15596026 
Invitrogen, Thermo 
Fisher Scientific 
Cryosectioning 
2-methylbutane ≥99%  #M32631 Sigma Aldrich 
Cryomold®, intermediate #4566 Sakura Tissue-Tek® 
Formaldehyde solution #47608 Sigma Aldrich 
Optimum cutting 
temperature compound 
(O.C.T.) 
#4583 Sakura Tissue-Tek® 
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Histological staining 
Alcian blue 8GX #A3157 Sigma Aldrich 
Acetic acid ≥99% #A6283 Sigma Aldrich 
Alizarin red #A5533 Sigma Aldrich 
Acetone #20066.330 VWR 
Ammonium hydroxide  #09859 Sigma Aldrich 
Histochoice clearing agent #H2779 Sigma Aldrich 
PermountTM, Toluene 
solution 
#SP15-100 Fisher Chemical 
2.1.5  Instruments and analytical softwares 
Instrument / Software Purpose Company /  Developer 
Prusa Berlin i3 printer 
3D-Printing of male mold 
for hMSC experiments 
Open source 
4-er magnetic stirrer 
Enable constant stirring 
of spinner flasks during 
hMSC expansion 
VWR 
ABI 7900HT qPCR cycler 
qPCR for mESC 
experiments 
Applied Biosystems, 
Thermo Fisher Scientific 
Agilent Stratagene 
Mx3005P qPCR cycler 
qPCR for hMSC 
experiments 
Agilent Technologies 
Axioskop 2 fluorescence 
microscope 
IF analysis Zeiss 
Autoclave, 3850 ELC 
Sterilising apparatus for 
cell culture 
Systec GmbH 
CO2 incubator for cell 
culture, MCO-9AIC(UV) 
Cell culture Sanyo 
Christ Epsilon 2-4 LSC 
freeze dryer 
aECM scaffold 
lyophilisation 
Christ Epsilon 
E-Spintronic system 
Electrospinning of PCL 
tubing 
Erich Huber GmbH, 
Gerlinden, Germany 
ESEM XL 30 scanning 
electron microscope 
Analysing fiber 
arrangement in PCL 
tubing 
Philips 
EveTM Automatic cell 
counter, NanoEnTek 
For cell counting VWR 
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Instrument / Software Purpose Company /  Developer 
Laboratory centrifuge 
with cooling function,                 
Sr: 50980/1996  
Nucleic acid isolation Sigma 3K30 
Microplate reader, 
Infinite® M200 Pro 
Colormatric analysis Tecan 
Nanodrop 1000 
Nucleic acid 
quantification 
Peqlab 
Nanowizard II atomic 
force microscope system 
(AFM) 
Measuring Young´s 
modulus of mESC-laded 
constructs 
JPK Instruments 
Texture Analyser 
Measuring the elasticity 
of PCL tubing 
Texture Technologies 
Corp, MA 
Ultrasonic cleaner,         
#142-6010 
Cleaning bone and 
vascular bioreactors 
VWR 
vivaCT 75 µCT 
Analysing mineralisation 
of hMSC-laded 
constructs 
SCANCO Medical, 
Brüttisellen, Switzerland 
Cura 14.3 3D-Printing Ultimaker, open source 
GraphPad Prism 6.0 Statistical analysis GraphPad Software 
Illustrator CS5 
Making illustrations used 
in the thesis 
Adobe 
ImageJ Measuring nodule size Wayne Rasband (NIH) 
Primer3 
Designing primers for 
hMSC 
Whitehead Institute for 
Biomedical Research, 
Steve Rozen, Maido 
Remm, Triinu Koressaar 
and Helen Skaletsky 
Scilab 5.5.2 
Mathematical modeling 
of pO2 distribution in 
bone bioreactor 
Scilab Enterprises, open 
source 
SolidWorks 2013 
Designing male mold for 
3D-printing 
Dassault Systèmes 
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2.2  The specifications of the bioreactors 
2.2.1  Vascular bioreactor 
2.2.1a  Estimating the hydrodynamics in the lumen of PCL tubing 
Generally, the hydrodynamic within the lumen of PCL tubing during medium 
perfusion was estimated using Reynolds number (Re) calculated with the formula 
below. The calculated values with the applied bioreactor specifications were 
subsequently compared against the physiological values to check for 
physiological congruity. 
𝑅𝑒 =
𝑄𝐷𝐻
ʋ𝐴
 
Re = Reynolds number (non-dimensional), 
DH  = internal diameter of tubing, 
ʋ  = kinematic viscosity (m2/s) 
Q  = volumetric flow rate (m3/s) 
A  = cross-sectional area of tubing (m2) 
2.2.1b  Deriving poly-ε-caprolactone (PCL) tubing through electrospinning 
This work was done with Dr. Ralf Wyrwa and Dr. Matthias Schnabelrauch 
from INNOVENT-Jena, as a collaborative project for my lab rotation program; to 
learn new lab techniques. The entire procedure for electrospinning was 
completed in Jena, with advices and full supervision. Briefly, electrospinning of 
PCL tubing was performed on the E-Spintronic system (Erich Huber GmbH, 
Gerlinden, Germany). In this instrument, the PCL fiber was dispensed from the 
top and the rotating rod collector was at the bottom (Figure 10), with constant 
maneuver along the x-axis. The parameters applied for electrospinning are 
summarised in Table 2. 
2.2.1c  Characterising the structural properties of PCL tubing 
The elasticity of PCL tubing was measured on a Texture Analyser (Texture 
Technologies Corp, MA). This was performed thrice with three different tubing. 
Further, the fibre distribution and dimension were analysed under a scanning 
electron microscope (SEM). Firstly, the tubing was cut and laid down flat on a 
sample holder with carbon tab, followed by sputtering with carbon in a Balzers 
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SCD 050 coater. Secondary electron images were taken on a Philips ESEM XL 
30 scanning electron microscope at high-vacuum mode with 5 kV acceleration 
voltage and 2000-fold magnification. 
 
 
Table 2: Parameters for electrospinning. 
 
Figure 10: The setup for electrospinning and the end-product. A) Synthesizing 
the PCL tubing through electrospinning. B)  Example of PCL tubing on the rotating 
rod collector after completion of electrospinning procedures. To remove the PCL 
tubing from the collector, a scalpel was used to cut both ends of the tubing (red 
lines). C) Subsequently, the PCL tubing was sprayed with 70% (v/v) ethanol/water to 
detach the tubing from the rod and transferred to an acrylic rod (Ø: 3 mm) for drying 
at RT. D) The end-product used in subsequent experiments. 
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2.2.1d  Bio-functionalising the PCL tubings 
Due to the hydrophobicity of poly-ε-caprolactone, additional functionalisation 
steps were done to facilitate cell adhesion. Five commonly used substrates,        
1) poly-L-lysine,  2) gelatin, 3) COL I only, 4) COL I + sHya1, and                         
5) COL I + sHya3, were investigated. After the PCL tubings were dipped in       
75% (v/v) ethanol/dH2O and air-dried under the UV lamp for 20 mins, the coating 
procedures listed in Table 3 were performed. Subsequently, the PCL tubing was 
cut into smaller pieces at 10 mm in length under sterile conditions and each 
piece was inoculated with HUVEC separately. Cell inoculation was performed in 
a 2.0 mL low binding eppendorf tube for 4 h, each with a single piece of PCL 
tubing, 100,000 HUVEC and 1.5 mL HUVEC medium. The setup was incubated 
at 37 °C with 5% CO2 and inverted every 30 mins to facilitate homogeneous cell 
adhesion on the PCL tubings. Following the cell inoculation procedures, the PCL 
tubings were transferred to a 48-well plate with 1.5 mL medium per well and 
medium change was performed every 3 days. The experiment was done in 
triplicates and the specimens were cultivated at 37 °C with 5% CO2 for 8 days. 
This was followed by analysis with MTT assay and only viable cells will 
accumulate the violet formazan in their cytoplasm. Through the accumulated 
stain, the distribution of HUVEC on the PCL tubing was documented. 
Table 3: The coating procedures of different substrates on the PCL tubings. 
Substrates 
(Concentration) 
Procedures 
Poly-L-lysine  
(0.1 mg/mL in DPBS) 
 Dilute the lyophilised powder (5 mg) in 50 mL sterile 
DPBS at RT to derive the working solution           
(0.1 mg/mL). 
 Place the entire PCL tubing in a 15 mL conical 
centrifuge tube and submerge the PCL tubing in   
11 mL working solution. 
 Incubate in the cell culture hood at RT for 1 h and 
remove the PCL tubing from the centrifuge tube. 
 Wash the PCL tubing twice with 10 mL cold sterile 
DPBS. 
 Air-dry the PCL tubing on a 100 mm petri dish 
under the cell culture hood for 3 h. 
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 Cut the PCL tubing into smaller pieces (10 mm per 
piece) with a pair of scissors and equilibrate these 
specimens together in 10 mL serum-free HUVEC 
growth medium at 37 °C, 5% CO2 for at least 2 h, 
before the cell inoculation procedures. 
Gelatin  
(1.0 mg/mL in DPBS) 
 Warm the gelatin stock solution (1 g/mL) in a 37°C 
waterbath for 15 mins. 
 Dilute the stock solution (5 mL) in 45 mL sterile 
DPBS at RT to derive the working solution             
(1 mg/mL). 
 Place the PCL tubing in a 15 mL conical centrifuge 
tube and submerge the tubing in 11 mL working 
solution. 
 Incubate at 37 °C for 1 h and remove the PCL 
tubing from the centrifuge tube. 
 Wash the PCL tubing twice with 10 mL cold sterile 
DPBS (4 °C) 
 Air-dry the PCL tubing on a 100 mm petri dish 
under the cell culture hood for 3 h. 
 Cut the PCL tubing into smaller pieces (10 mm per 
piece) with a pair of scissors and equilibrate these 
specimens together in 10 mL serum-free HUVEC 
growth medium at 37 °C, 5% CO2 for at least 2 h, 
before cell inoculation. 
a) COL I (1 mg/mL) 
 
 
 
 
 
 
b) COL I (1 mg/mL) 
+  
sHya1 (1 mg/mL) 
 
 
 
 Prepare the working solution for each collagen 
substrate as follows: 
a) 1 part COL I (2 mg/mL in 10 mM acetic acid) + 
1 part 60 mM phosphate buffer, 
b) 1 part COL I (2 mg/mL in 10 mM acetic acid) + 
1 part 2 mg/mL sHya1 in 60 mM phosphate 
buffer, 
c) 1 part COL I (2 mg/mL in 10 mM acetic acid) + 
1 part 2 mg/mL sHya3 in 60 mM phosphate 
buffer. 
 Place the PCL tubing in a 15 mL conical centrifuge 
tube and submerge in 11 mL working solution. 
 Incubate at 37 °C for 1 h and remove the PCL tubing 
from the centrifuge tube. 
 Wash the PCL tubing twice with 10 mL cold sterile 
DPBS (4 °C). 
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c) COL I 
+  
sHya3 (1 mg/mL) 
 Air-dry the PCL tubing on a 100 mm petri dish under 
the cell culture hood for 3 h. 
 Cut the PCL tubing into smaller pieces (10 mm per 
piece) with a pair of scissors and equilibrate these 
specimens together in 10 mL serum-free HUVEC 
growth medium at 37 °C, 5% CO2 for at least 2 h, 
before the cell inoculation procedures. 
* 60mM Phosphate buffer = 50.15 mM Na2HPO4 + 11.17 mM KH2PO4 
2.2.1e  Determining the optimal collagen coating  
Instead of the PCL tubing, round fleece (Ø: 12mm) of similar thickness and 
fibre diameter was used to optimise the coating procedures. The same coating 
procedures for a) COL I (1 mg/mL) described in Table 3 were performed and 
collagen concentrations at 0.1 mg/mL, 0.5 mg/mL and 1.0 mg/mL were 
investigated. With the same collagen concentrations, a second set of specimens 
with an additional freeze-drying step to further stabilise the collagen coating were 
prepared. The procedures to prepare these specimens are summarised below 
and the parameters for freeze-drying are listed in Table 4. 
Procedures 
 Place each PCL fleece in a 24-well plate. Spray 75% ethanol into each 
well and air-dry under the UV lamp for 20 mins to sterilise the fleece. 
 Prepare the working solution for each collagen substrate as follows: 
a) 1 part COL I (2 mg/mL in 10 mM acetic acid) + 1 part 60 mM 
phosphate buffer (final collagen concentration: 1.0 mg/mL), 
b) 1 part COL I (1 mg/mL in 10 mM acetic acid) + 1 part 60 mM 
phosphate buffer (final collagen concentration: 0.5 mg/mL), 
c) 1 part COL I (0.2 mg/mL in 10 mM acetic acid) + 1 part 60 mM 
phosphate buffer (final collagen concentration: 0.1 mg/mL). 
 Add 1.5 mL working solution with different COL I concentrations to the 
designated well that contains a PCL fleece.  
 Incubate at 37 °C for 1 h and aspirate the collagen working solution. 
 Wash each fleece twice with 10 mL cold sterile DPBS (4 °C), followed by 
freezing at -80 °C overnight. For the specimens that do not require 
freeze-drying, equilibration in 1.5 mL serum-free HUVEC growth 
medium at 37 °C, 5% CO2 was performed. 
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 Place the plates in Epsilon Christ Epsilon 2-4 LSC for freeze-drying and 
apply Program 7. The parameters for this program are listed in Table 4. 
 After freeze-drying, transfer the PCL fleece to a new 24-well plate for 
HUVEC inoculation. Equilibrate each piece of PCL fleece in 1.5 mL 
serum-free HUVEC growth medium at 37 °C, 5% CO2 for at least 2 h, 
before cell inoculation procedures. 
 
Table 4: Parameters for freeze-drying. 
# Procedures Temperature 
(°C) 
Duration  
(mins) 
Atmospheric 
pressure (atm) 
1 Equilibration 4 - 1 
2 Freeze -10 20 1 
3 Dry -10 105 1.030 
4 Dry 20 150 1.030 
5 Dry 20 12 h 1.030 
6 After dry 20 10 0.0010 
7 After dry 30 50 0.0010 
8 After dry 30 120 0.0010 
After equilibration, the serum-free medium was aspirated and 50,000 HUVEC 
were inoculated directly on each scaffold. The circular fleece were cultivated in 
1.5 mL HUVEC medium at 37 °C, 5% CO2 and three samples from each 
condition were retrieved at 24 h, 7 days and 14 days post-inoculation. The 
distribution of HUVEC and quantity of cells on each specimen was determined 
through MTT assay. 
2.2.2  Spinner flasks 
2.2.2a  Determining the hydrodynamics 
The maximum fluid shear stress exerted on microcarriers in the spinner flask 
was calculated with the list of formula below (99,100). The DMEM cell culture 
medium was considered a Newtonian fluid and the maximum shear stress was 
calculated by: 
𝝉𝑴𝑨𝑿 = 𝟓. 𝟑𝟑𝝆(𝝐ʋ)
𝟏 𝟐⁄                                                   [𝟏]       
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with τMAX representing the maximum shear stress (Pa), ρ is the medium density 
(kg/m3), vis the kinematic viscosity (m2/s) and ϵ is the power dissipation per unit 
mass that is calculated by:  
             𝝐 =  𝑷
𝑽𝑳𝝆
                                                                    [𝟐] 
withVL being the working volume (m
3) within the 250 mL spinner flask and P is 
the power input (W) and calculated by: 
𝑷 = 𝑵𝑷(𝑵
𝟑)(𝑫𝒊
𝟓)𝝆                                                       [𝟑]                                                     
with N being the agitation rate (rotation per second), Di is the impeller diameter 
(m), and NP is the dimensionless power number, as described by Nagata 
correlation (101).  
𝑵𝑷 =
𝑷
𝑵𝟑𝑫𝒊
𝟓𝝆
=  
𝑲𝟏
𝑹𝒆
+  𝑲𝟐 (
𝟏𝟎𝟑+𝟏.𝟐𝑹𝒆𝟎.𝟔𝟔
𝟏𝟎𝟑+𝟑.𝟐𝑹𝒆𝟎.𝟔𝟔
)
𝑲𝟒
                              [𝟒]  
with                        𝐾1 = 14 + (
𝑊
𝐷𝑇
) [670 (
𝐷𝑖
𝐷𝑇
− 0.6)
2
+ 185]  
𝐾2 = 10
𝐾3                              
𝐾3 = 1.3 − 4 (
𝑊
𝐷𝑇
− 0.5)
2
− 1.14 (
𝐷𝑖
𝐷𝑇
)  
𝐾4 = 1.1 + 4 (
𝑊
𝐷𝑇
) − 2.5 (
𝐷𝑖
𝐷𝑇
− 0.5)
2
− 7 (
𝑊
𝐷𝑇
)
4
  
Briefly, the power number relates the resistance force to the inertia force 
generated during stirring of a fluid in the spinner flask. The variable is dependent 
on the dimensions of vessel and impeller. The correlation can be further 
expanded to include the stir rate by introducing Reynolds number (Re) to the 
equation. The Re is typically used to describe the hydrodynamics generated by 
an impeller of defined dimension at a specific stir rate. It is a ratio of inertial force 
to the viscous force and is calculated by: 
𝑹𝒆 =  
𝑵(𝑫𝒊
𝟐)
ʋ
                                                             [𝟓]                                               
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The medium density of DMEM (ρ) (99) and kinematic viscosity of DMEM (ʋ) 
(102) were taken reference from previous studies and kept constant. The 
dimensions of the 250 mL flask, the different impellers and parameters applied in 
this thesis for up-scaling hMSC expansion are summarised in Figure 11. 
Additionally, the optimal parameters established by Megan et. al. (86) in the      
125 mL spinner flask were included for comparison. 
 
 
2.2.2b  Modified impellers and their effects on hydrodynamics and hMSC 
expansion 
Unlike the 125 mL flasks attached with a stir rod impeller, the default impeller 
in the 250 mL flasks (Figure 12A) came with a short stir rod and a wing attached 
(Figure 12B). Hence, additional modifications were made to the 250 mL flask 
impeller to derive a similar setup as the 125 mL spinner flask for comparison 
(Figure 12C, 12D). The flow pattern of microcarriers in the 250 mL spinner flask 
with different impellers was studied visually or taken reference from previous 
literatures. In previous studies, mathematical models on the flow behaviour of 
microcarriers in different spinner flasks and at variable stir rates was 
accomplished with a high-speed camera and a computational fluid dynamic (CFD) 
software, Flow3D (100,103–105). The results from these findings are 
summarised in Chapter 3.1.2. Furthermore, the effects of two impellers       
Figure 11: Parameters used to determine the Reynolds number and fluid shear 
stress: 250 mL versus 125 mL spinner flasks. The parameters required for the 
calculations include: ρ = medium density of DMEM, ʋ = kinematic viscosity of DMEM, 
VL = working volume, DT = vessel diameter, Di = impeller diameter and wi = impeller 
width, with the units indicated. 
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(Figure 12B and 12D) on hMSC morphology after expansion in each spinner 
flask were also investigated. Briefly, 1.00125 x 106 hMSC were inoculated on 
0.25 g Cultispher®-S beads in serum-free inoculation medium, as described in 
Chapter 2.2.2c. A constant stir rate (90 rpm) was applied for 12 days and            
3 x 2 mL aliquots were harvested from each spinner flask on 1 day, 6 days and 
12 days post-inoculation for cell counting procedures. Additionally, the harvested 
hMSC were cultivated on a 12-well cell culture plate with 3 mL HUVEC medium 
per specimen at 37 °C, 5% CO2 overnight and the cell morphology was 
documented on the Axiovert40 light microscope. 
 
2.2.2c  Procedures for hMSC inoculation on Cultispher®-S microcarrier beads, 
cultivation parameters and harvesting hMSC from beads 
Materials:  
human bone marrow-derived mesenchymal stem cells: Passage Phase (PP) 1-5 
Fetal bovine serum (FBS): Lot: #740B (Biochrom) 
DMEM: +1.0 g/L D-glucose, + 3.7 g/L NaHCO3 (Biochrom) 
Figure 12: Modifications made to the impeller in a 250 mL spinner flask. A) 
Spinner flasks in incubator and the dimensions of default impeller with wing from the 
manufacturer, NDS Technologies. B) Default impeller with wing, C) Default impeller 
without wing, D) Modified impeller with extra attachments for extension in length. 
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Conditions:  
Inoculation medium:  98 mL serum-free DMEM with 1% Pen/Strep and                 
1% L-glutamine  
Inoculation time:   8 h (3 mins stirring @ 90 rpm and 27 mins pause), 
    37 °C with 5% CO2  
Expansion medium:  11 mL FBS #740 + 139 mL DMEM with 10% FBS,          
1% Pen/Strep and 1% L-glutamine 
 
Procedures:  
Preparation of Cultispher®-S beads  (Sigma Aldrich, #M9043) 
1. Hydrate 0.25 g beads with 200 mL dPBS in glass bottle pre-coated with 
SigmaCote® at room temperature overnight. 
2. Autoclave using program 6 for liquid samples. Store in 4 °C for later use. 
3. Prior to cell seeding, pipette the beads from the glass bottle into two cell 
strainers placed over 50 mL centrifuge tube (~0.125 g per cell strainer). Cell 
strainer 70 µm nylon (Falcon). 
4. Wash the beads twice with sterile dPBS (25 mL each time) !!Do this slowly. 
5. Transfer all the beads to a spinner flask by washing the cell strainers over 
the spinner flask with 100 mL of inoculation media. 
6. Equilibrate the beads at 37 °C, 5% CO2 for 3 h with stirring at 100 rpm to 
achieve the inoculation medium, pH 7.6. 
Cell inoculation 
1. Thaw the hMSC, if removed directly from liquid nitrogen. Should the hMSC 
are primary culture or already on traditional cultivation vessels, trypsinise the 
hMSC at 37 °C with 0.05% trypsin/0.02% EDTA, and centrifuge at 1500 rpm 
for 5 mins. Discard the supernatant and resuspend the cell pellet in 5 mL 
serum-free DMEM media. Count the cells on automatic cell counter.  
2. The seeding density should be 267 cells/cm2 and this is equivalent to       
1.00125 x 106 cells/0.25 g beads. The cell number required was calculated as 
shown below: 
Surface area of Cultispher®-S: 15000 cm2/g 
Surface area of 0.25 g Cultispher®-S beads: 3750 cm2 
Cell number required: 3750 cm2 x 267 cells/cm2 = 1 001 250 cells 
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3. After cell counting, the calculated volume of cell suspension was inoculated 
into a spinner flask containing 100 mL of inoculation medium, pH 7.6. 
4. Proceed on with the intermittent stirring protocol for cell inoculation.  
(8 h: 3 mins stirring @ 90 rpm, followed by 27 mins pause) at 37 °C, 5% CO2. 
5. At the end, add in appropriate volume of serum media (stated above) for cell 
cultivation, the final medium volume should be 250 mL. 
6. The culture was maintained with stirring at 90 rpm for a total of 12 days and 
medium change was performed once after 6 days. 
Medium change: 
1. The flask was allowed to rest for 2 mins in the cell culture hood, allowing the 
beads to sink to the bottom. 
2. 225 mL of old medium was aspirated through vacuum suction and replaced 
with equal volume of fresh expansion medium 
Harvesting hMSC from beads: 
1. Remove the flask from the incubator and let rest for 2 mins in the hood to 
allow the beads to sink to the bottom. 
2. Aspirate about 225 mL medium and pass the remaining medium with beads 
through the cell strainer. Split the beads suspension equally between two cell 
strainers. 
3. Wash the beads twice with warm sterile dPBS and transfer all the beads to a 
single 50 mL centrifuge tube with 40 mL of 0.05% trypsin/0.02% EDTA. Next, 
incubate the centrifuge tube in the water bath for 15 mins. Keep the beads in 
suspension by inverting the centrifuge tube every 2-3 mins; to increase 
exposure of beads to trypsin and facilitate the hMSC to dislodge from the 
beads. 
4. After incubation, pass the beads through the cell strainers and neutralize the 
trypsin by adding 2.5 mL FBS to the cell suspension in each centrifuge tube. 
Retrieve the cell suspension with a 25 mL disposable pipette and pass the 
entire volume through the cell strainer two more times. This was done to 
ensure all the hMSC were dislodged from the beads and collected in the cell 
suspension. 
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5. Centrifuge the cell suspension at 1500 rpm for 5 mins. Discard the 
supernatant. Resuspend the cell pellet in 10 mL of serum media for counting. 
These hMSC could be applied directly in the bone bioreactor or further 
expanded in cell culture flasks. 
Cell counting: 
1. Mix 10 µL of cell suspension with 10 µL of trypan blue solution (count 
solution). 
2. Pipette 10 µL of count solution to a well on the EnTek cell counting chip      
(C-chip). 
3. Insert the C-chip into the cell counter and apply the designated program for 
HUVEC to start counting. 
2.2.2d  Investigating the effects of FBS supplementation in the inoculation 
medium 
The same procedures for hMSC inoculation on Cultispher® are performed 
(Chapter 2.2.2c). However, a second set of inoculation medium was 
supplemented with 10% FBS and the beads (3 x 2 mL aliquots) were harvested 
1 day post-inoculation. The hMSC-laded beads were fixed in cold 4% (v/v) 
formaldehyde/DPBS for 10 mins and washed twice with DPBS. Subsequently, 
the beads were stained in the dark with DAPI:DPBS (1:4000) for 10 mins at RT, 
followed by analysis under the fluorescence microscope with the blue filter      
(350 nm). The effects of FBS supplementation on hMSC inoculation was 
determined based on distribution of DAPI-positive cells. The remaining beads in 
the spinner flask were further cultivated with stirring at 90 rpm for 12 days; to 
elucidate the effects of inoculation medium with 10% FBS on cell proliferation. 
2.2.2e  Increasing the yield of hMSC from 250 mL spinner flask with rod impeller 
After identifying the rod impeller being a more proficient setup for hMSC 
expansion, additional experiments were performed to increase the yield of hMSC 
derived from this setup. Generally, the same hMSC inoculation procedures with 
serum-free inoculation medium were applied (Chapter 2.2.2c). However, the 
hMSC number was increased by two-folds and 2 x 106 hMSC were inoculated on 
0.25 g Cultispher®-S beads. The hMSC were cultivated with stirring at 90 rpm 
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and at 37 °C, 5% CO2 for 12 days. Corresponding static culture without 
microcarriers was also set up on conventional T175 cell culture flasks as control. 
The number of hMSC derived from respective approach was tabulated and the 
results from additional experiments that applied 1 x 106 hMSC on 0.25 g beads 
was also included for comparison. 
2.2.2f. Assessing the multipotency of hMSC after expansion in spinner flask 
The hMSC were retrieved from expanded culture applied in each set of bone 
bioreactor experiments and the hMSC from three donors were investigated 
(hMSC #282, #540, #575). As control, hMSC expanded on conventional T175 
flask for the same duration were used. Generally, two standard approaches were 
applied to assess the multipotency of hMSC after expansion in spinner flasks:  
1) Gene expression of CD90 and Sox2 through qPCR. 
(See Chapter 2.1.4c for primer sequences, and Chapter 2.5.4c 
and g for RNA isolation and qPCR procedures); 
2) Standard differentiation assays (chondrogenesis and osteogenesis). 
The procedures for each differentiation assay are described in Table 5. The 
chondrogenic differentiated hMSC were stained with alcian blue to detect 
glycosaminoglycan and the osteogenic differentiated hMSC were stained with 
alizarin red to detect calcium accumulation (See Chapter 2.4.3d for the staining 
procedures).  
Table 5: Procedures for differentiation assays. (Different from bioreactor culture) 
Chondrogenic differentiation Osteogenic differentiation 
 Standard micromass culture was 
applied. This was done by 
preparing a cell suspension of 10 x 
106 hMSC/mL in DMEM with 10% 
FBS. 
 On a 6 well-plate, droplets (12.5 
µL) of cell suspension were derived 
with care in each well. Ensure the 
droplets are widely apart when 
placed in a single well or a single 
droplet can also be derived in a 
well. 
 Standard monolayer culture was 
applied. This was done by 
inoculating 1 x 104 hMSC in each 
well on a 24-well plate. 
 Each well should contain 2 mL 
osteogenic differentiation medium. 
 Maintain the differentiation culture 
at 37 °C, 5% for 28 days, with 
medium change every 3 days. 
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 Incubate the droplets at 37 °C, 5% 
for 3 h to allow establishment of the 
micromass. 
 Add 5 mL of chondrogenic 
differentiation medium directly to 
each well. Add the medium 
slowly along the edge of the well. 
 Maintain the differentiation culture 
at 37 °C, 5% for 28 days, with 
medium change every 3 days. 
 Upon completion, aspirate the 
medium and prepare the 
differentiated cells for qPCR 
analysis and alcian blue staining 
procedures. 
Chondrogenic differentiation medium 
1. DMEM, with 1.0 g/L glucose,  
2. 10% FBS, 
3. 1% Pen/Strep, 
4. 10-7 M dex,  
5. 50 μg L (+) ascorbic acid,  
6. 10 ng/mL recombinant human 
TGF-β3 
7. 1x ITS premix (final concentrations: 
6.25 μg/mL bovine insulin, 
6.25 μg/mL transferrin, 6.25 μg/mL 
selenous acid, 5.33 μg/mL linoleic 
acid and 1.25 mg/mL BSA). 
 Upon completion, aspirate the 
medium and prepare the 
differentiated cells for qPCR 
analysis and alizarin red staining 
procedures. 
 
 
 
 
 
 
 
 
 
 
 
Osteogenic differentiation medium 
1. DMEM, with 1.0 g/L glucose,  
2. 10% FBS,  
3. 1% Pen/Strep, 
4. 10-9 M dex, 
5. 50 μg L (+) ascorbic acid, 
6. 10 mM ß-GP 
 
 
2.2.3  Bone bioreactor 
2.2.3a  pO2 distribution in bone bioreactor (Based on M.Sc. Thesis) 
The pO2 was measured in real-time with fibre-optic probes (OxyLite
TM, Oxford 
Optronix) and the configurations are described in Figure 13. The general setup of 
the bone bioreactor is also included (Figure 13, right), and additional details can 
be found in publication (53). Briefly, the measurements were performed over    
36 h at three distinct locations of the cultivation platform that contains the 
engineered constructs, at 12 h interval. The positions of the probes are indicated 
by black dots (Figure 13, left). Based on these experimentally derived results, a 
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mathematical model was built to describe the evolution of pO2 distribution in the 
bioreactor (Chapter 2.2.3b). This is also done to elucidate the causal factors that 
are responsible for the measured pO2 gradient and allow more precise control in 
future experiments. 
2.2.3b  Mathematical modelling of pO2 evolution in the bone bioreactor 
The bone bioreactor was modelled using a finite element approach and 
COMSOL Multiphysics was adopted to do the calculations. The incompressible 
Navier-Stokes equations were used to describe the hydrodynamics of cell culture 
medium perfusing through the bioreactor. Medium inflow was assumed equally 
distributed over the top surface, which reduces the size of the model to ¼ due to 
symmetry effects. The pressure at the opposing outlet was set to zero and the 
convective flux was calculated from the stationary velocity field. The diffusion 
coefficient of oxygen (O2) in cell culture, at 37 °C was assumed as DO2 = 1.71 x 
10-10 m2/s. The same value was also applied for the rest of the bioreactor, given 
the similarities in diffusion characteristics of O2 through agarose and culture 
medium (106). To simulate the experimental conditions, the starting pO2 in 
bioreactor and inflowing medium was assigned as 100 Torr; given that the 
measured mean pO2 in the medium reservoir was 99.65 ± 1.11 Torr after 36 h. 
The consumption rate of oxygen per cell (RO2) is described by the Michaelis-
Menten equation: 
RO2 = Vmax · pO2/(K0.5 + pO2), 
This equation limits the maximum consumption rate (Vmax), at low partial oxygen 
pressure (pO2) through a half-consumption parameter (K0.5). These parameters 
were unknown for mESC. Hence, the experimental values for human bone 
marrow stromal cells were applied here instead (107,108):  
Vmax = 7.91·10
-18 mol/(cell · s) ; K0.5 = 5.6 Torr, 
Nonetheless, these values were expected to be similar among differentiating 
stem cells and should not affect the accuracy of the mathematical model. 
Through interpretations of RO2 in relation to the dimensions of the cultivation 
platform, a cell per volume ratio was determined and oxygen development in the 
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bioreactor over time was modelled. The oxygen development was studied in 
three parts: (i) 30 mins without flow, (ii) 38 h with flow, and (iii) constant flow over 
infinite time. The sequence of oxygen development was formulated based on 
actual experimental scenario. In (i), it simulates the period from encapsulating 
cell-laded constructs in the agarose bedding, until bioreactor being connected to 
a peristaltic pump. In (ii), it includes the duration essential to fill up the bioreactor 
with medium and achieve stable medium perfusion (t = -2 h), followed by the 
time points that the pO2 was measured over 36 h (t = 0 h, 12 h, 24 h, 36 h). In 
(iii), it would be a predictive simulation for pO2 distribution over infinite time         
(t = ∞), with the assumption that the cell continued to propagate in stable state 
and rapid cell death or proliferation did not occur over the course of cultivation. 
 
 
Figure 13: The biomimetic perfusion bone bioreactor. (left) Schematic of 
cultivation platforms and hollow channels arrangement in 1.5% agarose bedding. 
Two platforms were casted to derive collateral samples for multiple analyses and 
alongside are the hollow channels for medium perfusion. (right) The perfusion 
bioreactor setup during cell culture experiments in an incubator. The medium 
reservoirs were specifically positioned 15-20 cm above the bioreactors to ensure the 
entire bioreactor would be filled with medium and this was further enhanced by tilting 
the bioreactors at approximately 30° angle. 
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2.3  Setting up the vascular bioreactor and cell culture experiments 
2.3.1  Setting up the vascular bioreactor 
2.3.1a  Medium reservoir 
Parts Specifications Illustrations 
#1 Flask 
 
 
 
 
#2 Inlet (right) 
and outlet (left) 
tubings; 
secured with 
silicone 
Sarstedt 75 cm2 cell culture 
flask with Polystyrene (PS) 
w/HDPE cap 
 
Tygon® ND100-65 medical 
tubing*, OD: 6.35 mm,      
ID: 3.18 mm, wall:1.59 mm 
Long: 220 mm 
Short: 150 mm, tip of tubing 
hanging at the 160 mL mark 
of flask. 
 
* Tubings were secured with 
silicone  
2.3.1b  Approach A: Agarose bedding with hollow channel 
Parts Specifications Illustrations 
#3 Medium 
Inlet (Long) /    
Medium Outlet 
(Short) 
 
 
 
Polycarbonate,  
See Appendix 1 for exact 
dimensions. 
 
O-ring (Black): ethylene 
propylene diene monomer 
(EPDM sulphur-cured).  
In the rod                        
OD: 25 mm,  
thickness: 3.5 mm 
On tube attachments 
OD: 14 mm,            
thickness: 2.5 mm 
 
#1 
#2 
#3 
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Parts Specifications Illustrations 
#4 Stopper for 
casting of 
agarose 
bedding 
 
 
 
Polycarbonate,  
See schematics in Appendix 
1 for exact dimensions. 
 
O-ring (Black): ethylene 
propylene diene monomer 
(EPDM sulphur-cured).  
On stopper                      
OD: 14 mm,                 
thickness: 2.5 mm 
 
#5 Stainless 
steel mold 
 
 
 
#6  
Bioreactor 
body 
 
Stainless steel rod grade 
316   Ø: 6 mm 
 
 
 
Polycarbonate                   
OD: 20 mm,  
ID: 16 mm,                     
length: 107.8 mm 
 
See Appendix 1 for exact 
dimensions. 
 
 
#4 
#5 
#6 
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Parts Specifications Illustrations 
#7 Casted 
agarose 
bedding with 
hollow channel 
(after the 
stainless steel 
mold is 
removed) 
1.5% (w/v) Ultra PureTM 
agarose (Invitrogen)/DPBS 
 
#8 PCL tubing  
 
 
 
#9 PVC 
adapter 
Poly-ε-caprolactone 
OD: 6 mm, ID: 5 mm,  
length: 45 mm 
 
Poly-vinyl-chloride (PVC) 
OD: 5 mm, ID: 2.79 mm,  
length: 25 mm 
 
Insert the prepared tubing 
through the agarose bedding 
(#7) and attach the other 
end to the Inlet tube 
attachments. 
 
Finally, enclose the setup 
with the Rod (Inlet). 
 
#7 
#8 
#9 
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#10  
Tension 
controllers 
 
(Threaded for 
tightening and 
loosening) 
Polycarbonate, 
See Appendix 1 for exact 
dimensions. 
 
 
 
Adjust the tension of PCL 
tubing by rotating the 
tension controllers at the 
ends.  
 
2.3.1c  Approach B: Complete encapsulation of PCL tubing in agarose bedding 
Parts Specifications Illustrations 
#6 Bioreactor 
body 
 
 
#8 PCL tubing  
 
 
 
#9 PVC 
adapter 
Polycarbonate 
OD: 20 mm, ID: 16 mm,    
length: 107.8 mm 
 
Poly-ε-caprolactone 
OD: 6 mm, ID: 5 mm,  
length: 45 mm 
 
 
Poly-vinyl-chloride (PVC) 
OD: 5 mm, ID: 2.79 mm,  
length: 25 mm 
 
 
#8, #9 
#6 
#10 
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#11  
1.5% agarose/ 
DPBS bedding 
PCL/PVC tubing is 
completely encapsulated 
within the agarose.  
 
Direct addition of 1.5% 
agarose to achieve complete 
encapsulation. 
Note: Adjustments to the 
tension of PCL tubing will not 
be possible at this point.  
 
 
Enclose the bioreactor by 
inserting the Inlet rod 
through the tubing 
attachment. Tighten with the 
tension controllers. 
 
#12 Bioreactor 
casing* 
 
Polycarbonate 
 
OD: 40 mm, ID: 34 mm,    
length: 200 mm 
 
*Anchoring point for sensors 
to be applied in future 
experiments.  
 
  
#12 
#11 
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2.3.1d  Final assembly of vascular bioreactors in the incubator 
Parts Specifications Illustrations 
#13 Stackable 
housing 
 
 
Polycarbonate 
 
length:137 mm 
width: 115 mm 
height: 111 mm 
 
#14 
Multichannel 
peristaltic 
pump 
 
#15  
Peristaltic 
pump tubing 
 
 
#16 
Polypropylene 
straight tubing 
connectors 
 
#17 
Connecting 
tubings from 
bioreactor to 
pump 
 
ISMATEC ® High Precision 
Multichannel Dispenser, 
ISM932 
 
Tygon® LMT-55  
Color code: purple/white,  
ID: 2.79 mm 
 
 
 
VWR®, Size: 3-5 mm 
 
 
 
Tygon® ND100-65 medical 
tubing,  
OD: 6.4 mm, ID: 3.2 mm, 
wall: 1.59 mm,  
length: 600 mm x 3 pieces 
 
 
#13 
#14-16 
#17 
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2.3.1e  Step-by-step descriptions to set up the vascular bioreactor  
1. Unless specified otherwise, all the hardware used in this set of experiments 
were sterilised with ultrasonic cleaner for 30 mins, followed by autoclaving; 
before the cell culture procedures.   
2. Prepare the medium reservoir by drilling two 6.5 mm holes on the top-side of 
a T75 flask (#1) with a hand drill. Insert the long inlet tubing until the bottom of 
the flask and hang the short outlet tubing at the 160 mL mark, to allow 
dripping of medium and enhance re-oxygenation of medium (#2). 
Subsequently, secure the tubings with silicone and air-dry for at least 12 h. 
Thereafter, wash each flask with 50 mL of sterile DPBS twice, followed by 
sterilisation under UV lamp for 20 mins. 
3. As shown by #3, the longer tube attachment was paired with the longer rod 
and vice versa. Further, the Outlet tube attachment had a protruded edge 
(red arrow) and could not go through the Outlet rod. Hence, this would be the 
“fixed end” of the bioreactor and minimal adjustments should be made when 
tightening the PCL tubing later; so as to prevent medium leakage. In contrast, 
the Inlet tube attachment had no protruded edge and could go through the 
Inlet rod. This would be the “flexible end” that enables attachment of 
PCL/PVC tubing (#8 / #9) and to control the tension of PCL tubing in the 
bioreactor. 
4. The agarose bedding could be set up in two ways: A) with lumen for 
additional cell layers in future experiments (Approach A), and B) complete 
encapsulation of PCL/PVC tubing within the agarose bedding; used only for 
HUVEC mono-culture (Approach B). 
5. Brief descriptions for building each setup are summarised below: 
With lumen in agarose bedding 
(Approach A, Chapter 2.2.2b) 
Complete encapsulation in agarose 
bedding (Approach B, Chapter 
2.2.2c) 
a) Attach the stopper to the Outlet 
rod, #4, followed by the stainless 
steel rod (#5) and the bioreactor 
body (#6). 
 
a) Assemble the Outlet rod and Outlet 
tube attachment (#3), followed by 
sealing the end with parafilm to 
prevent leakage of agarose gel 
during the casting process. 
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b) Prepare the 1.5% agarose 
bedding by melting 1.5 g agarose 
powder in DPBS (100 mL) in a 
microwave oven. Cool the 
agarose under a running tap and 
add 7 mL to each bioreactor.  
c) After the agarose gel hardened, 
remove the stainless steel rod and 
the stopper.  
d) Attach the PCL/PVC tubing (#8, 
#9) onto the Outlet tube 
attachment and pass the tubing 
through the lumen (#7) in the 
agarose bedding, until the 
protruded edge stops further 
forward movement. 
e) Attach the Inlet tube attachment to 
the PCL/PVC tubing, and pass 
through the Inlet rod. 
Subsequently, attach the Inlet rod 
on the bioreactor body (#6). 
f) Using the tension controller (#10), 
straighten the PCL/PVC tubing to 
facilitate constant laminar fluid 
flow through the lumen (Note: 
Start with the inlet end first). 
Further, the tension of the tubing 
can be controlled by loosening or 
tightening the tension controller. 
b) Attach the PCL/PVC tubing (#8, #9) 
onto the Outlet assembly from 
above, followed by attachment of 
bioreactor body (#6) to the 
assembly. To prevent the PCL/PVC 
tubing from collapsing, dip the 
tubing first in 1.5% agarose/DPBS 
and air-dry the tubing. Repeat this 
step 2--3 times before attaching the 
PCL/PVC tubing onto the Outlet 
assembly that is placed on a 
centrifuge tube rack for stability. 
c) Prepare the 1.5% agarose gel in a 
microwave oven and cool the gel 
under a running tap. Add 8 mL to 
each bioreactor (#11). 
d) Before the agarose harden, attach 
the PCL/PVC tubing onto the Inlet 
tube attachment, followed by 
passing the Inlet rod through and 
fixed onto the bioreactor body. 
(Note: the PCL/PVC tubing can still 
be straightened with the tension 
controller (#10) at this point and 
control the tubing tension from the 
inlet end first). 
e) Wait for the agarose gel to harden 
before proceeding further. 
6. Once the bioreactor was assembled, it was secured in the bioreactor casing 
(#12) for extra stability. Furthermore, the casing was also designed to 
become an anchoring point for oxygen probes and glucose/temperature 
sensors; to be applied in future experiments. 
7. To facilitate ease of handling in the incubator, the bioreactors with casing 
were secured in a stackable housing. Based on the size of the experiment, 
the housing could be stacked up to accommodate different number of 
bioreactors. In this thesis, only up to 4 bioreactors were used in each set of 
experiments. 
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8. Prepare the peristaltic pump (#14-16) and fill the medium reservoir with        
40 mL of HUVEC medium. Connect all the parts in the incubator and ensure 
that the medium reservoirs stand at least 10 cm above the bioreactor (#17). 
This ensured sufficient hydraulic back-pressure would be generated and the 
bioreactor completely filled with medium.  
9. Perform the cell seeding procedures and perfuse medium through the lumen 
of PCL/PVC tubing at designated perfusion rate stated in Chapter 2.2.7. 
10. Perform medium change every 5 days simply by detaching the outlet tubing 
to drain the old medium from the bioreactor to the reservoir. Subsequently, 
replace the entire medium reservoir with a new flask that contain fresh 
HUVEC growth medium. 
2.3.2  Functionalising the PCL tubing with 0.5 mg/mL rat-tail COL I 
The 0.5 mg/mL working solution [1 part COL I (1 mg/mL in 10 mM acetic acid) 
+ 1 part 60 mM phosphate buffer] was prepared and kept always on ice to 
prevent polymerisation of collagen gel. Further, the collagen mix was prepared 
immediately before the coating procedures. Next, the PCL tubings were dipped 
in 75% (v/v) ethanol/dH2O and air dried under an UV lamp in the cell culture 
hood for 10 mins. This was done to enhance the sterilisation and drying process. 
Subsequently in a 15 mL conical centrifuge tube, 1 mL collagen mix per cm of 
PCL tubing was applied (11 mL was used for coating here). The entire tubing 
was submerged in the collagen mix, with bubbles in the lumen removed with a 
glass pipette. The PCL tubing was incubated at 37 °C for 24 h to allow 
polymerisation of collagen mix. Next, the coated PCL tubing was transferred to a 
petri-dish and washed twice with 10 mL cold sterile DPBS; followed by air drying 
in cell culture hood for 3 h at RT. After drying, PVC adaptors were glued to both 
ends of the functionalized PCL tubing with instant adhesive (Chapter 2.2.5b). 
The entire PCL tubular setup (PCL tubing + PVC adapter) was equilibrated in 
serum-free HUVEC medium at 37 °C, 5% CO2 for 2 h, before the procedures for 
HUVEC inoculation were carried out. 
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2.3.3  HUVEC inoculation and cultivation procedures, Approach A 
Briefly, a customised cell inoculation apparatus (Figure 14) was applied to 
increase the exposure of HUVEC to the surface of PCL tubing and maximise cell 
adhesion. In each apparatus, an equilibrated PCL tubular setup was held within 
the hollow channel casted in 1.5% agarose/DPBS bedding. Subsequently, 1.5 x 
106 HUVEC were suspended in 1 mL warm HUVEC medium and pipetted slowly 
through the lumen of the PCL tubular setup. An additional 2 mL warm HUVEC 
medium was added directly to the apparatus, followed by incubation at 37 °C, 5% 
CO2 for 12-16 h. In the first 4 h, the cap of the apparatus was tightened and the 
entire setup was inverted every 30 mins to facilitate cell mixing and homogenous 
cell adhesion on the PCL tubing.  
 
As described in Chapter 2.3.1b, the agarose bedding within the vascular 
bioreactor contained a pre-casted hollow channel (Part #7) and the HUVEC-
laded PCL tubular setup was held within. The empty space was filled with 
HUVEC medium, before the bioreactor was sealed and active perfusion was 
Figure 14: Customised apparatus for HUVEC inoculation on PCL tubing.          
A) 1.5% (w/v) agarose/DPBS was poured into a 15 mL conical tube until the 12 mL 
mark. Pre-cooled (on ice) stainless steel rod was added to each tube and the lower 
temperature should shorten the time required for agarose bedding to harden.           
B) Casted hollow channel to hold the PCL tubular setup in position for cell 
inoculation. 
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applied. For this setup, the tension of PCL tubing could be adjusted simply by 
screwing/unscrewing the tension controllers (Part #10) at both ends. Since this 
was a preliminary study, the constructs were only cultivated for 10 days. As 
summarised in Figure 15, two perfusion rates were applied and a static culture 
was used as a control. It should be noted that the static control was cultivated on 
a petri dish in similar volume of medium applied in the bioreactor. This was done 
to ensure that any occurrence of cell death in the bioreactor culture was a result 
of medium perfusion and not degrading collagen coating. 
 
 
2.3.4  HUVEC inoculation and cultivation procedures, Approach B 
The bioreactor was set up as described in Chapter 2.3.1c; to achieve 
complete encapsulation of PCL tubing within the agarose bedding. Thereafter, 
1.5 x 106 HUVEC was resuspended in 500 µL of HUVEC medium and pipetted 
slowly into the lumen of the PCL tubular setup with a glass pipette; so as to avoid 
bubbles being trapped in the lumen. This was followed by connecting the PCL 
tubular setup to the Inlet attachments and sealed up for cell culture experiments. 
Figure 15: Flow-chart of the cell culture experiment applied in Approach A. The 
static control was cultivated on a petri dish to investigate the effects of perfusing 
medium on HUVEC propagation on the PCL tubing over 10 days. Further, two 
perfusion rates were investigated. The 5.5 mL/min perfusion rate was specifically 
selected as this is applied in the bone bioreactor and the potential of transferability 
can be elucidated through this study. 
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To facilitate HUVEC attachment on the PCL tubing, the bioreactors were 
incubated at static conditions for 12-16 h at 37 °C, 5% CO2. Subsequently, the 
bioreactors were connected to designated medium reservoirs via a peristaltic 
pump and 50 mL HUVEC medium was perfused through the bioreactor at         
2.5 mL/min. Medium change was performed every 4 days by replacing the entire 
medium reservoir with a new flask containing fresh HUVEC growth medium.      
To investigate the effects of medium perfusion on construct development, three 
approaches were investigated (Figure 16). 
 
 
2.3.5  Determining cell distribution and proliferation by MTT assay 
For all the experiments mentioned in this chapter, the gross distribution and 
viability of HUVEC on the PCL tubing and fleece was assessed by MTT assay. 
To perform the MTT assay, 1 mL of HUVEC medium per cm of PCL tubing would 
be set up in a 48-well plate and the MTT stock solution (5 mg MTT per mL DPBS) 
was added at 1/10 the volume of HUVEC medium. Similarly for circular PCL 
fleece used to determine the optimal collagen coating concentration         
(Chapter 2.2.1e), 1 mL of MTT staining solution was applied on each fleece; but 
Figure 16: Flow-chart of different medium perfusion approaches investigated in 
this thesis (Approach B). A complete static culture in the vascular bioreactor was 
set up as control and compared against bioreactors with continuous perfusion or 
intermittent perfusion applied. All the bioreactors were set up similarly in the 
incubator and intermittent perfusion was initiated simply by disconnecting the 
designated setup from the peristaltic pump. 
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the procedure was performed in a 24-well plate instead. All the specimens were 
then incubated for 4 h at 37 °C, 5% CO2 and viable cells will accumulate 
insoluble violet formazan in the cytoplasm. However, it should be noted that the 
formazan is not always visually obvious, especially in less metabolically active 
cells. Hence, additional analyses should be done to validate the presence of 
viable cells on the PCL tubing. Further, the number of cells present on the 
circular PCL fleece was quantitated by adding 1 mL solubilisation solution     
(99.4 mL DMSO + 0.6 mL acetic acid + 10 g SDS) to each specimen. This will 
dissolve the violet formazan and colorimetric measurements was performed on a 
micro-plate reader at adsorption wavelength = 570 nm, and a reference 
wavelength = 630 nm. The raw values were tabulated against a standard curve 
to elucidate the cell number on each specimen. 
2.3.6  Studying cell distribution on PCL tubing by DAPI staining 
The 50 mm PCL tubing retrieved from the vascular bioreactor was cut into       
5 mm in length after 10 days in culture. Three pieces were randomly selected 
and fixed in 4% (v/v) formaldehyde/DPBS solution for 30 mins at RT. 
Subsequently, the specimens were washed twice in DPBS at RT to remove 
residual formaldehyde and placed in a 96-well plate. The staining solution 
(DAPI:DPBS, 1:4000) was prepared fresh and 100 µL was given to each 
specimen, followed by incubation in the dark at RT for 15 mins and further 
dissection was done to lay the specimens flat on a glass slide. Next, 100 µL of 
mounting solution (9 part glycerol + 1 part DPBS) was given on top and a glass 
coverslip was laid down flat to prepare the specimens for analysis under a 
fluorescence microscope (Zeiss Axioskop 2). The specimens assessed at 
excitation wavelength = 350 nm and the cell nuclei were stained blue. 
2.3.7  Statistical analysis 
The variance in cell number present on PCL fleece coated with 0.1 mg/mL,            
0.5 mg/mL and 1.0 mg/mL COL I respective was evaluated by two-way ANOVA 
with n = 3 and colorimetric measurements by MTT assay was also performed in 
triplicates. All statistical analyses were performed using GraphPad Prism 6. A    
p-value < 0.05 is considered statistically significant. 
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2.4  The bone bioreactor and characterisation with mESC  
2.4.1  The bone bioreactor setup 
Briefly, cultivation platforms of customised dimensions were casted in 1.5% 
agarose bedding with grade 316 stainless steel rods. Alongside, hollow channels 
were included to allow medium perfusion and enhance mass transfer. The 
internal setup of the bone bioreactor is illustrated in Figure 17, followed by step-
by-step descriptions for setting up the bone bioreactor.  
 
  
Biomimetic bone bioreactor; internal 
Figure 17: Overall internal setup and dimensions of biomimetic bone 
bioreactor. (left) Longitudinal plane of entire bioreactor with the dimensions and 
position of cultivation platforms for encapsulating engineered bone constructs. 
(right) The position of cultivation platforms and hollow channels at top and bottom 
sections in transverse plane. The approximate distal length was also included. 
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2.4.1a  Medium reservoir 
Parts Specifications Illustrations 
#1 Flask 
 
 
#2 Inlet (right) 
and outlet 
(left) tubings; 
secured with 
silicone 
Sarstedt 75 cm2 cell culture 
flask with PS w/HDPE cap 
 
Tygon® ND100-65 medical 
tubing*,  
OD: 6.35 mm, ID: 3.18 mm,  
wall: 1.59 mm 
Long: 220 mm 
Short: 150 mm, tip of tubing 
hanging at the 160 mL mark 
of flask. 
* Tubings were secured with 
silicone. 
  
2.4.1b  Bioreactor body 
Parts Specifications Illustrations 
#3 Inlet/Outlet 
 
 
 
#4 Body 
 
 
 
 
#5 Top/Bottom 
attachments  
 
Disposable 3 mL slip tip 
syringe*,  
OD: 15 mm,                   
length (Inlet): 3 mm, 
length (Outlet): 1.5 mm 
 
Tygon® S50/L medical 
tubing,  
OD: 31.8 mm, ID: 25.4 mm,  
wall: 3.18 mm 
 
Polypropylene (PP) pipe,  
OD: 38.1 mm, ID: 31.8 mm,  
wall: 3.18 mm 
* Syringes were secured with 
silicone. 
 
Biomimetic bone bioreactor; external parts 
#4 
#5 
#3 
#1 
#2 
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2.4.1c  Mold for cultivation platforms in agarose bedding 
Parts Specifications Illustrations 
#6  
Platform 
molds 
 
 
 
 
 
 
 
 
Stainless stain rod grade 
316, Customized through 
lathe cutting,  
 
a) Bottom section: Ø: 3 mm,  
b) length: 30 mm 
 
c) Top section: Ø: 6 mm,  
length: 15 mm 
 
d) Top section extension: 
Ø: 8 mm, length 
(construct): 10 mm 
Ø: 8 mm,  
length (agarose plug): 10 
mm 
 
e) Handle extension: Ø: 3 
mm,  
length: 250 mm   
  
  
#7 Hose 
clamps 
 
#8 Channel 
mold 
 
 
#9 Agarose 
bedding (red) 
 
Stainless stain grade 316,  
hex head, range: 21–44 mm 
 
Stainless stain rod grade 
316,  
Ø: 3 mm, length: 250 mm 
 
 
1.5% (w/v) agarose in 
serum-free hgDMEM  
 
 
#7 
#9 
#8 
6a 
6d 
6b 
6c 
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2.4.1d  Preparing the agarose bedding for cell culture 
Parts Specifications Illustrations 
#10 
Polypropylene 
(PP) caps 
 
OD: 40 mm, ID: 33.5 mm,  
wall: 3.3 mm 
 
#11 
Murine COL IV 
coating 
 
Corning, 100 mg/mL in     
0.05 M hydrochloride acid 
(HCl) 
 
Coating procedure: 700 µL 
per platform at RT in cell 
culture sterile hood for 2 h. 
 
 
#10 
#11 
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2.4.1e  Connecting the bioreactor to peristaltic pump 
Parts Specifications Illustrations 
#12 
Collagen 
constructs with 
mESC 
Corning, rat-tail COL I 
Collagen gel composites:  
40% COL I  
(3 mg/mL in 10 mM acetic 
acid) 
40% serum-free hgDMEM  ±         
1 mg/mL CSA 
20% 5x hgDMEM 
 
Collagen construct in 
bioreactor: 
750 µL collagen gel with            
7.5 x 106 mESC 
  
#13 
Multichannel 
peristaltic 
pump 
 
#14 Peristaltic 
pump tubing 
 
 
#15 PP 
straight tubing 
connectors 
 
 
ISMATEC® High Precision 
Multichannel Dispenser, 
ISM932 
 
Tygon® LMT-55  
color code: purple/white,  
ID: 2.79 mm, wall: 0.86 mm 
 
 
VWR®, Size: 3-5 mm 
 
 
 
 
  
 
 
#12 
#13 
#14 
#15 
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Parts Specifications Illustrations 
#16 
Connecting 
tubings from 
bioreactor to 
pump 
Tygon® ND100-65 medical 
tubing,  
 
OD: 6.35 mm, ID: 3.18 mm, 
wall: 1.59 mm,  
length: 600 mm x 3 pieces 
 
 
2.4.1f  Procedures to set up the bioreactor 
1. Unless specified otherwise, all the hardware used in this set of experiments 
are sterilised by autoclaving before further applications. 
2. Prepare the medium reservoir by drilling two 6.5 mm holes on the top-side of 
a T75 flask (#1). Insert the long inlet tubing until the bottom of the flask and 
hang the short outlet tubing at the 160 mL mark, to allow dripping of medium 
and enhance re-oxygenation (#2). Subsequently, secure the tubings with 
silicone and air dry for at least 12 h. Thereafter, wash each flask with 50 mL 
sterile DPBS twice and sterilisation under UV lamp for 20 mins. 
3. Prepare the bioreactor body by softening the S50/L tubing (#4) in boiling 
water for    5 mins, followed by insertion of PP attachments (#5) into each end 
of the S50/L tubing. Insert the 3 mL slip tip syringe (cut at the 1 mL marking, 
#3) to the 6 mm holes drilled in the middle of PP attachments. Secure the 
syringe with silicone and air dry for at least 12 h. Sterilise in an ultrasonic bath 
for 15 mins, before further applications in cell culture experiments. 
4. Secure the S50/L tubing further with hose clamps (#7) to prevent leakage. 
Enclose the outlet end (bottom) of the perfusion bioreactor with a PP cap 
(#10) and seal the syringe with parafilm to prevent agarose leakage in step 5. 
5. Secure the bioreactor with clamps and ensure it stands straight-up. Prepare 
the agarose bedding by melting 1.5 g agarose powder in 100 mL serum-free 
hgDMEM (1.5% agarose) in microwave. Cool the agarose under a running 
tap and pour it into the partially sealed bioreactor prepared in step 4 (#9). 
# 16 
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6. Insert the platform molds (#6) and channel molds (#8) into the bioreactor 
according to the arrangement shown in Figure 19. This should be 
accomplished with ease using a “casting PP cap” that already has designated 
holes for the mold. 
7. Once the agarose has hardened, remove only the platform molds and leave 
the channel molds in the bioreactor. Wash the cultivation platforms twice with 
sterile DPBS at RT. Subsequently, coat each cultivation platform with 750 µL 
murine COL IV (100 mg/mL). Allow the COL IV to polymerise for 2 h at RT 
(#11), before aspirating it and washing the platforms with RT dPBS twice.  
Air-dry the cultivation platforms for 30 mins in the sterile cell culture hood, 
before proceeding with further procedures. 
8. Prepare the collagen constructs with mESC (#12) and inoculate 750 µL into 
each cultivation platform using a glass pipette. Introduce the collagen 
construct slowly from the bottom of the cultivation platform; so as to allow 
homogenous mixing and prevent bubbles being trapped within the platform. 
Ensure that the cultivation platform is not completely filled, so that an agarose 
plug can be derived later to achieve complete encapsulation of collagen 
constructs within the agarose bedding. 
9. Prepare 30 mL of 1.5% agarose in hgDMEM. It should be noted that the 
agarose had to be cooled to at least 42 °C under a running tap. This will 
ensure that the collagen constructs will not be “cooked” upon addition of 
agarose and the agarose will harden within 20 mins.  
10. Add the agarose slowly at the edge of the bioreactor with a 50 mL pipette, so 
that the collagen construct will not be displaced from the cultivation platform. 
Without excessive disturbance, the difference in density will keep the collagen 
constructs within the cultivation platform, while the agarose stays on top. 
Further, the additional space left in step 8 will create an agarose plug and 
achieve complete encapsulation of constructs within the agarose bedding. 
11. Prepare the peristaltic pump (#13-15) and fill the medium reservoir with 170 
mL of differentiation medium. Connect all the parts in the incubator and 
ensure that the medium reservoirs stand at least 15 cm above the bioreactor 
(#16). This was done to attain sufficient hydraulic pressure that is essential 
for filling up the bioreactor and achieving a stable cultivation environment. 
12. Perfuse medium through the bioreactor at 5.5 mL/min and perform medium 
change by replacing the entire medium reservoir with those containing fresh 
medium, after draining the old medium.   
 
Materials and Methods 
77 | P a g e  
 
2.4.2  Cell culture experiments 
2.4.2a  mESC and murine embryonic fibroblasts (MEF) 
D3ES, a mouse embryonic stem cell-line (mESC) derived from 129S2/SvPas 
mouse was kindly donated by Dr. Jürgen Rohwedel from Universität Lübeck. The 
cell-line at passage phase 17 (PP17) was kept frozen in freezing medium        
(10% DMSO/ESC medium) at -80 °C during shipping. Upon arrival at our lab, the 
frozen vials were transferred to the liquid nitrogen tank for storage. The passage 
phase of D3ES was considered low, because at least 10–15 passage phases 
were necessary for isolating undifferentiated embryonic stem cells from the 
blastocyst (109). In this set of experiments, D3ES from PP18-25 were applied.  
Primary mouse embryonic fibroblasts (MEF) were isolated from fetuses 
extracted from three female C57BL/6 mice. The mice were kindly donated by Dr. 
Axel Roers from Medical Faculty Carl Gustav Carus, Technische Universität 
Dresden. The procedures for MEF isolation was based an established protocol of 
Dr. Derrick Rancourt from University of Calgary(See Appendix 2). The MEF were 
essential for expanding and maintaining the pluripotency of mESC in vitro. 
2.4.2b  Cell culture and expansion 
D3ES was cultured in ESC medium: hgDMEM, 15% FBS, 1% MEM NEAA,   
1% Anti-Anti and 1 µM 2-mercaptoethanol; and maintained at 37 °C with 5% CO2 
and 95% humidity. For regular maintenance, D3ES was co-cultured with 
mitomycin-deactivated MEF in ESC medium on T75 culturing flasks. MEF were 
deactivated with mitomycin C to stop cell division and prevent competition with 
mESC for nutrients. Instead, the non-dividing MEF should continue to secrete 
growth factors needed to retain the pluripotency of mESC and prevent the stem 
cells to undergo random differentiation. Generally, the deactivated MEF were 
prepared a day before the co-culture begins. This was done by adding 1 mg/mL 
mitomycin c/serum-free hgDMEM to a T75 flask with MEF at 80% confluency 
and incubated at 37 °C, 5% CO2 for 2 h. Subsequently, the MEF were washed 
thrice with warm DPBS to remove excess mitomycin c and incubated overnight in 
ESC medium. If not used immediately, the deactivated MEF were maintained in 
ESC medium for up to 6 days and used in subsequent D3ES passaging.  
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One week prior to a bioreactor experiment, the D3ES-MEF co-culture would 
be passaged and transferred to 175cm2 (T175) culturing flask coated with 0.1% 
(w/v) gelatin/H2O and expanded in ESC medium with 100 µg/mL recombinant 
mouse leukemia inhibitory factor (LIF) for 2 passages. During expansion, the 
deactivated MEF would be depleted and colonies of mESC were retrieved. In 
replacement of MEF, LIF was added to the mESC culture to maintain 
pluripotency. When 80% confluency was attained, the cells were trypsinised with 
0.05% Trypsin/0.02% EDTA and split at 1:5 ratio for further expansion. 
2.4.2c  Composites of differentiation media 
The differentiation media were designed based on the aim to recapitulate 
bone development events in vitro (Chapter 1.6, and Figure 5). Briefly, the CMOM 
differentiation protocol was formulated to recapitulate early processes of 
endochondral ossification that begins from stem cell differentiation to derive 
chondrogenic lineages, followed by transition to osteogenic lineages. As controls, 
CMCM differentiation protocol was used to study the effects of prolonged 
cultivation in acidic DMEM:F12 medium and CSA, as well as a point of 
comparison to assess the occurrence of chondro-osteo transition. Further, 
OMOM differentiation protocol was used to assess the efficacy of osteogenic 
differentiation medium applied in this thesis; to derive osteogenic lineages from 
mESC. The composites of respective differentiation medium and the time of 
application are described in Table 6. Briefly, 170 mL differentiation medium was 
applied and would be circulating within individual bone bioreactor at all times. 
Further, 5 mL aliquots were retrieved from respective medium reservoir every     
5 days and the medium pH was measured. Generally, medium pH would stay 
within ±0.15 range from the initial pH (freshly prepared medium) over 15 days. 
For media changes that occur every 15 days, the old medium was first 
completely drained from the bone bioreactor and collected in the old medium 
reservoir. Subsequently, the reservoirs were replaced with new flasks containing 
170 mL freshly prepared differentiation medium. 
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Table 6: Composites of differentiation medium applied at designated time points. 
Time / 
Protocol 
OMOM CMOM CMCM 
Day  
0-15 
hgDMEM 
15% FBS 
1% Anti-Anti 
1% NEAA 
1% MycoZapTM  
1 µM 2-
mecaptoethanol 
50 µg/mL L-ascorbic 
acid  
10-9 M dex  
10 mM ß-GP 
 
pH: 7.6 ± 0.15 
hgDMEM 
15% FBS 
1% Anti-Anti 
1% NEAA  
1% MycoZapTM 
1 µM 2-
mecaptoethanol 
50 µg/mL L-ascorbic 
acid  
10-7 M dex  
1 mg/mL CSA 
 
pH: 7.6 ± 0.15 
hgDMEM 
15% FBS 
1% Anti-Anti 
1% NEAA 
1% MycoZapTM 
1 µM 2-
mecaptoethanol 
50 µg/mL L-ascorbic 
acid  
10-7 M dex  
1 mg/mL CSA 
 
pH: 7.6 ± 0.15 
Day  
16-30 
DMEM, 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
10 mM ß-GP 
 
pH: 7.6 ± 0.15 
DMEM:F12 (1:1) 
10% FBS 
2 mM L-glutamine  
1% Anti-Anti  
50 µg/mL L-ascorbic 
acid  
10-7 M dex  
1 mg/mL CSA 
 
pH: 6.9 ± 0.15 
DMEM:F12 (1:1) 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
50 µg/mL L-ascorbic 
acid  
10-7 M dex 
1 mg/mL CSA 
 
pH: 6.9 ± 0.15 
Day  
31-45 
α-MEM 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
1% NEAA 
10 mM ß-GP 
 
pH: 7.4 ± 0.15 
DMEM:F12 (1:1) 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
1 mg/mL CSA 
10 mM ß-GP 
 
pH: 6.9 ± 0.15 
 
Same as 16 – 30 days 
 
 
 
 
 
pH: 6.9 ± 0.15 
Day  
46-60 
 
Same as 31 – 45 days 
 
 
 
 
 
 
 
pH: 7.4 ± 0.15 
DMEM 
10% FBS  
2 mM L-glutamine  
1% Anti-Anti  
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
10 mM ß-GP 
  
pH: 7.6 ± 0.15 
 
Same as 16 – 30 days 
 
 
 
 
 
 
pH: 6.9 ± 0.15 
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2.4.2d  Preparation of collagen hydrogel and mESC-laded constructs 
Table 7: Composites of collagen hydrogels applied in this set of experiments. 
CM hydrogels OM hydrogels 
40% rat-tail COL I (3 mg/mL) 
40% CSA in hgDMEM (2.5 mg/mL) 
20% 5x hgDMEM* 
40% rat-tail COL I (3 mg/mL) 
40% serum-free hgDMEM 
20% 5x hgDMEM* 
 
The rat-tail COL I hydrogels were prepared as described in Table 7 above. 
Generally, CM hydrogels were applied in the CMOM and CMCM regimes to 
induce chondrogenesis. Corresponding OM hydrogels had CSA replaced with 
serum-free hgDMEM and were used independently in OMOM regime to induce 
only osteogenesis. It should be noted that the hydrogel preparations were always 
performed on ice to reduce polymerisation of collagen. Subsequently, 1 x 107 
mESC per mL hydrogel was constituted and thoroughly mixed with a 1 mL 
Pipetman to attain a homogeneous collagen construct. Thereafter, 750 µL 
collagen construct was aliquoted with a glass pipette into each cultivation 
platform and rested for 10 mins at RT to allow the hydrogel to stabilise. Further 
procedures would proceed on as described in Chapter 2.4.1f, Step 10 and 
designated differentiation medium (Table 6) was perfused through each 
bioreactor at 5.5 mL/min using a multi-channel peristaltic pump. Overall, the 
constructs were cultivated for up to 60 days in the bone bioreactor and 
specimens were harvested on 30 days and 60 days post-inoculation for analyses. 
2.4.3  Procedures for analytics 
2.4.3a  Documenting the gross morphology of constructs 
At designated time point, the constructs were harvested from respective bone 
bioreactors and kept in 20 mL DPBS (4 °C) on a 100 mm polystyrene petri dish. 
The gross morphology of each construct, along with a ruler by the side, was 
documented with a 8-megapixel camera. The cold DPBS should minimise rapid 
cell necrosis and nucleic acid degradation during the process. Following 
documentations, the constructs were further processed for nucleic acid isolation. 
* 5x hgDMEM = Dissolve DMEM powder and 10 mM ß-GP in 1/5 volume 
of Ultra Pure water + 1 part FBS + 0.1 part Anti-Anti + 0.1 part NEAA. 
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2.4.3b  Atomic force microscopy (AFM) 
The measurements were completed by Dr. Jens Friedrichs from the Institute 
of Biofunctional Polymer Materials and a blind test was conducted to eliminate 
bias assessments. Briefly, the Young´s modulus of individual construct was 
determined using a Nanowizard II AFM (JPK Instruments) mounted on an 
inverted optical microscope (Axio ObserverD1, Zeiss). Freshly isolated 
specimens were secured on a petri dish with cyanoacrylate adhesive 
(Histoacryl®, B.Braun), and submerged in DPBS at RT. Tipless silicon nitride 
cantilever with a nominal spring constant of 80 mN.m-1 (PNP-TR-TL-Au, 
Nanoworld) were modified with silica beads (Ø: 10 µm, Kisker Biotec GmbH) as 
described in literature (110,111). Spring constants of the modified cantilevers 
were calibrated using the equipartition theorem (112) prior to each measurement. 
Force-distance curves were acquired in closed loop at constant height mode with 
3 nN contact force and 5 µm/s approach/retract velocity. Measurements were 
made on at least 50 different spots along the surface of each specimen. The 
data processing software provided by the AFM manufacturer (JPK Instruments) 
was used to extract the Young’s modulus E from approach force distance curves. 
2.4.3c  Preparation of frozen specimens for cryosectioning 
The entire construct was removed from the bioreactor together with the 
agarose bedding and fixed in 4% (v/v) formaldehyde/DPBS, at 4 ˚C overnight. 
Subsequently, the top and bottom sections were separated and washed two 
times with cold DPBS to remove excess formaldehyde. Next, the specimens 
were blot dry on Kimwipe and submerged in Optimum Cutting Temperature 
compound (O.C.T.) medium at RT for 20 mins to allow infiltration of O.C.T. 
medium into the construct. This is a critical step and would affect the structural 
integrity of specimens during and after cryosectioning. Next, individual specimen 
was embedded in an intermediate Cryomold® with O.C.T and the orientation 
was adjusted with a 21G needle. The entire Cryomold® was then submerged 
and froze rapidly in 2-methylbutane in dry ice and were kept at -80 °C until 
cryosectioning was performed. On the cryostat, the frozen blocks were cut at        
-25 °C and the cross-sections (10 µm) were collected on SuperfrostTM Plus 
 
Materials and Methods 
82 | P a g e  
 
microscope slides. This was followed by air-drying at RT for 10 mins to allow 
better adhesion of cryosections. The glass slides with cryosections were kept at  
-80 °C until further processing. 
2.4.3d  Histological staining 
Generally, the cryosections of each specimen derived in this thesis were 
stained with two histological stains. 1) Alcian blue was used to detect 
glycosaminoglycan (GAG) accumulation, an indicator for chondrogenesis. 2) 
Alizarin red was used to detect calcium accumulation, an indicator for 
osteogenesis. The staining protocols for the histological stains are summarised 
in Table 8. 
2.4.3e  Measuring aggregate and nodule sizes 
Briefly 4 randomly selected histological sections derived from three 
independent experiments (n = 4) were used. Images derived from the histologic 
staining were processed using ImageJ to measure the diameter of aggregates 
and spherical nodules present in the all the constructs. Since it is relatively 
ambiguous to distinguish the differences between cell aggregates and spherical 
nodules, both were tabulated together. A box and whiskers chart was plotted to 
show the range of aggregate/nodule sizes available in each construct and their 
frequency of occurrence. Further, the mean diameter of aggregates/nodules, as 
well as the mean quantity present in a single section was also tabulated. This 
was done to better illustrate the effects of different protocol on 
aggregates/nodules formation. 
2.4.3f  Immunofluorescence staining (IF) 
The cryosections of CMOM and OMOM constructs (only top section) were 
used for further IF analysis, to characterise the cell aggregates/spherical nodules. 
The procedures for IF are described in Table 9 and a total of four antibodies 
were investigated. The antibodies and cell types they represent are as follows: 1) 
OCT3/4 (H-134): mESC, SOX9 (H-90): primary chondrocytes, COL IIA (H-300): 
mature chondrocytes and SP7 (M-15): osteoblasts. After the staining procedures, 
the specimens were studied on Zeiss Axioskop 2 fluorescence microscope and 
fluorescence images were documented with ZEN software from the manufacturer. 
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Table 8: Procedures for histological staining. 
Alcian blue Alizarin red 
 Dip slides in dH2O for 3 mins to 
dissolve the O.C.T. 
 Dip in 3% glacial acetic acid for      
1 minute. 
 Transfer to alcian blue solution and 
stain slides for 2 h at RT. 
 Wash slides under running tap 
water for 10 mins. 
 Dip slide in 70% (v/v) ethanol/dH2O 
for 2 mins for dyhydration. 
 Dip slides in 95% (v/v) 
ethanol/dH2O for 2 mins. 
 Dip slides in absolute ethanol for        
2 mins. 
 Dip slides in 50% (v/v) ethanol/ 
Histochoice® clearing agent for           
2 mins. 
 Clear slides in Histochoice® 
clearing agent twice for 2 mins 
each. 
 Mount slides with PermountTM. 
 Air dry overnight before visualizing 
under the light microscope. 
 
Reagents 
3% (v/v) acetic acid:  
3 mL acetic acid 
97 mL distilled water (dH2O) 
Alcian blue solution* 
100 mL 3% acetic acid 
1 g 8GX Alcian blue  
Adjust pH to 2.5 using 3% acetic acid 
*Filter before use 
 Dip slides in dH2O for 3 mins to 
dissolve the O.C.T. 
 Dip in alizarin red solution for         
3 mins.  
 Shake off excess dye, blot dry the 
slides. 
 Dip slides in acetone (20 dips). 
 Dip slides in 50% (v/v) acetone/ 
Histochoice® clearing agent. 
 Clear slides in Histochoice® 
clearing agent twice for 2 mins 
each. 
 Mount slides with PermountTM. 
 Air dry overnight before visualizing 
under the light microscope. 
 
Reagents 
Alizarin red solution 
100 mL dH2O 
2 g Alizarin red S 
Adjust pH to 4.1-4.3 using 0.5% 
ammonium hydroxide * 
 
*pH of alizarin red S solution is critical. 
Make fresh. 
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  Table 9: Procedures for IF staining 
Primary antibody staining  
1. Remove the slides from -80 oC freezer and thaw in the chemical fume 
hood at RT for 10 mins. 
Note: Do not let the sections dry completely, or they will detach from 
the glass slides easier during the immunostaining procedures. 
2. Draw a circle around each specimen with a waterproof PAP Pen 
(Invitrogen) and air-dry at RT for another 5 mins. 
3. Wash the slides for 5 mins in DPBS at RT to remove the O.C.T. and give a 
droplet (~50 µL) of 0.2% (w/w) Triton X-100/DPBS on top of each 
specimen. The waterproof enclosure should keep the droplet intact and the 
specimen hydrated at all times. 
4. Wash the slides for 5 mins in DPBS at RT and apply 50 µL of blocking 
solution* on each specimen. Incubate the slides for 1 h at RT, in a moist 
chamber (a tupperware with 3 layers of wet tissue laid at the bottom). 
*Blocking solution = 1% (w/v) bovine serum albumin (BSA) in DPBS 
5. Add 50 µL of primary antibody/blocking solution (1:250) to designated 
samples. Set up a negative control with 50 µL blocking solution only. 
Incubate the specimens with primary antibody over 18-24 h at 4 oC in a 
moist chamber. (Alternatively, the incubation can be done over 2 h at RT). 
Secondary Antibody Staining 
1. Wash the slides for 5 mins in cold DPBS and perform this 3 times. 
Subsequently, add 50 µL of blocking solution on each specimen and 
incubate at RT for 1 h in the dark. 
2. Aspirate the blocking solution and add 50 µL of designated secondary 
antibody mix* to each specimen. Apply donkey-anti-goat IgG to specimen 
with SP7 primary antibody and apply goat-anti-rabbit IgG to specimens 
with other primary antibodies. 
*Secondary antibody mix = Antibody (AlexaFluor488):blocking 
solution:DAPI (1:1000:4000) 
3. Incubate the specimens with secondary antibody for 2 h at RT, in the dark. 
(Also can be done for 4 h at 4 oC).  
Note: Incubating longer than this period causes a lot of background 
to appear and should be avoided. 
4. Wash the slides for 5 mins in cold DPBS and perform this 3 times. 
Subsequently, apply 100 µL of mounting solution (9 part glycerol + 1 part 
DPBS) on the slide before laying a glass coverslip on top. 
5. If not used immediately, keep the slides in the moist chamber at 4 °C, in 
the dark for up to 7 days. 
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2.4.3g  Total RNA isolation, cDNA synthesis and qPCR 
Each construct was dissected in half; the top and bottom sections were 
homogenised separately in 1 mL TRIzol® (Invitrogen) at RT for 5 mins. Total 
RNA was isolated according to manufacturer protocol for TRIzol® and cDNA was 
synthesized with 1500 ng total RNA in 150 µL high capacity cDNA reverse 
transcription reaction mix as per manufacturer protocol (Applied Biosystems). 
The cDNA isolated from respective sample was probed with validated murine 
Taqman® gene expression assay primers from Applied Biosystems and the 
product information for each primer set are summarised in Chapter 2.1.4b. Each 
sample was analysed in triplicates as per manufacturer’s protocol for Taqman® 
Universal PCR Master Mix on the ABI 7900HT PCR-cycler. Relative gene 
expression against undifferentiated mESCs was determined using the 2-∆∆CT 
method (113).  
2.4.3h  Statistical analysis 
The collagen constructs used for Young’s modulus measurements were 
derived from the same set of experiment, but cultivated in two separate 
bioreactors (n = 2). Measurements were tabulated as mean ± SD and evaluated 
with unpaired t-test. The significant difference of CMCM, CMOM and OMOM 
constructs was later evaluated with one-way ANOVA. The statistical differences 
of aggregates and nodules size were evaluated using non-parametric Kruskal-
Wallis test. The relative gene expression profile was tabulated using the results 
of a representative experiment selected from three independent experiments. 
The qPCR was performed in triplicates and presented as mean ± SD, followed 
by evaluation with two-way ANOVA. Subsequently, Holm-Sidak test, α = 0.05, 
was applied to compare the differences between the top and bottom sections of 
individual samples. All statistical analyses were performed using GraphPad 
Prism 6. A p-value < 0.05 would be considered statistically significant. 
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2.5  Deriving clinically applicable constructs in bone bioreactor with hMSC 
2.5.1  The bioreactor 
2.5.1a  Setup and pO2 distribution  
The procedures to set up the bone bioreactor were similar to the mESC 
experiments as described in Chapter 2.4.1. However, the pO2 gradient would not 
be applicable to this set of experiments and both the top and bottom sections of 
cultivation platform were oxygenated. This was attributed by the reduced cell 
inoculation density (3.0 x 106 hMSC versus 7.5 x 106 mESC) and the modified 
approach for cell inoculation (Chapter 2.5.3).  
2.5.1b  Preliminary experiments 
The CM and OM collagen hydrogels applied in the mESC experiments 
(Chapter 2.4.2d) were inoculated with 3.0 x 106 hMSC. The CMOM and OMOM 
differentiation protocols were then applied to respective hMSC-laded constructs. 
However, the experiment was terminated prematurely at 40 days post-inoculation, 
due to severe condensation of these constructs. Based on the results from these 
preliminary experiments, a structurally stable artificial extracellular matrix (aECM) 
scaffold was subsequently derived through indirect 3D-printing approach and 
slight modifications were made to the differentiation media to better support 
hMSC differentiation.  
2.5.2  Preparation of tailored aECM scaffolds 
2.5.2a  Making standardised molds for aECM scaffolds by 3D-printing 
This work was done in collaboration with Dr. Matthias Schumacher from the 
Medizinisch-Theoretisches Zentrum, Dresden. A 3D model of the male mold was 
constructed using SolidWorks 2013. The raw file was exported as STL-files to 
Cura 14.3 software (open source) as printing instructions with the following 
parameters: layer height 0.1 mm and 50% fill density, were defined and 
programmed. The printing was performed using a self-build Prusa Berlin i3 
printer (open source) working with crystal clear red polylactic acid (PLA) filament 
(3dk, Berlin) at 210 °C extrusion temperature on a 60 °C heated build platform. 
Due to height constraints, the male molds were printed at longitudinal orientation 
in two-halves and glued together with instant adhesive (UHU). Next, silicone 
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female molds were casted by inserting the printed male mold into a 15 mL 
conical centrifuge tube containing 12 mL platinum cured silicone (Silikonfabrik, 
Germany). The entire casting setup was left in an oven at 60 °C for 1 h to harden. 
Thereafter, the male PLA mold was removed and the silicone female mold was 
cleaned in an Ultrasonic bath for 30 mins, followed by drying in the oven at 60 °C 
overnight (Figure 18). Before the silicone female molds were used to produce 
tailored artificial extracellular matrix (aECM) scaffolds, the silicone molds were 
dipped in 75% (v/v) ethanol/dH2O and air-dried under a UV lamp in the cell 
culture hood. 
 
 
2.5.2b  Production of tailored aECM scaffolds 
The aECM scaffolds with pre-designed dimensions were prepared by adding 
2 mL of collagen gel mix (final concentration = 1 mg/mL) into a female silicone 
mold, with the bottom section holding 0.7 mL and the top section holding 1.3 mL 
of collagen gel mix. Two variants, the CM scaffold and OM scaffold were 
prepared and applied in designated bioreactors. The compositions of initial 
collagen gel mix for each scaffold are listed in Table 10. 
Figure 18: Synthesizing consistent aECM scaffolds with tailored dimensions 
using 3D-printed molds. A) 3D-printed PLA male mold as a template for consistent 
production of aECM scaffolds. B) Casting of female mold in silicone. C) Silicone 
female mold during aECM casting (top) and the aECM scaffold (within the dotted 
circle) after freeze-drying procedures (bottom). To retrieve the aECM scaffold, the 
silicone mold was cut open with a pair of scissors. 
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Table 10: Composites of collagen gel mix for synthesizing CM and OM scaffolds. 
CM 
Scaffold 
1 part 2 mg/mL rat-tail COL I / 10 mM acetic acid 
1 part 2 mg/mL CSA  / 60 mM phosphate buffer*  
OM 
Scaffold 
1 part 2 mg/mL rat-tail COL I / 10 mM acetic acid 
1 part 60 mM phosphate buffer* 
* 60 mM Phosphate buffer: 0.712g Na2HPO4 + 0.152g KH2PO4 
+ 1L Ultra Pure water, pH 7.4 
A stock solution for respective collagen gel mix was prepared, to ensure 
consistency of the CM and OM scaffolds. The collagen gel mix was added to 
individual sterilised female silicone mold slowly with a glass pipette to avoid 
accumulation of bubbles, and the entire setup was incubated at 37 °C for 18 h to 
initiate fibrillogenesis. Next, the setup was froze at -80 °C overnight, followed by 
freeze-drying in Christ Epsilon 2-4 LSC freeze dryer with the parameters in Table 
4 for 19 h. Subsequently, the female molds were cut open with a pair of scissors 
and the freeze-dried aECM scaffolds were removed from the mold with care 
(Figure 19A). This was followed by crossed-linking procedures with 25% 
glutaraldehyde vapour in an air-tight Tupperware at 40 °C for 48 h (Figure 19B). 
The cross-linked scaffolds were ventilated in a biochemical fume hood at RT for 
at least 3 days prior to experimentations with hMSC; in order to allow residual 
glutaraldehyde on the scaffolds to evaporate off (Figure 19C). 
 
Figure 19: Cross-linking aECM scaffolds with glutaraldehyde vapour after 
freeze- drying. A) Examples of aECM scaffolds after freeze drying, B) Cross-linking 
of aECM scaffolds (stacked above) with 25% glutaraldehyde (laid below) in a 
Tupperware, C) Scaffolds after ventilation in chemical fume hood for at least 3 days. 
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2.5.3  Cell culture experiments with hMSC 
2.5.3a  Human bone marrow-derived mesenchymal stem cells (hMSC) 
hMSC from bone marrow aspirates of three healthy male donors (between 20 
to 40 years of age) were isolated as previously described (114–116), with 
reference number #282, #540, #575. These hMSC were kindly provided by       
Dr. Bornhäuser, from University Hospital Carl Gustav Carus, Technische 
Universität Dresden. Briefly, the hMSC were separated and isolated using flow 
cytometry. These hMSC were tested positive for CD105, CD73, CD166, CD90, 
CD44 makers and typical markers for hematopoietic were absent. Further, 
standard differentiation assays for chondrogenesis, osteogenesis and 
adipogenesis had been performed, and the multipotency of isolated hMSC was 
validated. Generally, hMSC were expanded and maintained at 37 °C, 8% CO2 in 
hMSC medium containing: DMEM with 1.0 g/L glucose, 10% FBS,                       
2 mM L-glutamine and 1% Pen-Strep.  
2.5.3b  hMSC expansion in spinner flasks 
The inoculation and cultivations conditions were based on previous 
publications by Yuan, et.al (85) and Hunt, et.al (86). However, additional 
optimisations were performed to fulfill the needs required by the experiments 
performed in this thesis. The procedures for inoculating hMSC on microcarrier 
beads, cultivation and expansion, as well as harvesting hMSC from the beads 
are listed in Chapter 2.2.2c. Briefly, intermittent stirring (8 h: 3 mins stirring at     
90 rpm, followed by 27 mins pause) was applied in the spinner flask to inoculate 
hMSC on microcarriers. Subsequently, continuous stirring at 90 rpm was applied 
over 12 days for hMSC expansion. Similar for all three hMSC donors, the 
customised stir rod propeller (Figure 12d) was used to maximise hMSC 
expansion and a total of four spinner flasks were applied to produce sufficient 
amount of hMSC required for experimentations (80 x 106 hMSC). 
2.5.3c  Inoculating hMSC on the aECM scaffolds 
Firstly, CM scaffolds were equilibrated in serum-free DMEM:F12 medium and 
OM scaffolds in serum-free DMEM (Figure 20A) at 37 °C, 5% CO2 for at least   
16 h. Next, the serum-free medium was aspirated and a single scaffold was 
 
Materials and Methods 
90 | P a g e  
 
placed in each agarose well (Figure 20B). 3 x 106 hMSC were suspended in 200 
µL hMSC medium and pipetted into each wall. The scaffolds were incubated at 
37 °C, 5% CO2 for 3 h, with periodic mixing every 20 mins with a P100 pipetman. 
Through constant mixing and the smaller volume of the agarose well, this 
inoculation approach was designed to achieve homogenous distribution of hMSC 
throughout the aECM scaffold. Interestingly, the hMSC-laded scaffolds were 
found capable of returning to their original shape spontaneously. This was simply 
accomplished by placing the clumps (Figure 20B) in warm serum medium for      
1 minute (Figure 20C). Using a pair of forceps, each scaffold was transferred into 
each cultivation platform in the bone bioreactor (Figure 20D). Subsequent 
procedures for setting up the bioreactor are described in Chapter 2.4.1d.  
 
 
2.5.3d  Cultivation in perfusion bioreactor and composites of differentiation media 
Unlike the embryonic stem cells, mesenchymal stem cells are lineage-specific 
and are able to propagate in the same basal medium as their differentiated 
derivatives. Hence, application of hgDMEM medium in the first 15 days (mESC 
setup, Table 6) would be redundant and chondrogenic/osteogenic differentiation 
media were applied directly. Based on the results from the mESC setup, similar 
differentiation protocols (CMCM, CMOM, OMOM) were applied on the hMSC-
Figure 20: Inoculating hMSC on the tailored aECM scaffolds. A) Example of 
aECM scaffolds after equilibration in designated medium for 16 h, CM scaffolds in 
serum-free DMEM:F12 and OM scaffolds in serum-free DMEM. B) From (left) 
Customised agarose casting apparatus made with Ø: 3 mm acrylic rods and 48-well 
polystyrene plate, (middle) Example of casted wells in agarose, (right) Wells 
containing single aECM scaffold with 3 x 106 hMSC. C) Example of hMSC-laded 
constructs, D) Bone constructs (within dotted box) in cultivation platforms pre-coated 
with acidic human placenta COL IV (yellow region) within the bioreactor. 
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laded constructs. An additional approach (OMOM*) was included by cultivating 
CM scaffolds in osteogenic media (Table 11). Corresponding static cultures were 
set up in tissue culture flasks and the hMSC-laded constructs are submerged in 
the same volume of differentiation medium applied on the perfusion culture and 
medium change was performed at the same time points as the perfusion culture. 
Table 11: Composites of differentiation medium for hMSC-laded constructs 
applied at designated time points.. Similar to the mESC experiments, medium pH was 
measured every 5 days and was ±0.15 range from the pH of freshly prepared medium. 
Time / 
Protocol 
OMOM / OMOM* CMOM CMCM 
Day  
0-30 
DMEM 
10% FBS 
1% Anti-Anti 
2 mM L-glutamine 
50 µg/mL L-ascorbic 
acid  
10-9 M dex  
10 mM ß-GP 
 
pH: 7.6 ± 0.15 
DMEM:F12 (1:1) 
10% FBS 
1% Anti-Anti 
 
50 µg/mL L-ascorbic 
acid  
10-7 M dex  
1 mg/mL CSA 
 
pH: 6.9 ± 0.15 
DMEM:F12 (1:1) 
10% FBS 
1% Anti-Anti 
 
50 µg/mL L-ascorbic 
acid  
10-7 M dex  
1 mg/mL CSA 
 
pH: 6.9 ± 0.15 
Day  
30-45 
α-MEM 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
1% NEAA 
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
10 mM ß-GP 
 
 
pH: 7.4 ± 0.15 
DMEM 
10% FBS 
2 mM L-glutamine 
1% Anti-Anti 
 
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
1 mg/mL CSA 
10 mM ß-GP 
 
pH: 6.9 ± 0.15 
Day  
46-60 
Same as 31 – 45 days 
 
 
 
 
 
 
 
pH: 7.4 ± 0.15 
DMEM 
10% FBS  
2 mM L-glutamine  
1% Anti-Anti  
50 µg/mL L-ascorbic 
acid 
10-9 M dex 
10 mM ß-GP 
 pH: 7.6 ± 0.15 
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2.5.4  Procedures for analytics  
2.5.4a  Determining the collagen and CSA contents in aECM scaffolds 
After equilibration, cell-free CM and OM scaffolds were isolated for collagen 
and CSA quantification. Measurements were done on the top and bottom 
sections separately, to allow better interpretation of results from subsequent 
analyses. For each assay, three aECM scaffolds were retrieved from each set of 
experiments (n = 9) and measurements were also done in triplicates. Briefly, the 
collagen content was determined by FluoraldehydeTM o-Phthaldialdehyde 
Reagent Solution (OPA) assay. The aECM scaffolds were first transferred to a 
1.5 mL conical eppendorf tube and submerged in 900 µL of TES-buffer (50 mM 
TES + 0.36 mM CaCl, pH 7.4). Subsequently, the specimens were incubated at 
100 °C for 10 mins and cooled at RT for 15 mins. This was followed by adding of 
100 µL 1% (w/v) Collagenase A/TES solution, and collagen digestion was 
initiated by incubating the specimens on a shaker at 37 °C for 18–24 h. Next, the 
collagen substrate was vortexed briefly and 20 µL was aliquoted into a black UV-
Star™ 96-Well Microplate, followed by 200 µL OPA solution to each well. The 
fluorescence intensity was measured on a microplate reader at excitation 
wavelength = 340 nm and emission wavelength = 440 nm. The raw values were 
tabulated against a standard curve to determine the collagen content. 
Dimethyl-methylene blue (DMMB) assay was used to quantitate CSA content 
in the CM scaffolds. First, the top and bottom sections were transferred 
separately to a 1.5 mL conical eppendorf tube and 400 µL 1% (w/v) 
Papain/DPBS solution was added to each tube. Cleavage of sulfated groups on 
CSA was initiated by incubation at 60 °C for 24 h. Next, the substrate was 
vortexed briefly and 40 µL was aliquoted in a transparent 96-well microplate. 
Immediately after 250 µL DMMB solution (2.1 mg DMMB in 100 mL 0.002% (w/v) 
sodium formate/DPBS, pH 1.5) was added to each well, colorimetric 
measurements were performed on a microplate reader at 595 nm adsorption. 
The raw values were tabulated against a standard curve to determine CSA 
concentration in each specimen. 
 
 
Materials and Methods 
93 | P a g e  
 
2.5.4b  Documenting the gross morphology of constructs 
After the cultivation procedures, the constructs were removed from the 
perfusion bioreactor and agarose bedding. The gross morphology of each 
construct was documented as described in Chapter 2.4.3a and these constructs 
were subsequently used in nucleic acid isolation. 
2.5.4c  Total DNA and RNA isolation 
The top and bottom sections of each construct were separated and 
homogenised in 1 mL TRIzol® at RT for 5 mins. The total RNA was isolated 
according to manufacturer protocol and cDNA was synthesized from 1500 µg 
total RNA in 50 µL reaction solution of AffinityScript qPCR cDNA synthesis kit 
(Agilent Technologies) as per manufacturer protocol. After the cDNA was 
synthesized, additional 100 µL DNAse/RNAse-free water was added to achieve 
a final cDNA concentration of 10 µg/mL. 
After the aqueous phase was removed from the Trizol® homogenate for total 
RNA isolation, DNA was isolated from the interphase. Briefly, 0.3 mL of absolute 
ethanol per mL of Trizol® used was added to each specimen and mixed by 
inverting with hand. The samples were rested at RT for 3 mins and centrifuged at 
200xg, 4 °C for 5 mins. The supernatant was discarded and the precipitated DNA 
pellet was washed in 1 mL 0.1 M sodium citrate/10% ethanol; pH 8.5, per mL of 
Trizol® used. Next, the specimens were rested at RT for 30 mins, with mixing by 
inverting every 5 mins. The samples were centrifuged for 5 min at 200xg, 4 °C 
and the washing step was repeated once more. After centrifugation, the 
supernatant was discarded and 1.5 mL 75% ethanol/dH2O was added to each 
specimen. The samples were rested at RT for 15 mins, with mixing by inverting 
every 5 mins; followed by centrifugation at 200xg, 4 °C for 5 mins and the 
supernatant discarded at the end. Finally, the DNA pellets were air-dried for      
10 mins, before being resuspended in 100 µL 8 mM sodium hydroxide to derive 
a DNA substrate. 
2.5.4d  DNA quantification 
Quant-iT™ PicoGreen® dsDNA Assay Kit was used for DNA quantification. 
Briefly, 10 µL DNA substrate was aliquoted in a black UV-Star™ 96-Well 
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Microplate; followed by addition of 190 µL Pico-green working solution (1:380, 
Pico-green:TRIS-EDTA buffer) and incubation at RT for 10 mins. Orbital shaking 
for 5 s was applied before fluorescence intensity was measured on a microplate 
reader at excitation wavelength = 485 nm and emission wavelength = 535 nm. 
The raw values were tabulated against a standard curve to determine the DNA 
concentrations and all the measurements were performed in triplicates. 
2.5.4e  Micro-computed tomography (µCT)  
The scans were completed by Dr. Ricardo Bernhardt from the workgroup of 
Prof. Scharnweber and a blind test was conducted to avoid bias assessments. 
Briefly,  the 60 days constructs were fixed in 12 mL 4% formaldehyde/DPBS at 
4 °C for 12 h; followed by washing with cold DPBS for two times. Next, each 
specimen was dissected and the top/bottom sections were kept in DPBS at 4 °C; 
until µCT was performed. The specimens were scanned with vivaCT 75 
(SCANCO Medical, Brüttisellen, Switzerland), using an isotropic voxel size of 
20 µm (45keV, 88 µA, 130 ms, 1000 projections). Next, the Image Programming 
Language software (IPL) from SCANCO Medical was used to compile the 2D 
images and derive the 3D form of each specimen. Further, the mineralisation 
degree of the specimens was also estimated with the software. Firstly, the 
scanner was calibrated using hydroxyapatite (HA) phantoms and contours were 
drawn manually around the sample surface (the 2D images) to determine the 
total volume (TV) of each specimen. The threshold for mineral volume content 
(MV) was set to 10 mg HA/cm³ and the mineral volume ratio of each specimen 
were calculated by MV/TV that estimates the mineralisation degree. Since the 
specimens could not be used for other form of analyses and the constraints to 
generate additional constructs for optimising scanning procedures with µCT, only 
one set of specimen (hMSC #540) is presented in this thesis. 
2.5.4f  Histological analysis 
The procedures applied in the mESC experiments were replicated here and 
these include the procedures for sample preparation, cryosectioning and staining         
(Chapter 2.4.3c, 3d and Table 8). Similarly, the specimens were also stained with 
alcian blue and alizarin red.  
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2.5.4g  qPCR 
The effects of respective differentiation regime on hMSC differentiation and 
construct development was investigated through studying a series of genomic 
markers and the primer sequences were either taken reference from established 
sources or generated using Primer3 program (117,118). These genes include:    
A) stem cells: CD90, Sox2, B) chondrocytes: Sox9, Col IIa1, C) hypertrophic 
chondrocytes: Col Xa1, D) osteo-progenitors / osteoblasts: Runx2, Col Ia1, ALP, 
Sp7, E) osteocytes: Dmp1, Mepe, Sost, G) endogenous control: 36B4, β-actin. 
The samples were probed using Brilliant II SYBR® green QPCR mastermix with 
low ROX (Agilent Technologies) in triplicates as per manufacturer’s protocol on 
the Agilent Stratagene Mx3005P cycler. Relative gene expression against 
undifferentiated hMSCs was calculated using 2-∆∆CT method (113).  
2.5.4h  Statistical analysis  
The expression of pluripotency markers by hMSC after expansion in spinner 
flasks for 12 days was normalized against cell cultures from the T175 flask. The 
bar chart is tabulated as mean ± SD and the variance is evaluated by student t 
test. For the COL I and CSA content present in the CM and OM scaffolds, the 
bar chart is tabulated as Absolute content (µg) ± SD; followed by evaluation with 
two-way ANOVA for COL I content and student t test for CSA content. 
The hMSC density in CM and OM scaffolds at 24 h post-inoculation, and after 
30 or 60 days of cultivation in respective differentiation regime was tabulated as 
mean hMSC per cm3 aECM scaffold ± SD. The variance of specimens retrieved 
24 h post-inoculation was evaluated by student t test, while the specimens 
retrieved after 30 or 60 days of cultivation were evaluated by two-way ANOVA. 
The qPCR was performed in triplicates and tabulated as mean ± SD, followed 
by evaluation through two-way ANOVA. This is followed by Holm-Sidak test, α = 
0.05, to compare the differences between the static and perfusion cultures. All 
statistical analyses were performed using GraphPad Prism 6 and p-value < 0.05 
would be considered statistically significant. 
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CHAPTER 3: Results and Discussion 
3.1  Specifications of bioreactors applied in this thesis 
3.1.1  Vascular bioreactor 
While designing this perfusion bioreactor, working principles of commercially 
available hollow fiber bioreactors are considered and integrated in this vascular 
bioreactor. The the bioreactor was built, a leak test was performed by perfusing 
water through the bioreactor at multiple perfusion rates (Figure 21). The general 
technical specifications are summarised in Table 12. Further, Figure 22 
illustrates the internal setup and describes how the PCL/PVC tubing is attached 
to the bioreactor attachments and prepared for cell culture experiments. 
  
 
Table 12: Technical specifications of vascular bioreactor. 
 Parameters Values 
Medium perfusion rate  
(min-max) 
0.5-10.0 mL/min 
Length of PCL tubing 
(min-max) 
25-55 mm 
Internal diameter of PCL tubing 
(min-max) 
4-8 mm (adjustable by 
changing the PVC adapter) 
Means of sterilization Standard autoclaving 
Cell culture duration Up to 15 days was tested 
Figure 21: The stand-alone perfusion bioreactor prototype (vascular 
bioreactor) developed in this thesis to support large vessel tissue 
engineering. This prototype was built with Dirk Schmidt, a student from the 
Faculty of Mechanical Engineering, for his Großer Beleg.  
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Additionally, some unique modifications and specifications were also 
implemented to better support single large blood vessel constructs in vitro. These 
include (Figure 23):  
1. Direct attachment of single tubing to the inlet/outlet and perfusing 
medium through the lumen.  
2. Customised adaptors that accommodate PCL tubing of different 
length and diameter.  
3. Achieving stable cultivation niche by encapsulating construct in 
agarose bedding. 
4. Adjustable ends that enable manipulation of tubing tension.  
5. Stackable housing that enables more systematic organisation of 
multiple bioreactors in the incubator.  
6. Durable bioreactor parts constructed with polycarbonate to 
enable repeated use after sterilisation by autoclaving. 
Figure 22: Internal setup of bioreactor with PCL tubing. PCL tubing (white) glued 
to polyvinyl chloride (PVC) adapter (clear). The PVC adapter will allow adjustments of 
PCL tubing stiffness; as well as facilitating easier and tighter attachment to the 
bioreactor tubing attachments. 
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3.1.1a The parameters applied in vascular bioreactor and the estimated 
hydrodynamics at different medium perfusion rate 
The parameters applied on the vascular bioreactor in this thesis are 
summarised in Table 13A and the range of perfusion rate that will achieve 
laminar flow in this setup are also mentioned in Table 13B. Briefly, fluid flow 
through the lumen of a tubular structure is at laminar state when Re < 2300. At 
2300 < Re < 4000, fluid flow is at transient state and Re > 4000 will indicate a 
turbulent flow through the lumen of a tubular structure (119). At normal 
physiological conditions in a healthy person (Table 13C), blood flow will occur at 
laminar state in most blood vessels; with exception to the ascending and 
descending aorta (120,121). Hence, it is important to ensure that the perfusion 
rate applied to the vascular bioreactor is Re < 2300. It should also be noted that 
the kinematic viscosity of Newtonian fluid is used to calculate the Re. Hence, the 
values are not an accurate representation of the physiological conditions, as 
blood is a non-Newtonian fluid. Nonetheless, the calculated Re values remain 
Figure 23: Added features of vascular bioreactor for large blood vessel tissue 
engineering. 1) Attaching single PCL tubing (white tubing) to bioreactor attachments 
allow consistent medium perfusion, 2) Customisable bioreactor attachments, 3) PCL 
tubing encapsulated in agarose bedding, 4) Tuneable knobs to adjust PCL tubing 
tension, but only possible without complete encapsulation in the agarose bedding,     
5) Stackable housing to better organise the bioreactors during cell culture. 
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adequate for preliminary characterisations of the vascular bioreactor; since 
Newtonian fluid (cell culture medium) is applied to support cell propagation in 
vitro. However, this should be noted as a limiting factor for mathematical 
modelling in the future. 
Further, the aim of this part of the thesis is to engineer large blood vessels in 
vitro and the PCL tubing applied has a DH of 0.005 m. This is relevant to the 
physiological range of femoral or carotid arteries (0.002–0.008 m) present in a 
healthy individual (122,123). In order to recapitulate complete physiology 
condition in the bioreactor, perfusion rate between 153--510 mL/min should also 
be applied (124). However, this is not achievable in vitro as the existing 
laboratory peristaltic pumps are not designed and are unable to support such 
high perfusion rate. Hence, a compromise is made and medium is perfused 
through the PCL tubing in the vascular bioreactor at 2.5 mL/min instead. This 
perfusion rate is selected with consideration that the initial PCL tubing inoculated 
with only HUVEC are rather fragile and the mechanical shear stress generated 
by high perfusion rate will simply displace the cells from the tubing or is lethal. 
Further, this is the minimum perfusion rate that will keep the PCL tubing dilated 
and ensure consistent medium flow through the tubing. With lower perfusion rate, 
the PCL tubing will collapse and the wall of the tubing will stick together.  
3.1.1b  Structural properties of PCL tubings 
Generally, the electrospun PCL fibres are 2 µm in diameter and are randomly 
arranged. However, it should be noted that the conditions applied during 
electrospinning are optimal, as the fibres are uniform and no blobs are observed 
(Figure 24A). This is important as inconsistent fibres will introduce variabilities in 
mechanical properties within the same PCL tubing, as well as batch variations 
among PCL tubings made at different time. Consequently, cell adhesion and 
behavior will vary between different set of experiments. In Figure 24B, the 
specifications of the PCL tubing are listed. These PCL tubings are specifically 
designed to match the structural properties similar to the arteries that are 
typically 0.002–0.008 m in diameter and possess an elasticity of 2–6 MPa (124). 
In this thesis, PCL tubings with 0.005 m internal diameter and a mean elasticity 
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of 2.79 MPa was applied for preliminary investigations. It should be noted that 
further modifications can be accomplished simply by changing the collector rod 
to derive PCL tubings with different diameter or length, while the elasticity can be 
manipulated by adjusting the duration of fibre deposition during electrospinning. 
Furthermore, the PCL fibres can also be aligned to the same orientation by 
adjusting the rotation rate and direction of maneuver by the collector rod. 
 
 
Table 13: Physiological relevance of applied specifications in vascular 
bioreactor. A) Parameters applied in this thesis and the range of perfusion rate 
to achieve laminar flow. B) Perfusion rates required to achieve a specific Re.   
C) Internal diameter of different blood vessels in physiology and their Re (124). 
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Figure 24: Structural properties of PCL tubing. A) The morphology of PCL fibres 
at 2000-fold magnification, scale bar: 20 µm. B) The overall specifications of PCL 
tubing. 
Figure 25: Cell culture experiments using PCL tubing functionalised with five 
different substrates after 8 days. For all the coatings, 1 mL substrate per cm PCL 
tubing was applied and conducted in triplicates. The documented specimens shown 
here possess the average appearance among the triplicates after staining with MTT. 
The yellow arrows on the specimen with COL I coating indicated the dense cell 
clusters that had accumulated over the course of cultivation. 
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3.1.1c  Optimal coating for bio-functionalisation of PCL tubing 
Based on the presence of violet formazan that can only be produced by 
viable and metabolic active cells, the COL I coating was shown most effective 
and suitable for subsequent cell culture experiments (Figure 25). However, the 
coating and cell culture procedures still require additional optimisations. Instead 
of the desired homogeneous HUVEC monolayer, the cells have accumulated in 
dense clusters instead (indicated by dense spots, yellow arrows). 
3.1.1d  The optimal collagen concentration and coating for bio-functionalisation 
After identifying rat-tail COL I being the most effective substrate for PCL 
tubing functionalisation, additional experiments were performed to determine the 
optimal COL I concentration for subsequent cell culture experiments up to         
15 days. Due to the limited quantity of PCL tubings, the optimisation procedures 
were performed on flat PCL fleece. It should be highlighted that the flat PCL 
fleece possesses the same fibre diameter and thickness as the PCL tubing and 
was electrospun on glass coverslips for ease of handling. Unlike the PCL tubing 
with curvature, the flat surface of the PCL fleece has ensured consistent and 
homogenous cell inoculation among different specimens. Hence, the effects of 
variable collagen concentrations for cell propagation can be assessed more 
accurately. Further, another set of specimens were freeze-dried to achieve more 
stable collagen coating on the PCL fleece. The efficacy of these freeze-dried 
samples to support HUVEC propagation was compared against the non-freeze-
dried specimens. As shown in Figure 26, HUVEC cultivated on freeze-dried PCL 
fleece tends to aggregate in clusters (large dense spots) after 7 days, while the 
non-freeze-dried fleece has more homogenous cell distribution and lesser cell 
aggregates. Despite higher cell number being recorded on the freeze-dried 
fleece after 7 days, much lesser is recorded against the non-freeze-dried fleece 
after 15 days (Figure 27). This trend is the same across all collagen 
concentrations applied and has demonstrated lesser efficacy of HUVEC 
propagation on freeze-dried fleece; caused by cell aggregation. 
Based on the observations from Figure 26 and 27, non-freeze-dried PCL 
fleece coated with 0.5 mg/mL COL I was selected and used in subsequent 
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bioreactor experiments. Taking good manufacturing practice (GMP) into 
consideration, removing the 19 h freeze-drying procedure will further eliminate 
the risks for pathogen or microbial contamination and reduce the labour required 
for deriving a functionalised scaffold. Furthermore, the non-freeze-dried PCL 
fleece coated with 0.5 mg/mL COL I had supported the most number of HUVEC 
after 15 days in culture (Figure 27). 
 
  
Figure 26: Identifying the optimal mode of collagen coating and the optimal 
concentration that support HUVEC propagation over 15 days. The COL I 
coating on PCL fleece was prepared through two methods: 1) used immediately after 
coating procedures (top), and 2) with 19 h freeze-drying after coating procedures 
(bottom). A total of 100,000 HUVEC was inoculated on each sample and cultivated 
at 37 °C with 5% CO2. 
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Figure 27: Cell number on different concentrations of COL I coating at 24 h,      
7 days and 15 days post-inoculation. The MTT assay showed little significant 
difference between the non-freeze-dried and freeze-dried PCL fleece. Overall, there 
is significant increase in cell number over the duration of cell culture among all 
samples, regardless of coated COL I concentration. Nonetheless, the 0.5 mg/mL 
non-freeze-dried PCL fleece had recorded the highest cell number after 15 days. 
Two-way ANOVA, p < 0.05; *** p < 0.001, **** p < 0.0001. 
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3.1.1e  Key specifications of vascular bioreactor 
 Active medium perfusion up to 10 mL/min can be applied to this setup. 
Even though this flow rate does not correlate with the physiological 
conditions, it is more than sufficient to support the naïve constructs derived 
in this thesis. 
 The adjustable ends of the bioreactor allow manipulation of PCL tubing 
tension with ease and induce variation in fluid flow dynamics. However, this 
feature is only applicable when the PCL tubing is cultivated in a pre-casted 
lumen (Approach A) and not completely encapsulated within the agarose 
bedding (Approach B). 
 PCL tubing of various diameter and length can be derived simply by 
changing the rod collector in the electrospinning apparatus, which enabled 
rapid prototyping in the future. 
 The electrospun PCL tubing is a suitable template for constructing a 
vascular structure. Using the layer-by-layer approach, a endothelial cell 
monolayer is first laid on the surface of the PCL tubing as foundation and 
subsequent cell layers can be stacked on top of this template thereafter. 
 Complete encapsulation of engineered vascular construct in 1.5% agarose 
bedding provides additional physical support to the PCL tubing, when 
medium was perfused through the lumen. Thus retaining the overall 
structural integrity of the naïve construct until it matured and gained 
structural stability. 
 Overall, this perfusion bioreactor prototype would generate a confined and 
stable environment that will allow construct development and maturation 
over time. This was done in an attempt to recapitulate the physiological 
environment in vitro and achieve functional off-the-shelf large vessel 
constructs. 
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3.1.2 Spinner flask for up-scaling hMSC expansion  
3.1.2a  The calculated hydrodynamics in the spinner flasks at various settings 
The efficacy of up-scaling hMSC expansion is strongly dependent on impeller 
design and its position in the spinner flask. Other than enhancing mass transfer, 
the resulting fluid shear force also exert mechanical cues that enhance hMSC 
proliferation (125–127). At optimal conditions, a stable laminar flow in the spinner 
flask will distribute the microcarrier beads homogeneously throughout the flask. 
This ensures each bead is exposed to similar fluid shear stress and homogenous 
batches of undifferentiated hMSC are derived after each set of cell expansion 
procedures. In contrast, a turbulent flow will cause inhomogeneous distribution of 
beads and the inconsistency in fluid shear force at different parts of the spinner 
flask will initiate either cell death or stem cell differentiation. Consequently, the 
efficacy of hMSC expansion is greatly reduced and the homogeneity of 
undifferentiated hMSC will fluctuate among different batches. This is detrimental 
for subsequent bone tissue engineering applications, as the requirements for 
good manufacturing practices (GMP) are not fulfilled. Since engineered bone 
constructs that do not comply with the GMP requirements are prohibited from 
clinical applications, it is important to characterise the hydrodynamic in the      
250 mL spinner flask, so that consistent production of undifferentiated hMSC in 
large quantity can be achieved. As an initial step, fluid flow patterns created by 
different stir rates and impeller dimensions are estimated by calculating the 
Reynolds number (Re); using Formula [5] mentioned in Chapter 2.2.2a. 
Generally, Hemrajani et.al. (128) described that a Re higher than 10,000 
indicates turbulent flow in the spinner flask and a range between 2500 to 5540 is 
typically applied in previous literatures for cell expansion (86,103,129). 
 Shown by Megan et. al. (86), a stir rod impeller is applied in the 125 mL 
spinner flask to achieve laminar flow. A Re of 5540 and max shear stress of      
8.45 dyn/cm2 is most effective for expanding human embryonic stem cells (hESC) 
in the spinner flask. Using the same formulas, Re, power dissipation and 
maximum shear stress are calculated using the parameters applied in the       
250 mL spinner flask and are summarised in Table 14. 
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Flask / 
impeller 
Stir rate 
(rpm) 
Re 
Power dissipation 
(W/kg) 
Maximum shear 
stress (dyn/cm2) 
125 mL/ 
rod 
100 5540 2.94 8.45 
250 mL/ 
wing 
90 5767 1.96 6.89 
250 mL/ 
rod 
90 7500 1.61 6.25 
3.1.2b  The hydrodynamics imposed by modified impellers and their effects on 
hMSC expansion  
Other than estimating the hydrodynamics in different spinner flask settings by 
calculating the Re, additional mode of analyses is available for more accurate 
assessments. This is typically accomplished using a high-speed camera and a 
computational fluid dynamic (CFD) software, Flow3D in this field of study     
(101–103). However, these pieces of equipment are not available in my 
laboratory. Hence, the fluid flow patterns of beads in the 250 mL/rod impeller 
settings were determined by analyzing multiple recordings at slow motion setting 
taken with an iPhone7. Together with the results from previous literatures, the 
hydrodynamics of each spinner flask setting are summarised in Figure 28. Briefly, 
the 250 mL/wing setup (Figure 12B) with 90 rpm stir rate will form three distinct 
zones in the flask (103,104). Majority of the beads will accumulate either at the 
bottom of the flask or near the edge of liquid surface (Figure 28A). The fluid 
shear stress at each zone are also different and the highest was recorded at the 
edge of the wing and near the liquid surface, where most beads accumulate 
(104,105). Further, the beads in the middle also have an increased tendency to 
hit against the flat surface of the wing impeller and induce cell necrosis. 
Table 14:  Calculated Reynolds number, power dissipation and maximum 
shear stress in specific spinner flask setup. The calculations are based on 
parameters from Figure 11. The values for the 125 mL/rod setup established 
by Megan et.al. are also listed here for comparison. 
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By removing the wing from the impeller (Figure 12C), the magnetic stir rod 
alone is too short to achieve a constant laminar flow. At low stir rate (≥ 60 rpm), 
the beads will simply accumulate at the bottom of the flask (Figure 28B). In 
contrast, a high stirring speed (≤ 120 rpm) will generate a vortex and two 
independent zones with different shear stress are generated. The beads will 
accumulate either within the vortex or remain stagnant along the edge of the 
spinner flask (Figure 28C). Under optimal conditions in a 125 mL flask with     
100 rpm stir rate (Figure 28D), a consistent laminar flow that enhances hMSC 
proliferation is generated (85,86,102). Similar principle is transferred to the     
250 mL flask, but an exact replication of the optimal condition is not possible in 
this thesis; due to technical difficulties to reconstruct a completely new impeller. 
Instead, custom-made acrylic rods are attached to both ends of existing rod 
impeller to increase the diameter and width of the stir rod (Figure 12D). Using the 
modified impeller, comparable fluid flow as the 125 mL spinner flask is also 
achieved in the 250 mL spinner flasks when a stir rate at 90 rpm is applied. 
 
 
Figure 28: Hydrodynamics in spinner flask with 90 rpm stir rate. A) Beads 
distribution when default impeller with wing is applied in 250 mL flask. B) Default 
impeller without wing in 250 mL flask, and with stirring at 50 rpm. C) Default impeller 
without wing in 250 mL flask, and with stirring at 90 rpm, D) Homogeneous beads 
distribution achieved in 125 mL spinner flask with stir rod impeller of appropriate 
diameter and width, and stirring at 100 rpm. 
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Interestingly, the Re of 250 mL/wing and 125 mL/rod are comparable, but 
lesser maximum shear stress was generated. Despite similar laminar fluid flow 
achieved in both setup, the wing impeller (Figure 12B) is shown ineffective for 
hMSC expansion in initial trials (Figure 29) and hMSC lose their spindle shape to 
become polygonal (indicated by red arrows), an indicator for hMSC undergoing 
differentiation. In contrast, a higher Re at 7500 is attained when the extended stir 
rod impeller (250 mL/rod, Figure 12D) is applied; an indication that the fluid flow 
generated with the modified impeller being more turbulent than the 250 mL/wing 
and 125 mL/rod setup. However, the maximum shear stress is lower             
(6.25 dyn/cm2); due to higher medium volume and lower stir rate. Nonetheless, 
the 250 mL/rod setup is efficient at deriving large quantity of undifferentiated 
hMSC required for subsequent experiments in the bone bioreactor.  
3.1.2c  Optimising the inoculation medium for the 250 mL flask setting  
Since a larger spinner flask and more microcarriers can potentially be applied, 
additional experiments are set up to establish a working protocol for the 250 mL 
spinner flask. The final parameters applied in this thesis and those of the 125 mL 
flask are summarised in Table 15. Unlike the 125 mL that applied inoculation 
medium at pH 8.0, hMSC adhesion on microcarrier beads is enhanced in serum-
free DMEM inoculation medium at pH 7.6 in the 250 mL flasks. Due to the larger 
volume of medium used in this thesis, at least 4.5 g of sodium bicarbonate 
(NaHCO2) has to be added to the medium to achieve pH 8.0 with 5% CO2. 
However, the concentration of NaHCO2 is detrimental to hMSC and does not 
support stable cell propagation. Furthermore, additional pH adjustments to return 
the acidity of medium to pH 7.6 (optimum for hMSC proliferation) had to be done 
before the cultivation phase begins. To keep the expansion protocol simplified, 
the inoculation medium is maintained at pH 7.6 in this thesis. 
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Table 15: Parameters applied during the cell inoculation and cultivation phase. 
Parameters 250 mL flask 125 mL flask 
Medium volume (mL) 250 100 
hMSC : microcarrier 
ratio 
5:1 / 10:1 5:1 
Inoculation conditions 
37 °C, 5% CO2 
Intermittent stirring at 100 rpm 
(8h: 3 mins stirring, 27 mins pause) 
Inoculation medium Serum-free DMEM 
pH 7.6 8.0 
Cultivation conditions 
37 °C, 5% CO2 
Constant stirring at 90 rpm 
Cultivation medium DMEM with 10% FBS 
Figure 29: hMSC morphology and proliferation at various stir rates with wing 
impeller. (left) Cells cultivated for 12 days in spinner flask at 30 rpm (top) and 90 
rpm (bottom) lost their regular spindle shape and became polygonal in shape (red 
arrows), scale bar: 50 µm. (right) The higher stirring rates at 70 rpm and 90 rpm 
(dotted lines) do not support hMSC proliferation. Although the lower stirring rates at 
30 rpm and 45 rpm (solid lines) have supported hMSC proliferation after 1 day, they 
remained rather ineffective. The final hMSC number was similar to the initial 
inoculated amount despite 12 days of cultivation. 
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3.1.2d  Inoculation medium with FBS induced higher hMSC accumulation in a 
bead  
Using a serum-free inoculation medium, hMSC are evenly distributed and at 
least one cell is detected on majority the beads (Figure 30). In contrast, cell 
adhesion is rather inhomogeneous when the inoculation medium is 
supplemented with 10% fetal bovine serum (FBS). While some beads may 
contain many hMSC; there are many other beads that contained no cells at all. 
Since hMSC do not migrate between the beads during the cultivation phase, it is 
most ideal to have small quantity of hMSC distributed homogeneously in every 
bead. This will maximize the surface area available for cell proliferation and yield 
the most number of hMSC after expansion. With a high density of hMSC already 
accumulated in a bead upon inoculation, the capacity for further cell proliferation 
is compromised. Shown in Figure 31, the most hMSC is harvested after 12 days 
of cultivation when serum-free inoculation medium is applied; despite more cells 
are recorded 24 h post-inoculation with 10% serum inoculation medium. 
 
  
Figure 30: hMSC inoculation on Cultispher®-S beads. Cell-free beads viewed 
under a light microscope and microcarriers strained with DAPI (white spots) at 24 h 
post-inoculation, scale bar: 200 µm. At least one cell is detected on majority of 
microcarriers when serum-free inoculation medium at pH 7.6 is applied (white 
arrow). When 10% FBS is supplemented, hMSC would tend to accumulate on a 
single bead, while many others remained cell-free (yellow arrow). 
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3.1.2e  Increasing the yield of hMSC from 250 mL spinner flask with rod impeller 
Other than increasing the efficacy of cell inoculation, the larger quantity of 
beads applicable in the 250 mL spinner flask can also be exploited to increase 
the yield of hMSC further. Shown in Figure 30, there remained beads that 
contained no hMSC when a cell:bead ratio of 1:5 is applied during cell 
inoculation. Hence, additional experiments with a ratio of 1:10 is applied and the 
total yield of hMSC harvested after 12 days from a single flask is increased from 
7.6 x 106 to 18.3 x 106 hMSC (Table 16). Nonetheless, additional exploitations 
remained possible, as empty microcarrier beads are still observed after the 
higher cell:bead ratio is applied. 
Additionally, application of freshly thawed hMSC to the beads during the 
inoculation procedures is also investigated. Interestingly, preliminary 
observations showed that similar yield of hMSC described in Table 16 is 
achieved, despite prior expansion in cell culture flask for 1 passage phase was 
not performed. However, it should be noted that the stir rate of freshly thawed 
hMSC has to be reduced from 100 rpm to 70 rpm during the cell inoculation step 
to ensure success. 
Figure 31: Effects of FBS supplement over hMSC inoculation on 
Cultispher®-S beads. Despite higher cell number recorded at 24 h post-
inoculation with 10% FBS inoculation medium, a higher yield of hMSC is 
harvested after 12 days when serum-free inoculation medium is applied. This is 
likely an effect of variable hMSC distribution on the beads shown in Figure 30. 
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Table 16: Comparing the efficiency of hMSC expansion after 12 days in 
traditional vessel (T175) versus the 250 mL spinner flask. 
 
3.1.2f  hMSC remained undifferentiated after expansion in spinner flask  
Unlike the polygonal shape described in Figure 29, the unique spindle shape 
of hMSC is retained after 12 days of expansion in spinner flask with the modified 
stirred rod impeller (Figure 32A, left). Furthermore, the cell morphology is 
retained even after further expansion in a cell culture flask for another 6 days 
(Figure 32B, right). These observations indicated that hMSC expansion in the 
modified 250 mL spinner flask will not result in spontaneous hMSC differentiation. 
The effect is also sustainable and hMSC will continue to propagate stably even 
after being removed from the spinner flask. 
The multipotency of hMSC is further assessed through two methods: 1) gene 
expression profiling with qPCR and 2) differentiation assays. The expression of 
two major stem cell markers, CD90 and Sox2, is evaluated. The relative gene 
expression of hMSC from spinner flask is normalized against hMSC from T175 
flask (control); both expanded for 12 days on respective vessels. Generally, 
CD90 and Sox2 expression are elevated in the hMSC from spinner flask and 
they are 1.09 ± 0.202-folds and 3.99 ± 1.87-folds higher than hMSC from T175 
flask respectively. Nonetheless, student t-test performed on each gene has 
showed no statistical differences (Figure 32B). Additionally, standard 
differentiation assays are performed on hMSC from both sources to validate 
multipotency of expanded cells. The potential for hMSC to undergo 
chondrogenesis is assessed by aggregate formation and positive alcian blue 
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staining, while osteogenesis is assessed by positive alizarin red staining. Shown 
in Figure 32C, there are also no significant variabilities between the differentiated 
derivatives from both hMSC sources. Taken together, it is concluded that the 
hMSC expansion procedures conducted in the spinner flasks for 12 days with 
continuous stirring at 90 rpm will not affect the multipotency of the hMSC and are 
similar to hMSC derived from conventional cell culture flasks. 
 
 
 
Figure 32: Characterisation of hMSC and validating their multipotency after 
expansion for 12 days in spinner flasks. A) Morphology of hMSC after 12 days 
expansion in the spinner flask and laid down overnight in cell culture flask (left). 
hMSC after further cultivation in cell culture flask for 6 days (right). Scale bar: 
100µm. B) The relative gene expression of stem cell markers, CD90 and Sox2, with 
hMSC from spinner flask normalised against hMSC from T175 flask; n = 9, hMSC 
#282, #540, #575 in triplicates, p = 0.056, no statistical differences. C) Differentiation 
assays to check the potential for expanded hMSC (#282, #575) to undergo 
chondrogenesis (blue, alcian blue) and osteogenesis (red, alizarin red). 
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3.1.2g  Key specifications of spinner flasks 
 The porous beads have increased the surface area for hMSC adhesion and 
proliferation significantly; in comparison to traditional cell culture flask. Thus, 
increasing the potential for up-scaling hMSC expansion. 
 Effective cell inoculation on microcarrier beads (at least 1 cell per bead) is 
achieved, when a serum-free inoculation medium, pH 7.6 is applied. The 
procedure is also sufficiently stable to support freshly thawed hMSC retrieved 
from the liquid nitrogen. 
 A stir rod impeller will generate the most favorable hydrodynamics required 
for effective hMSC expansion. The modified impeller applied in this thesis 
would generate more turbulent fluid flow (Re = 7500), but lesser maximum 
fluid shear stress of 6.25 dyn/cm3. 
 Additional modifications can be made to the existing stir rod impeller to 
achieve similar optimal parameters applied in the 125 mL spinner flask. The 
impeller diameter (Di) can be shorten to reduce turbulence and increased 
impeller width (W) will induce higher fluid shear stress. 
 The applied hydrodynamics have reduced the doubling time of hMSC 
effectively and is generally not lethal to the hMSC over 12 days. At least 4-
fold more hMSC is achieved in the spinner flask than in conventional cell 
culture vessels. The final cell number can be further increased by inoculating 
more hMSC to the beads. 
 The multipotency of hMSC is not affected by the expansion procedures in 
spinner flask and can still be expanded stably on cell culture flask thereafter. 
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3.1.3  Bone bioreactor 
3.1.3a  Real-time pO2 measurements from M.Sc. thesis 
Real-time measurements of oxygen partial pressure (pO2) at different parts of 
the bioreactor were conducted using OXYLITE 2000E multi-channel modular 
monitoring system (Oxford Optronix). The black dots (Figure 13, left) indicate the 
positions that the probes were positioned on the bioreactor. Generally, little pO2 
fluctuation was recorded in the medium reservoir and 99.65 ± 1.11 Torr (14.0%) 
was recorded after 36 h. The recorded measurements suggested a highly 
efficient re-oxygenation mechanism of medium in place. Hence, the pO2 of 
circulating medium should be similar to the medium reservoir, until being 
consumed by the cells in the bioreactor. With the settings described in Figure 13, 
pO2 distribution could be manipulated simply by adjusting the rate of medium 
perfusion. Further, the added distance between the bottom section and hollow 
channels had also increased the distance for oxygen diffusion, and enforced the 
development of a hypoxic environment. In turn, a pO2 gradient in longitudinal 
direction was achieved, when 5x106 mESC and medium perfusion at 5.5 mL/min 
was applied. The mean pO2 recorded at the top section was 83.26 ± 1.41 Torr 
(11.7%), the middle portion was 39.63 ± 2.14 Torr (5.6%), and the bottom section 
was 0.64 ± 0.09 Torr (0.09%). Further, the pO2 gradient was established 36 h 
after inoculation of mESC-laded collagen hydrogel construct (Figure 33). In 
contrast, a uniform hypoxic environment with mean pO2 of 0.24 ± 0.16 Torr 
(0.03%) was recorded throughout the construct, when medium perfusion at      
1.5 mL/min was applied. 
3.1.3b  Mathematical modelling of pO2 evolution in the bone bioreactor 
A mathematical model is derived based on the experimental measurements, 
so that the primary causal factor and evolution of pO2 in the bone bioreactor can 
be elucidated. Generally, the simulation showed that the entire bioreactor will be 
well-supplied with oxygen, regardless of medium perfusion rate. Oxygen 
depletion is primarily a localised effect caused by cellular oxygen consumption 
(Figure 34). Based on the experimentally measured oxygen concentrations over 
time at both perfusion rates, pO2 evolutions of similar trends were derived 
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(Figure 35A) by fitting cell concentration evolutions. The curves (Figure 35B) are 
constructed by parametric sweeps over the cell concentration at selected time 
points. The different points are then connected with piece wise cubic 
interpolations. As shown in Figure 35B, distinct fluctuations in cell concentration 
occurred when the medium is perfused at 1.5 mL/min. In contrast, changes in the 
fitted cell concentration were more gradual when the medium is perfused at 
5.5 mL/min. At 5.5 mL/min, the simulation also indicated that the regions of with 
highest pO2 is achieved when the cell per volume ratio is ≤ 0.25 x 10
6 cells/cm3, 
while hypoxia would be induced with ≥ 1.5 x 106 cells/cm3 (Figure 35B). Further, 
a lower cell per volume ratio will still generate similar trend when the medium 
was perfused at 1.5 mL/min. These results demonstrated the secondary effects 
of medium perfusion rate on pO2 evolution in the perfusion bioreactor.  
 
 
Figure 33: The effects of medium perfusion rate on pO2 distribution in the 
perfusion bioreactor over 36 h. The solid lines represent pO2 measurements made 
in bioreactors with 5.5 mL/min medium perfusion rate; while dotted lines at the 
bottom had 1.5 mL/min applied over 36 h. The darker lines represent measurements 
made in the top section of the mESC-laded constructs and the lighter lines represent 
measurements made in the bottom sections. The top-most dotted line represents 
measurements made in the medium reservoir. Two-way ANOVA, **** p < 0.0001. 
 
Results and Discussion 
118 | P a g e  
 
 
 
 
 
Figure 34: A summarised schematic of oxygen distribution in perfusion 
bioreactor over time, derived through mathematical modelling. A) pO2 
development in bioreactors with 1.5 mL/min medium perfusion rate. B) With 5.5 
mL/min medium perfusion rate. 
Figure 35: Mathematical modelling of local oxygen development in relation to 
cell concentration over time. A) Simulated oxygen evolution with mathematical 
model (lines) and actual measured values from experiments (points). The simulation 
was conducted in a way that the simulated values were made as close to the 
measured values as possible, so that a similar trend was achieved. B) Using the 
simulated pO2 values derived from (A), the cell concentration required to derive each 
measured pO2 value was determined. 
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In summary, the mathematical model has identified local cell per volume ratio 
as the primary causal factor for pO2 gradient development in the bone bioreactor. 
Other implemented parameters such as medium perfusion rate and proximal 
distance between cultivation platforms and hollow channels are identified as 
secondary factors that further enforced the pO2 gradient. As shown in Figure 36, 
the spatial distribution of cells in the broad top section is relatively sparse, while 
cells in the narrow bottom section are closely packed together. In complementary 
with the higher convection flux when 5.5 mL/min medium perfusion is applied, 
oxygen diffusion through the construct will occur at a faster pace through the 
spaces between the cells. Consequently, an oxygenated niche is generated at 
the top section, since oxygen is quickly replenished while being consumed by the 
cells. In contrast, the compact cell arrangements in the bottom section will greatly 
reduce the efficiency for oxygen diffusion through the construct; it will already be 
consumed by cells along the periphery before reaching the inner volume.  
Further, it should be highlighted that the high cell seeding density applied in this 
study also plays a critical role. Unlike typical in vitro studies (130–132) , at least 
five times more cells are used in this study and a cell per volume ratio of 1 x 107 
cells/cm3 is applied. Although such high cell density is physiologically relevant 
(83,133,134), many previous studies maintain cell viability until the engineered 
constructs reached maturity and attained resemblance to the native bone tissue. 
Although efforts are made by increasing the rate of medium perfusion (135–137), 
this approach has its own limitations. Even though mass transfer is enhanced, 
the excessive fluid shear stress generated is destructive to the engineered bone 
constructs, especially biological hydrogels that are structurally fragile. To address 
the issues with excessive fluid shear stress, collagen hydrogel constructs applied 
in this thesis are encapsulated within agarose bedding and medium is perfused 
through hollow channels casted alongside the constructs. This approach is 
shown effective as hydrogel constructs have propagate stably over 60 days, 
even when a high continuous medium perfusion rate at 5.5 mL/min is applied. 
Interestingly, the higher perfusion rate (5.5 mL/min) investigated in this study has 
a secondary effect on pO2 distribution. Shown in the model (Figure 35B), the 
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higher perfusion rate has consistently kept the bottom sections compact with 
cells (high cell per volume ratio), while the ratio in the top sections decreased 
gradually over 36 h. In contrast, this ratio is similar throughout constructs 
cultured at a lower perfusion rate (1.5 mL/min). In relation to the direction of 
medium flow, the higher perfusion rate have moved the mESC in a top to bottom 
direction and kept the bottom sections compact with cells (Figure 36). As a result, 
a stable pO2 gradient is developed and for the first time, direct investigations on 
the effects of pO2 over stem cell differentiation could be done on the same 
construct. Additionally, the proximal distance between the constructs and hollow 
channels has further enforced the stability of pO2 gradient (Figure 13, left). Being 
further away from hollow channels, oxygen diffusion is slower at the bottom 
section than the top section. This is validated by higher measured pO2 at the top 
sections (0.41 ± 0.23 Torr) than the bottom sections (0.07 ± 0.08 Torr), when 
medium is perfused at 1.5 mL/min and both sections have similar cell per volume 
ratio.  
 
 
Figure 36: Hypothesized spatial distribution of mESC in the top and bottom 
section of bone construct applied in this study. The larger dimensions of the top 
section allow sparse distribution of mESC and oxygen to diffuse between the cells. 
The narrow bottom section has kept the cells compact and reduced oxygen diffusion 
has derived a hypoxic environment. Further, the top-down medium flow also kept the 
bottom section compact with cells, specifically by high perfusion rate (5.5 mL/min). 
 
Results and Discussion 
121 | P a g e  
 
3.1.3c  Key specifications of the bone bioreactor 
 3D cultivation environment with enhanced mass transfer is achieved by 
applying high medium perfusion rate (5.5 mL/min). 
 At 5.5 mL/min perfusion rate, the recorded mean pO2 at the top section was      
83.26 ± 1.41 Torr (11.7%), the middle portion was 39.63 ± 2.14 Torr (5.6%), 
and the bottom section was 0.64 ± 0.09 Torr (0.09%) after 36 h. Further, the 
medium reservoir recorded a relatively stable pO2 at 99.65 ± 1.11 Torr 
(14.0%). 
 Cultivation platforms of irregular dimensions could be casted within the 
agarose bedding and allowing tailored bone grafts to be generated in vitro.  
 Agarose bedding provided an isolated niche that support propagation of bone 
constructs and also protected the fragile hydrogel from the destructive effects 
of excessive fluid shear stress. 
 Stable longitudinal pO2 gradient that allowed for the first time, an accurate 
assessment on the effects of pO2 over the development of a single construct. 
 Easy manipulations of pO2 distribution by adjusting: 
1.  Medium perfusion rate. 
2. Reconfiguring dimensions of cultivation platforms or hollow channels for 
medium perfusion. 
3. Cell seeding density and dimensions of cultivation platforms/bone 
constructs (cell per volume ratio).  
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3.2 Deriving engineered large blood vessels in bioreactor: A proof-of-
concept 
After deriving a tubular poly-ϵ-caprolactone (PCL) template through 
electrospinning and determining the optimal collagen concentration to 
functionalise the material, human umbilical vascular endothelial cells (HUVEC) 
are applied on the material and cultivated in the vascular bioreactor. The aim of 
this set of experiments is to gain insights on the effects of different cell 
inoculation methods, and cultivation parameters on construct development. At 
the end, specifications that are essential for deriving tubular construct with a 
monolayer of HUVEC in such bioreactor is identified.  
3.2.1 Cultivating HUVEC-laded PCL tubing in hanging space disrupts cell 
propagation (Approach A) 
As described in Chapter 2.3.3, a hollow channel is pre-casted within the 
agarose bedding and the PCL tubing is cultivated with physical space around it 
in the bioreactor. A total of 1.5 x 106 HUVEC is inoculated onto the 50 mm PCL 
tubing and cultivated for 10 days. Medium is perfused through the lumen of the 
tubing at either 2.5 mL/min or 5.5 mL/min. A static control is prepared separately 
and cultivated on a petri dish with same volume of medium and duration applied. 
Generally, the procedures for cell inoculation is effective (24 h) and the HUVEC 
continued to propagate in static culture (increasing violet staining from MTT 
assay) over 10 days. In contrast, violet staining is absent on both tubings 
cultured in continuous medium perfusion for 10 days, despite positive staining 
still being detected at 5 days post-inoculation (Figure 37). 
A possible explanation for the lack of staining in the perfusion culture is that 
the cells are potentially displaced from the tubing by the perfusing medium. 
Without a physical support, the HUVEC are likely washed out of the bioreactor or 
are induced to undergo apoptosis (Figure 38). Hence, it is concluded that a 
dense surface has to be applied together with the mono-cellular culture and this 
is subsequently accomplished through complete encapsulation of PCL tubing in 
agarose bedding. Interestingly, this has highlighted the importance of the Tunica 
media (the smooth muscle cell layer) of the blood vessel in physiology (138,139). 
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Similar in both conditions, HUVEC require additional physical support to continue 
with propagation; in the presence of actively perfusing medium/blood. 
 
 
 
 
Figure 37: MTT staining of HUVEC-laded PCL tubings cultivated in static or 
with active medium perfusion (Approach A). The 50 mm PCL tubing is cut into 
shorter specimens of ~15 mm and stained separately with MTT for 4 h at 37 °C. The 
figure illustrates the distribution of viable cells (violet colour) across the specimens 
cultivated in 1) static condition, 2) with continuous medium perfusion at 2.5 mL/min, 
and 3) at 5.5 mL/min. The specimens are isolated at 24 h, 5 days and 10 days post-
inoculation of on PCL tubing. 
 
 
Figure 38: The potential of active medium perfusion to displace HUVEC from 
PCL tubing. With the highly porous PCL scaffold, the medium would have perfused 
through the tubing into the PCL-agarose interphase and displacing HUVEC from the 
PCL tubing during the process. 
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3.2.2 Complete encapsulation of HUVEC-laded PCL tubing in agarose 
enhanced construct maturation in perfusion culture (Approach B) 
Described in Chapter 2.3.4, the PCL tubing is encapsulated completely in the 
agarose bedding and 1.5x106 HUVEC are inoculated directly into the lumen. The 
setup is incubated at 37 °C, 5% CO2, overnight in static condition to facilitate cell 
adhesion on the PCL tubing; before active medium perfusion at 2.5 mL/min is 
applied. In this set of experiments, medium perfusion is applied in two regimes:  
1) continuously for 10 days, 2) intermittent: 1 day with perfusion, 3 days static; 
followed by analysis conducted at 24 h and 10 days post-inoculation. As shown 
in Figure 39, the efficacy of HUVEC inoculation is less homogeneous than the 
approach applied in Approach A (Figure 37). Furthermore, less intense violet 
stains are observed in all the specimens after 10 days in culture. Hence 
additional analyses with DAPI staining are performed to validate the presence of 
HUVEC on the PCL tubing. 
 
 
Figure 39: MTT staining of HUVEC-laded PCL tubings that were completely 
encapsulated in agarose. The 24 h specimen is representative for all condition 
applied, since they all shared a common start point and the method for HUVEC 
inoculation was the same. The positions that the specimens were isolated from the 
PCL tubing are indicated by the red lines. Further, the appearances of constructs 
cultivated at each condition for 10 days are shown at the bottom. The violet stain 
indicates metabolic active viable cells on the PCL tubing and it most obvious when 
intermittent perfusion was applied. 
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3.2.3  Analysing with DAPI fluorescence stain 
Further analysis with DAPI staining (blue dots) have validated the presence of 
HUVEC on respective PCL tubing and the light violet staining in Figure 39 are not 
false positive. Based on the fluorescence images, the effects of each applied 
conditions on HUVEC propagation are as follows: Intermittent > Static > 
Continuous (Figure 40). The application of intermittent medium perfusion is most 
effective and has best supported HUVEC propagation. Interestingly, continuous 
application of medium perfusion is found least effective, even with a rather low 
perfusion rate (2.5 mL/min) being applied. Further, it is noted the HUVEC on 
specimens cultivated in perfusing medium have accumulated on the surface of 
PCL tubing that was in contact with the agarose bedding. Almost no cells are 
detected at the lumen surface, which is possibly a cellular response to fluid shear 
stress and can be correlated to the observations made in Approach A (Figure 38). 
In contrast, cells are detected on both sides of the tubing that were cultivated in 
static.  
 
 
3.2.4   Intermittent medium perfusion promotes stable HUVEC propagation 
on PCL tubing 
The positive effects of fluid shear stress on blood vessel development and 
maturation are indisputable and are shown by multiple literatures in the field 
(140–144). Furthermore, blood perfusion at physiological condition occurs 
Figure 40: DAPI-fluorescence staining of HUVEC-laded PCL tubing cultured in 
the bioreactor at variable conditions for 10 days. The intensity of DAPI staining 
(blue dots) is relative to the amount of viable cells attached on the PCL tubing. The 
images suggested that the intermittent medium perfusion approach had best 
supported HUVEC propagation, while continuous medium perfusion at 2.5 mL/min for 
10 days was least effective. Scale bar: 100µm 
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continuously round the clock. Hence, this is a critical feature that has to be 
included for vascular tissue engineering. However, it should be highlighted that 
the constructs derived in this thesis are still in a rather naïve state and only 
HUVEC are applied to the PCL tubing. The construct still lacks the structural 
integrity and the support from other cell layers (smooth muscle cells and 
connective tissue) to handle the fluid shear stress generated by continuously 
perfusing medium. And this is further supported by the observations made in 
Approach A. Hence, the focus should be directed at identifying the optimal 
perfusion approach that supports stable HUVEC propagation on the PCL tubing.  
The results described in Chapter 3.2.2 and 3.2.3 showed that the application 
of intermittent medium perfusion (1 day perfusion, 3 days static) has supported 
HUVEC proliferation most effectively. Instead of exposing the HUVEC to 
constant fluid shear stress (continuous perfusion), the 3 days static condition has 
given sufficient time to the cells to become stabilised on the PCL tubing. 
Subsequently, the next burst of mechanical stimulation applied through 1 day 
continual medium perfusion would have activated the proliferative mechanisms 
(144–146), and the cycle continues until the construct matures. Such postulation 
on the enhancing effect of fluid shear stress over HUVEC proliferation can be 
validated through the corresponding static culture. When no active medium 
perfusion is applied, cell proliferation is reduced. Apart from the mechanical 
stimulation, the intermittent application of medium perfusion also helped to 
refresh the exhausted medium in the bioreactor and replenish the nutrients and 
oxygen that are already depleted by the cells. Hence, future investigations 
should be designed to improve 1) the HUVEC inoculation protocol, and               
2) medium perfusion regime; before further experimentations with smooth 
muscle cell co-culture or increment of perfusion rate should be set up. 
Nonetheless, the results derived in this thesis are good leverages for future 
studies. 
3.2.5 The cell inoculation procedures require further optimisations 
As shown in the illustrations representing specimens that are derived 24 h 
post-inoculation (Figure 37 and Figure 39), a significant difference in the efficacy 
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of both cell inoculation approaches is observed. A better outcome is achieved 
when cell inoculation on the PCL tubing is performed in a customised apparatus 
(Figure 14). The constricted space within the hollow channel has increased the 
tendencies for cell-scaffold interactions and facilitated cell adhesion. Additionally, 
this effect is enhanced by the relatively hydrophobic agarose bedding, which 
denied cell adhesion and facilitated further cell-scaffold interactions. Ultimately, 
extensive HUVEC proliferation is ensured when the PCL tubing is cultivated on a 
petri dish in static. However, this effect is negated with application of active 
medium perfusion at 2.5 mL/min and 5.5 mL/min through the lumen of PCL 
tubing (Figure 37). Hence, an alternative cultivation method that encapsulated 
the entire PCL tubing in agarose bedding (Approach B) is applied. However,  
pre-seeding of HUVEC on the PCL tubing is impossible, as the gelation 
temperature of agarose is approximately 42 °C and a 1.5% agarose gel will 
generally require 15-20 mins to harden. These conditions will be lethal to the    
pre-seeded HUVEC during the casting procedures. Based on a previous 
literature (137), HUVEC are inoculated directly onto the PCL tubing in the 
vascular bioreactor and left in static for 12–16 h to facilitate cell adhesion onto 
the surface of PCL scaffold. Unfortunately, this cell inoculation approach is less 
effective. It is observed that the cells had accumulated at specific region of the 
PCL tubing (Figure 39, 24 h, specimen on the left) and no cells are observed 
near the inlet/outlet end of the tubing (specimen on the right). Such 
inhomogeneity in cell inoculation is undesirable for tissue engineering purposes, 
and possibly explains the light violet MTT staining on the specimens isolated 
after 10 days in culture. Hence, better inoculation methods have to be developed 
in future experiments, so that a more homogeneous HUVEC distribution can be 
achieved on the PCL tubing. Some potential approaches (148) may include:        
1) rotating the bioreactor during inoculation phase, 2) applying short bidirectional 
perfusion to enhance mixing, 3) increasing inoculating cell density, 4) applying 
low melting agarose to reduce gel casting temperature and duration, 5) deriving 
agarose bedding through multiple dip-coating of PCL tubing in melted agarose. 
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3.3  Characterisation of bone bioreactor with mESC 
3.3.1  Gross physical properties of constructs 
The gross physical appearance of all collagen constructs after 30 days and 
60 days in culture are summarised in Figure 41A, together with their mechanical 
stiffness in Figure 41B. The CM (30 days) is representative for both CMOM and 
CMCM constructs, since both are cultivated similarly in the first 30 days and no 
significant differences are observed. Generally, both OM and CM constructs 
have retained gel-like morphology after 30 days. However, the OM constructs 
are relatively fragmented and distinct shrinkage is observed, while CM constructs 
have remained structurally stable and have adopted the dimensions of the 
cultivation platform (Figure 41A, left). Nonetheless, more distinctive differences 
between the constructs are observed after 60 days. The OMOM constructs have 
condensed further to form compact and slender constructs with uniform 
dimensions from top to bottom. Despite lesser shrinkage observed in CMCM 
constructs, they possess lesser structural integrity than the CMOM. Furthermore, 
irregular structural condensation is observed on CMCM constructs and a gel-like 
texture is retained. In contrast, the CMOM constructs are structurally stable and 
the geometries of the cultivation platform pre-casted in the agarose bedding are 
retained.  Additionally, the CMOM constructs have a dense ivory coloration 
(Figure 41A, right). 
In Figure 41B, only the measurements taken from the top section of collagen 
hydrogels are tabulated. Due to the slender dimension of the bottom section, it 
will disintegrate during the measuring procedures and inaccurate values are 
retrieved. Hence, the bottom sections of cell-free hydrogels are omitted. 
Generally, the mean Young’s modulus of cell-free CM hydrogel is 55.40 ± 4.653 
Pa and OM hydrogel is 96.15 ± 11.32 Pa. The mean Young’s modulus of 
constructs after 60 days is: CMCM top: 184.7 ± 13.43 Pa, CMCM bottom: 396.6 
± 35.38 Pa, CMOM top: 434.6 ± 82.73 Pa, CMOM bottom: 652.2 ± 99.65 Pa,                           
OMOM top: 2333 ± 220.7 Pa and OMOM bottom: 1915 ± 245.9 Pa. All the 
constructs are significantly stiffer than their corresponding cell-free hydrogels, 
specifically with OMOM constructs that recorded a 22-fold increase. Within the 
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same construct, only the top and bottom section of CMCM are significantly 
different, while no differences are recorded in CMOM and OMOM constructs. 
Nonetheless, a step-wise increment in mechanical stiffness of the same section 
from each construct was recorded: CMCM top < CMOM top < OMOM top; and 
similar trend is also observed for the bottom sections.  
  
Figure 41: Physical appearance and Young´s modulus of constructs after 60 
days in culture. A) The illustration on the extreme left showed the actual 
dimensions of cultivation platform casted in the agarose bedding. When compared 
across all the samples, CM (30 days) and CMOM (60 days) have adopted the 
dimensions of the cultivation platform. In contrast, condensation is observed on OM 
(30 days), OMOM (60 days) and CMCM (60 days) and the dimensions of cultivation 
platform are not preserved. B) The mean Young’s modulus ± SD derived from at 
least 50 measurements from individual sample is presented. As a point of reference, 
measurements from corresponding cell-free collagen hydrogel are included.  n=2,    
* p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001. 
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3.3.2 Correlating cell nodules and mineralised contour to Young´s modulus 
Initial investigations on the potential causal factors for variability in 
mechanical stiffness and morphologies among the constructs are done with 
histological staining. The cross-section of each construct is stained with alizarin 
red and alcian blue; to identify calcium and glycosaminoglycan (GAG) 
respectively. Shown in Figure 42, positive staining is observed mainly in cell 
aggregates or nodules (black arrows) and along the periphery of the constructs 
(red arrows). Although, the intensities of both stains are similar in all samples, 
the number and size of cell aggregates/nodules are significantly different. Further, 
a defined mineralised contour is also absent in CM and CMCM constructs. 
 Along the periphery of OM construct (30 days), cell nodules are present 
throughout the construct and fragmented contour (red arrow) is observed. In 
contrast, only small cell aggregates (black arrows) are observed in the top 
section of CM constructs (30 days) and a mineralised contour is absent. After 60 
days, the entire OMOM construct has a uniform mineralised contour that 
contributed a defined cylindrical geometry (red arrow). In addition, three distinct 
structures are observed along the periphery: 1) dense cell aggregates of 
irregular sizes; stained positive by alcian blue, 2) nodules with discoloration in 
alcian blue but with more intensive alizarin red, and 3) nodules with defined 
edges and a detached condensed core stained positive for alizarin red. Similarly, 
mineralised contour is also observed in CMOM constructs, but is fragmented and 
has resembled the OM construct (30 days). Nonetheless, comparable cell 
aggregates and nodules are observed and fibrillation is also observed in some 
nodules. Unlike the OMOM and CMOM constructs, CMCM constructs do not 
have a mineralised contour. Large cell aggregates stained positive for alizarin 
red or alcian blue are observed throughout the construct, and nodules were 
scarce. Interestingly, the presence of cell nodules and mineralised contour can 
be correlated to the mechanical stiffness measured. With a uniform mineralised 
contour, OMOM constructs recorded the highest Young’s modulus. This is 
reduced in CMOM constructs with fragmented mineralised contour and CMCM 
constructs without mineralised contour have the least Young´s modulus. 
 
 
 
 
 
Figure 42: Alizarin red and alcian blue staining of cross-sections from all constructs. The schematics were presented at 5x 
(scale bar: 100 µm) and 20x magnification (scale bar: 200 µm) panels to illustrate the overall morphology of each construct and a 
closer look at the cell aggregates, nodules and mineralised contour present in respective samples The mineralised contour (red 
arrow), cell aggregates and spherical nodules (both in black) in each construct are indicated with arrows. 
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3.3.3  Effects of differentiation regimes on cell nodules development 
Since the presence of cell nodules correspond to mineralised contour 
formation and increased mechanical stiffness of CMOM and OMOM construct, 
the contributions of nodule size and quantity of nodules are further investigated 
and summarised in Figure 43. Generally, cell aggregates/nodules are observed 
in both sections of OM constructs at similar size and quantity, while only cell 
aggregates are observed in CM constructs. Further, aggregate size in CM 
constructs has corresponded to pO2. The oxygenated top section has larger 
aggregates (46.3 ± 4.6 µm) than the hypoxic bottom section (18.8 ± 2.2 µm).  
After 60 days, the size and quantity of nodules in OMOM constructs remained 
similar to OM constructs. Interestingly, larger nodules are now visible in CMOM 
constructs and the quantity is comparable to the OMOM constructs; despite only 
30 days of osteogenic differentiation. In both OMOM and CMOM constructs, pO2 
has little influence over nodule size, but more nodules are found in top section. In 
contrast, continual cultivation in acidic chondrogenic medium has formed 
minuscule aggregates/nodules in CMCM constructs. Also unlike the CMOM and 
OMOM constructs, pO2 has stronger influence over the size and quantity of cell 
aggregates in CMCM constructs. The oxygenated top section generally has 
smaller aggregates but in larger quantities than the hypoxic bottom section that 
contained larger aggregates but are fewer in numbers (Figure 43, right). 
3.3.4  Further characterisation of cell nodules with immunofluorescence (IF) 
Further IF analysis (Figure 44) showed accumulation of SOX9–positive cells 
(primary chondrocyte marker) within nodules undergoing fibrillisation in CMOM 
constructs and expression of SP7 (osteoblast marker) is negative. In contrast, 
the matured nodules that lacked an inner core have SOX9- and SP7-positive 
cells accumulated along the edge of the nodules, also extensive accumulation of 
COL IIA (mature chondrocyte marker) at the exterior of cell nodules (OMOM). In 
contrast, only a little amount of COL IIA is detected within the cell nodules. 
Further, the absence of pluripotency marker, OCT3/4, indicated that nodule 
development is a terminal differentiation process. 
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Figure 43: Cell aggregates and nodules distribution in respective constructs. 
The diameter of cell aggregates/nodules is tabulated with box & whiskers chart to 
illustrate their range in sizes present in each construct. Each black dot represents 
an aggregate or nodule. Statistical difference is assessed using Kruskal-Wallis non-
parametric unpaired t test, n = 4,** p ≤ 0.01, **** p ≤ 0.0001. The mean diameter ± 
SD and mean quantity of aggregates/nodules are described in the table on the right. 
Figure 44: Immunofluorescence staining for OCT3/4, SOX9, COL IIA and SP7.  
The antibodies are applied only to the top sections of OMOM and CMOM constructs 
to identify the constituents of the larger cell nodules (green: protein of interest; blue: 
cell nucleus). Scale bar: 20 µm. 
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3.3.5  Effects of differentiation regimes and pO2 on gene expression 
The effects of each differentiation regime used in this study are correlated to 
pO2 distribution established in the perfusion bioreactor. The relative gene 
expression is tabulated in Figure 45 and Figure 46. Generally, the stem cell 
markers, Oct3/4 and Sox2, are down-regulated in all constructs, especially those 
with CSA. Further, Oct3/4 down-regulation is most significant in the oxygenated 
region than the hypoxic region among the CMCM and CMOM constructs    
(Figure 45). With hypoxia and CSA, expression of Sox9 and Col IIa (chondrocyte 
markers) are generally higher in the bottom-section of CMCM and CMOM 
constructs. The trend remained unchanged in samples from 30 days and 60 
days. Despite removal of CSA from the CMOM protocol in the final 15 days of 
cultivation, chondrogenesis has persisted. However, the potency of CSA to 
support mature chondrocytes over 60 days is limited, since Col IIa expression in 
CMCM constructs is significantly lesser than the CM constructs. Instead, the 
expression of primary chondrocyte marker, Sox9, is extensively elevated after  
60 days. Interestingly, both chondrogenic markers (Sox9 and Col IIa) are also 
up-regulated in OM and OMOM constructs, even though CSA and chondrogenic 
differentiation medium are not applied on these constructs. Further, the Col IIa 
expression is only most distinctive in the oxygenated sections, which also 
contained more nodules than the hypoxic sections. As for hypertrophic 
chondrocyte marker, Col Xa, a negligible amount is detected in both CM and OM 
constructs after 30 days. However, it is generally elevated in all constructs after 
60 days and least significant in CMCM constructs. It is also noted that Col Xa 
expression is generally higher in the oxygenated sections and most prominent in 
CMOM constructs after osteogenic medium is applied. 
Osteoclast marker, TRAP5b, is also assessed in this study to elucidate the 
efficacy of physical niches in the bioreactor to derive other cell types that are 
essential for regulating bone homeostasis from mESCs. Generally, TRAP5b is 
detected in all constructs after 60 days, but is up-regulated by lesser than 4-fold 
in OMOM and CMOM constructs. Further, higher up-regulation of TRAP5b is 
also recorded at the hypoxic sections of both constructs. In contrast, TRAP5b is 
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distinctively up-regulated by at least 8-folds in CMCM constructs. Interestingly, 
the elevated expression of TRAP5b is distributed similarly throughout the entire 
construct and the pO2 had no direct influence. 
The relative expression of all osteogenic-related markers in the constructs is 
summarised in Figure 46. All osteogenic markers in both OM and OMOM 
constructs are significantly up-regulated. These are most significant after 60 days 
and have correlated directly with oxygen tension. As anticipated, the osteogenic 
lineages have accumulated mainly at the oxygenated section, with little amount 
in the hypoxic region. Especially for osteocyte marker (Dmp1), which is            
up-regulated by 13061-fold in the top section and 3540-fold in the bottom section. 
In contrast, higher accumulation of osteoprogenitors (Runx2 and Col Ia) and 
osteoblasts (Sp7) have occurred in the bottom section of CMOM and CMCM 
constructs. Although Dmp1 was up-regulated by 355-fold at the top section and 
410-fold at the bottom section of CMCM construct, this is not comparable to the 
CMOM construct. Dmp1 is up-regulated by 2149-fold at the top and 9186-fold at 
the bottom section. Further, Sost expression is found higher in the CMCM rather 
than the CMOM construct. Similar to other osteogenic markers, the osteocyte 
markers have accumulated in the hypoxic regions of both CMOM and CMCM 
constructs.  
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Figure 45: Relative gene expression of stem cells, primary chondrocytes, 
hypertrophic chondrocytes and primary osteoclast markers in all specimens. 
The bar charts for each gene from 30 days samples are shown on the left; the 60 
days samples on the right. Holm Sidak analysis was used to correlate interactions of 
gene expression within the oxygenated top sections and hypoxic bottom sections of 
individual sample. n = 3, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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Figure 46: Relative gene expression of osteoprogenitor, osteoblast and 
osteocyte markers in all specimens. The bar charts for each gene from 30 days 
samples are shown on the left; the 60 days samples on the right. Holm Sidak 
analysis is used to correlate interactions of gene expression within the oxygenated 
top sections and hypoxic bottom sections of individual sample. n = 3,.* p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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3.3.6  Discussion 
This study aimed to formulate a systematic differentiation approach that will 
accurately recapitulate endochondral ossification in vitro from single source of 
stem cells. Furthermore, the efficacy of such approach should not be limited to 
the cellular level that derives various osteo-chondral cell types. It should also 
support further intercellular interactions, in order to derive constructs with 
structural properties resembling the native bone tissues. However, a dynamic yet 
stable niche would be essential to support such intention. Using a customised 
perfusion bioreactor described previously (53), defined cultivation niches are 
accomplished in this study by combining the following three factors: 1) defined 
COL I hydrogels of cm scale that induce osteogenesis by default, and controlling 
chondrogenesis through CSA supplementation, 2) systematic differentiation 
approach by applying differentiation medium with varying pH at specific time 
points, and 3) applying a pO2 gradient to elucidate the effects of oxygen on a 
single construct. In this thesis, comparable physiological events that occur during 
bone development are recapitulated in the bioreactor. These include impaired 
mineralisation incurred by chronic acidosis, early stages of endochondral 
ossification and intramembranous ossification.  
3.3.6a  CMCM attenuated mineralisation but favoured osteoclastogenesis 
 After extended cultivation in acidic medium for 60 days, a mineralised contour 
is absent in CMCM constructs and smaller cell aggregates have accumulated 
along the periphery of the entire construct (Figure 42). In contrary to CMOM and 
OMOM constructs, formation of mineralised contour and spherical nodules are 
attenuated despite elevated expression of osteogenic markers (Runx2, Col Ia 
and Sp7). Hence, the suppressive effects exerted by the acidic environment are 
post-transcriptional. Furthermore, the acidic medium also induced an elevated 
expression of markers for mineralised osteocyte (Sost) and osteoclast (TRAP5b). 
Remarkably, these observations have correlated to previous in vitro and in vivo 
reports that showed the suppressive effects of chronic acidosis on osteoblast 
development (65) and Sost on the mineralisation mechanism (149,150). Further, 
osteoclasts are detected despite originating from the hematopoietic lineage. This 
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is also a dominant effect of acidosis, as TRAP5b expression is similar in both top 
and bottom sections of CMCM construct and differential pO2 distribution has 
negligible effects. Nonetheless, it is not surprising to find osteoclasts, as the 
pluripotent capacity of mESC will support cell types of other origins to be derived. 
Also shown in other literatures, acidosis is reported to enhance osteoclast 
formation in cat (151) and essential for mature rat osteoclast survival (152,153). 
The elevated expression of sclerostin (Sost) would have also induced Trap5b 
expression via the RANKL-dependent pathway for bone remodelling and 
resorption (154–156). Taken together, the phenotype presented by CMCM 
constructs can be correlated to chronic acidosis in physiology, which induced 
calcium efflux and cell-mediated bone resorption (157,158). Hence, the CMCM 
constructs are potential disease model for impaired bone healing caused by 
chronic acidosis. However, further exploitations of current cultivation conditions 
are essential, but are not within the scope of this report. 
3.3.6b  Cell nodules and mineralised contour contribute to increased Young´s 
modulus 
Through histological analyses, the mineralised contour (Figure 42) is 
identified as the primary factor that resulted differences in mechanical stiffness 
among constructs (Figure 43B). Generally, OMOM constructs with a complete 
mineralised contour along the periphery have recorded the highest Young’s 
modulus. This is reduced in CMOM constructs with a fragmented contour and 
CMCM constructs that do not possess a defined contour have recorded the least 
Young’s modulus, with the compact bottom section being stiffer than the top 
section. After more thorough analysis, spherical nodules present mainly in the 
CMOM and OMOM constructs are found critical for the formation of mineralised 
contour. In contrast, CMCM constructs without a mineralised contour contained 
significantly lesser and smaller nodules (Figure 43).  
Further comparisons are made between the CMOM and OMOM constructs to 
elucidate the progression of nodule development over time. Based on the 
number of spherical nodules observed (Figure 42 and 43), in combination with IF 
staining (Figure 44) and gene expression profile (Figure 45 and 46), it is 
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concluded that the spherical nodules found in CMOM and OMOM constructs are 
similar. However, the shorter period of osteogenic differentiation meant that 
majority of the nodules in the CMOM constructs are still at an earlier stage of 
development, while those in the OMOM constructs are more matured. The 
predicted progression of nodule development and formation of mineralised 
contour is illustrated in Figure 47.  
 
The process would have started from the condensation of irregular cell 
aggregates that are positive for alcian blue; observed in all constructs. However, 
further development of cell aggregates is attenuated with continual application of 
acidic chondrogenic medium (CMCM). In contrast, the application of slightly 
basic osteogenic medium to the constructs has induced further condensation of 
cell aggregates to form spherical nodules (CMOM, OMOM). IF analysis in Figure 
44 showed that SOX9–positive chondrocytes have accumulated within these 
newly formed nodules and expression of SP7 (osteoblast marker) is negative 
(CMOM). As the spherical nodules developed, they continued to grow in size and 
remodelling of the inner volume occurs. This is accompanied with decreasing 
Figure 47: Hypothesized pathway of cell nodule development. The development 
of cell aggregates to nodules and formation of mineralised contour is illustrated here. 
The hypothesis is based on the frequency these structures in CMOM and OMOM 
construct, in relation to the duration of osteogenic differentiation. CMOM contain 
more naïve aggregates and OMOM containing more mature nodules. The yellow 
arrow indicates mineralised contour found on CMOM, OM and OMOM constructs. 
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alcian blue staining and increasing alizarin red staining within the nodules 
(Figure 47). Finally, the inner volume becomes fibrillated and SOX9- and SP7-
positive cells start accumulating along the periphery of the nodules (OMOM; 
Figure 44). Eventually the nodules will contribute to mineralised contour 
formation. Taken together, these observations showed the transition of 
chondrogenic aggregates to osteogenic nodules, followed by formation of 
mineralised contour in the CMOM and OMOM constructs. In correlation to 
previous literatures, nodules composed of osteoblasts are also commonly found 
in osteogenic differentiated in vitro cultures. They are postulated to be essential 
for mineralisation, but a mineralised contour is not observed in these studies 
(159,160). Hence, the results described in this report have shown for the first 
time in large 3D constructs; the direct participation of such nodular structures in 
the formation of a mineralised contour. Further, the observed phenomenon in 
CMOM and OMOM constructs has coincided with the ossification processes at 
the primary ossification centre during both endochondral ossification and 
intramembranous ossification in vivo (35). The mineralised contour is 
comparable to compact bone formation that provided structural stability, while the 
spherical nodules resemble the osteoid-secreting osteoblasts clusters.  
3.3.6c  Superseding effects of CSA and construct architecture over pO2 on 
osteogenic gene expression 
Interestingly, higher osteogenic gene expression (Col Ia, Runx2, Sp7) is 
recorded in the hypoxic section of both CMCM and CMOM constructs (Figure 46), 
despite previous literatures reported attenuating effects of hypoxia on 
osteogenesis (161,162). However, further comparisons made with OMOM 
constructs have validated that an oxygenated niche is indeed preferred and has 
enhanced the expression of osteogenic markers. Hence, the occurrence 
observed in CMCM and CMOM constructs is likely a localised effect of the CSA 
embedded hydrogel (163). Other than its capability to retain water molecules in 
the hydrogel, the higher charge density of CSA will also accumulate calcium ions 
within the hydrogels (164,165). However, it is shown that more than 30 days are 
necessary for the accumulated calcium to have an effect, since osteogenic gene 
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expression in the CM constructs is negligible. In combination with the slender 
dimensions of the bottom section, the higher calcium per volume ratio would 
have increased the tendency for calcium ions and cells to interact. These 
observations demonstrated the superseding effects of CSA and construct 
architecture over pO2, which are significant for construct design in future studies 
and enhancing the recapitulation of physiological niches in vitro.  
3.3.6d   Endochondral ossification (CMOM) versus Intramembranous ossification 
(OMOM) 
Based on the results described, the CMOM and OMOM constructs have 
shared comparable in vivo developmental processes as endochondral 
ossification and intramembranous ossification respectively. These include the 
distinct differences in their Young´s modulus, physical appearances and gene 
expression in response to pO2. 
After 60 days of cultivation in the osteogenic differentiation media, the OMOM 
constructs underwent extensive condensation to form a compact and uniform 
structure. The periphery is lined with a complete mineralised contour and the 
recorded Young´s modulus is also the highest among all the specimens. 
Comparable to intramembranous ossification, mesenchymal condensation is 
critical for initiating cranial-facial bone development and to derive the thin, 
compact flat bones. Further, the cortical bone layer possess a higher Young´s 
modulus than the trabecular bone in the inner volume (166,167). The immediate 
participations of osteogenic cell types in construct development and 
mineralisation are also shown by elevated expression of osteogenic gene 
markers (Runx2, Col Ia, Sp7, Dmp1, Sost) and the presence of fragmented 
mineralised contour in the oxygenated top section of OM constructs. Further, the 
enhancing effect of oxygenation on osteogenic gene expression has further 
extended to the OMOM constructs. Interestingly, the nodules are also found 
responsible for synthesizing COL II and secreting it into the construct as they 
mature (Figure 44, OMOM). Although this event can be correlated to the 
transitional presence of COL II during initial stage of intramembranous 
ossification (168,169), it is still poorly understood and no definitive conclusions 
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can be based on existing observations. Nonetheless, the existing setup can be 
further exploited to investigate the role of COL II during intramembranous 
ossification. Taken together, the developmental progression of OMOM constructs 
is found intimately related to early developmental events of intramembranous 
ossification and similar compact mineralised structures are derived. 
As for constructs derived from the systematic differentiation protocol (CMOM), 
the initial gel-like CM constructs became more structurally-defined and have 
gained an ivory coloration after 60 days (Figure 41A). Furthermore, the CMOM 
constructs have grown to adopt the tailored dimensions of the cultivation platform 
that is pre-casted in the agarose bedding (Figure 41A, left). Despite being 
cultivated in similar osteogenic medium for 30 days, severe structural 
condensation has occurred in the OM constructs that eventually led to the 
compact and slender OMOM constructs. In contrast, this phenomenon is not 
observed on the CMOM constructs. The differences in structural integrity of the 
CMOM constructs to the OM and OMOM constructs are expected to be a 
complementary effect of CSA and the systematic differentiation approach. The 
high charge density of CSA will trap water molecules within the initial                
CM hydrogels, which attributed to the retention of pre-designed dimensions in 
CM constructs. As a result, there is sufficient time for the mESC-derived 
chondrocytes to proliferate and infiltrate the hydrogel without causing severe 
condensation. Comparable to the early stages of endochondral ossification in 
vivo, a hyaline cartilage model made up of chondrocytes forms the initial 
template for subsequent long bone formation; without incurring distinctive 
structural condensation. Nonetheless, this effect in CM constructs is not 
permanent as the construct still collapse after prolonged cultivation in the acidic 
chondrogenic medium; as shown by the CMCM constructs. In order to 
strengthen the structural integrity of CM constructs, the transition from 
chondrogenesis to osteogenesis is critical. Chondrocyte hypertrophy needs to 
occur, in order to facilitate infiltration of osteogenic cell types that will then 
proceed on with construct mineralisation. This is achieved by applying a slightly 
basic osteogenic medium to the CM constructs after 30 days in acidic 
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chondrogenic medium and validated by the elevated expression of   Col Xa in 
the CMOM constructs; specifically at the oxygenated top section (Figure 45). 
Similar to previous in vitro reports, an oxygenated niche will favour chondrocyte 
hypertrophy more than a hypoxic niche (170). In vivo, the process will typically 
occur at the primary centre of ossification during endochondral ossification; 
which is also oxygenated due to infiltration of vasculatures (170). Due to the 
additional chondrogenic differentiation step, CMOM constructs are shown to 
have lesser Young´s modulus than the OMOM constructs. However, this is 
comparable to the physiological events as long bone formation (endochondral 
ossification) generally requires a longer time span to complete, in comparison to 
cranial formation (intramembranous ossification) during embryonic skeletal 
development (171). Taken together, these observations have emphasized the 
importance of initial chondrogenic differentiation steps for the hydrogels to adopt 
pre-designed dimensions and retaining their structural stability; until subsequent 
osteogenic differentiation medium is applied to initiate mineralisation. More 
importantly, the results provided valuable insights for future exploitations to 
derive and maintain customised biological constructs with irregular dimensions 
for clinical applications. 
In conclusion, the bone bioreactor is shown as an effective platform for 
generating and maintaining a stable dynamic in vitro niche; favourable for long-
term cultivation of engineered bone constructs. The synergistic interactions 
between each combination of differentiation approaches, media pH and oxygen 
tension; have generated specific mixture of osteochondral cell lineages from a 
single source of mESC. Through this, physiological congruent events of bone 
development are recapitulated in vitro. Specifically, the developmental processes 
of CMCM constructs have resembled chronic acidosis during impaired fracture 
healing; the CMOM and OMOM constructs can be correlated to the early stages 
of endochondral ossification and intramembranous ossification respectively. The 
importance of initial chondrogenic differentiation step and CSA to maintain 
structural integrity of bone constructs is emphasized in this study (CMOM). In 
contrast, direct application of osteogenic differentiation will induce extensive 
 
Results and Discussion 
145 | P a g e  
 
condensation, thus producing compact and dense constructs (OMOM). 
Furthermore, the cultivation niche (collagen hydrogel and pO2) generated in the 
customised perfusion bioreactor is also shown to be specific but not exclusive to 
osteochondral cell types. Cells of other origin can also be derived, when specific 
inducing parameter was applied. In this case, osteoclastogenesis is initiated 
through prolonged cultivation in acidic medium. Hence, this can potentially be 
exploited further to derive other cell types, such as haematopoietic cell lineages 
and achieve bone constructs with higher degree of resemblance to the native 
bone tissue. 
3.4  Bone tissue engineering with hMSC 
After characterising the biomimetic bioreactor with mESC, a number of 
specifications that are critical for osteochondral development are identified. 
These include the interplay of oxygen tension with CSA and medium pH, as well 
as the systematic differentiation regime (CMOM) applied to derive mineralised 
constructs. Based on the results from the mESC experiments, the transferability 
and reproducibility of these parameters to derive mineralised constructs with 
hMSC are investigated and the results are described here. Furthermore, 
additional efforts are made to achieve tailored mineralised constructs that are 
relevant for subsequent generic clinical applications or for personalised medicine. 
Briefly, the differentiation regimes and the applied scaffolds are summarised in 
Table 17. 
Table 17: The abbreviations and parameters applied for construct 
cultivation. 
Abbreviations Differentiation regime 
aECM 
scaffold 
applied 
OMOM 60 days osteogenic OM scaffold 
OMOM* 60 days osteogenic CM scaffold 
CMOM 
30 days chondrogenic + 
30 days osteogenic CM scaffold 
CMCM 60 days chondrogenic CM scaffold 
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3.4.1  hMSC reacted differently in COL I hydrogel  
Preliminary experiments with hMSC embedded in CM and OM collagen 
hydrogels have shown severe condensation of hMSC-laded constructs after 40 
days (Figure 48). This effect is most severe in the OMOM construct, as rapid 
condensation is already observed within 10 days of culture. However, this is not 
unexpected as hMSC condensation is an essential phase for osteochondral 
development in vivo (172–175). Nonetheless, this is detrimental for our research 
aims to achieve bone-like constructs with physiological congruent structural 
properties. Hence, a new approach favorable for hMSC is developed to achieve 
our aims. This is accomplished by synthesizing structural aECM scaffold though 
3D-printing; in combination with the cast and mold concept. 
 
 
3.4.2  Deriving structural aECM scaffolds with 3D-printing and freeze-drying 
In this thesis, male molds with tailored geometries are printed with a            
3D-printer and used to derive silicone female molds that are subsequently 
applied in the aECM casting procedures. The rationale of this approach is to 
facilitate rapid manufacturing of aECM scaffolds in large quantities, and assuring 
consistency among manufactured scaffolds. This is critical for subsequent 
cultivation experiments aimed to attain more accurate assessments on the 
effects of applied cultivation parameters over construct development in the bone 
bioreactor and ensuring reproducibility between different trials. 
Based on the established work done by the colleagues from Transregio67 
(176–180), the aECM scaffolds used in this thesis are synthesized by fibrillising 
rat-tail COL I with 60 mM phosphate buffer and lyophilized to attain a stable 
OMOM (40 days) 
Figure 48: hMSC-laded CM and OM collagen scaffolds after 40 days of 
cultivation in the bone bioreactor.  Rapid condensation and shrinkage of 
constructs were observed. The effect was most obvious in OMOM constructs. 
 
 
CMOM (40 days) 
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structure. However, slight modifications are made to the cross-linking buffer to 
further enforce the structural integrity of the aECM scaffolds. With the commonly 
applied EDC/NHS cross-linking buffer, the freeze-dried 3D aECM scaffolds will 
collapse and lose their tailored geometries. Hence, 25% glutaraldehyde vapour 
is applied instead. Although it is also a common cross-linking buffer for proteins 
(181–183), there are safety concerns over the application of glutaraldehyde on 
biomaterials. Generally, it is a cytotoxic fixative that can potentially release toxic 
monomeric glutaraldehyde as the biomaterial undergoes hydrolysis during cell 
culture. Further, biomaterials that are cross-linked with glutaraldehyde have also 
been reported to exhibit reduced cellular ingrowth, both in vitro and in vivo 
(184,185). Hence, extra cautions should be taken and residual glutaraldehyde 
from the cross-linking procedure is minimised by thorough ventilation of aECM 
scaffolds in a chemical fume hood for at least 3 to 4 days in this thesis. 
Additionally, the scaffolds are equilibrated in serum-free medium at 37 °C for at 
least 16 h prior to hMSC inoculation. In preliminary experiments, extensive cell 
death is not recorded and the cells are still viable in aECM scaffold after 40 days 
(data not shown). Hence, glutaraldehyde is used for cross-linking in subsequent 
experimentations. 
 3.4.3  Collagen and CSA contents in the aECM scaffolds 
In this thesis, two variants are produced, CM and OM aECM scaffolds. 
Specimens for OPA and DMMB analyses are retrieved from a pool of scaffolds 
immediately after the equilibration step in designated serum-free medium. Shown 
in Figure 49A, the mean absolute COL I content in respective scaffold is: CM Top 
section: 644.2 ± 128.9 µg (49.6%), CM Bottom section: 576.1 ± 287.7 µg (82.3%), 
OM Top section: 687.5 ± 156.0 µg (52.9%),OM Bottom section: 652.1 ± 251.2 µg 
(93.2%). Additionally, the mean absolute content of CSA (Figure 49B) in the     
CM scaffold is: CM Top section: 48.5 ± 17.7 µg (3.7%), CM Bottom section: 37.7 
± 21.6 µg (5.3%). The percentage values are calculated against the initial 
content added to the female mold before the lyophilisation procedure. This is 
1300 µg in the top section and 700 µg in the bottom section for both COL I and 
CSA. Despite the difference in dimensions, the absolute COL I and CSA content 
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in the top and bottom sections are statistically similar. Further, there are also no 
significant variances between the CM and OM scaffolds. 
 
 
3.4.4  Efficacy of hMSC inoculation method  
The efficacy of hMSC inoculation and propagation on respective aECM 
scaffold are estimated with DNA content isolated from each specimen, through 
quantitation by pico-green assay. Due to the limited quantity of specimens that 
can be generated in each set of experiment, this method of analysis is selected 
to maximise the usability of each isolated specimen. Furthermore, it also 
increased the accuracies for further correlations between cell number and the 
gene expression profiles, since both the DNA and RNA are isolated from the 
same TRIzol® homogenate. Nonetheless, it is recognized that further validations 
with additional tests such as, presto-blue assay or lactate dehydrogenase assay 
on separate replicates are required, so as to improve the reliability of the 
recorded results. However, this is beyond the means of this proof-of-concept 
study and will be considered in future experiments.  
As described in Figure 20B, a customised apparatus is constructed for hMSC 
inoculation procedure in this thesis. Based on the results retrieved from the pico-
Figure 49: Absolute content of COL I and CSA in CM and OM scaffolds after 
equilibration in serum-free medium. A) The dotted lines indicate the initial COL I 
present in female mold before lyophilisation. After the procedure, the absolute COL I 
content in the top and bottom section are statistically similar (p = 0.42) and this is the 
same between the CM and OM scaffolds (p = 0.80) B) Similar to the COL I content, 
the absolute CSA content in the top and bottom section of CM constructs are 
statistically similar (p = 0.11). n = 9; specimens from hMSC #282, #540, #575 trials, 
done in triplicates. 
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green assay, the number of hMSC in each scaffold is tabulated in Figure 50A. 
Briefly, the mean inoculation proficiency for CM scaffolds is 80.0% and 70.9% for 
OM scaffolds. Nonetheless, the large standard deviations indicated that the 
variability between samples from each trial is rather high and there are still room 
for improvements. Furthermore, the cell density in each section (hMSC per cm3 
aECM scaffold) is also plotted and shown in Figure 50B. Despite lesser number 
of hMSC are detected in the bottom section, the overall cell density in both 
sections are similar and the mean value is 3.0 x 106 hMSC per cm3 aECM 
scaffold. This is consistent with the similar COL I content in both sections shown 
by Figure 49A. 
3.4.5  Estimated cell density over the course of cultivation and 
corresponding pO2 
Similar to the previous section, the cell number in each scaffold after 30 and 
60 days is estimated through DNA isolated from the TRIzol® homogenate. In 
contrast to the cell density at 24 h post-inoculation (Figure 50B), the cell density 
(cell per cm3 aECM) in 30 and 60 days constructs are significantly lesser. 
Generally, the cell density falls within a range of 0.25 x 106 to 1.3 x 106 after the 
first 30 days of cultivation. This is approximately 10–40% of cell number recorded 
24 h post-inoculation. The constructs cultivated in static do not have a significant 
difference from the corresponding perfusion bioreactor culture. Nonetheless, the 
number of cells in respective scaffold has increased by 10-15% from Day 30–60. 
Hence, it is concluded that approximately 30 days are needed by the hMSC to 
become adapted to the aECM scaffolds, before further proliferation is initiated. 
However, it is also noted that there are some exceptions. Interestingly, the cell 
number is elevated in CM scaffolds cultivated with osteogenic differentiation 
medium (OM*, CMOM and OMOM) and the static culture contained a higher cell 
number than their corresponding perfusion culture (Figure 51).  
As described by the mathematical model for pO2 evolution in the bone 
bioreactor (Figure 34 and 35), the cell per volume ratio in each section of a 
construct is the primary factor to generate a pO2 gradient in the bone bioreactor; 
with medium perfusing at  5.5 mL/min. The threshold to derive a hypoxic niche (< 
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5 Torr) is calculated with the model. As indicated by the horizontal solid line in 
Figure 51, at least 1.5 x 106 cells per cm3 is required to attain a hypoxia. 
However, the cell density in all the perfusion cultures is well below the threshold 
and there are no significant differences between the top and bottom section. 
Hence, it is concluded that the hMSC-laded constructs in the bone bioreactor are 
generally cultivated in an oxygenated niche and the estimated oxygen tension is 
between 30–85 Torr. However, further validations by real-time measurements 
with oxygen probes should also be done in future experiments.  
 
Figure 50: hMSC density in each aECM scaffold 24 h post-inoculation. A) The 
mean number of hMSC in respective part of the scaffolds. The percentage 
inoculation proficiency is calculated against the initial seeded density at 3.0 x 106 
hMSC. B) Cell density per cm3 of aECM scaffold. The volume used for calculation is 
top section = 0.57 cm3 (height: 2 cm, Ø: 0.6 cm) and bottom section = 0.18 cm3 
(height: 2.5 cm, Ø: 0.3 cm). Refer to Figure 20 for the dimensions of aECM scaffolds. 
n = 3 (1 specimen from hMSC #282, #540, #575 trials). The hMSC density in the top 
and bottom section is statistically similar (p = 0.08). There is also no significant 
variance in hMSC density between the CM and OM scaffolds (p = 0.20). 
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3.4.6  Gross morphology of respective constructs and histological staining  
The CM scaffolds have a higher tendency for spontaneous accumulation of 
positively-charged calcium ions, due to the negatively-charged sulfate-groups on 
CSA. This effect will also be more pronounced with increasing period of cell 
culture experiments. To validate the extend of this effect in this thesis, cell-free 
CM and OM scaffolds are kept in the same conditions as  the cell-laded scaffolds 
for 60 days. As shown in Figure 52, spontaneous calcium accumulation occurs 
only after osteogenic medium is given to the cell-free CM scaffolds (CMOM and 
OMOM*). There are no occurrences of spontaneous calcium accumulation when 
these scaffolds are kept only in chondrogenic medium (CMCM). Furthermore, it 
is also noted that the alcian blue and alizarin red staining will overlap at such 
circumstances. Hence, this should be taken into consideration when positive 
staining is observed in subsequent analyses with hMSC-laded scaffolds. In the 
Figure 51: Cell density in constructs cultivated with variable differentiation 
regimes for 30 and 60 days. Generally, there are no significant differences 
between the static culture and the perfusion culture, except for the CMOM and 
OMOM* constructs that have significantly more cells in the static culture than the 
perfusion culture. Furthermore, a minimum cell per volume ratio is necessary to 
generate a hypoxic niche (< 5 Torr) in the perfusion bioreactor with medium 
perfusing at 5.5 mL/min. This is indicated by the solid black line and at least             
1.5 x 106 hMSC per cm3 is required. n = 9, specimens from hMSC #282, #540, #575 
trials, done in triplicates, *** p < 0.001, **** p < 0.0001.  
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cell-free OMOM constructs, spontaneous calcium accumulation is observed only 
in the top section; but this is less intense and more sparsely distributed than the 
CMOM and OMOM* cell-free scaffolds. Other than the potential for calcium 
accumulation in cell-free CM scaffolds, it is also observed that the CM scaffolds 
will condense and shrunk in size after 60 days, while the original dimensions are 
retained by cell-free OM scaffolds. 
The hMSC-laded constructs cultivated in perfusion bioreactor are isolated at 
30 days (Figure 53) and 60 days (Figure 54) post-inoculation for histological 
analyses. These are compared against corresponding static cultures cultivated in 
tissue culture flasks with the same volume of medium applied to the perfusion 
culture (170 mL). After 30 days, all static cultures are slightly more condensed 
and shorter than their corresponding perfusion culture. However, the overall 
physical appearance and coloration of constructs derived from both cultures 
remained similar. Comparing among the differentiation regimes, CM constructs 
cultivated in chondrogenic medium have a relatively fragile structure and positive 
alcian blue staining validated retention of CSA in both the top and bottom section. 
Without exposure to any osteogenic medium, both CM static and CM perfusion 
cultures are alizarin red-negative and calcium accumulation is absent. This has 
further supported the observations made on cell-free scaffolds and spontaneous 
calcium accumulation in CM scaffolds will only occur after osteogenic medium is 
applied. In contrast, the constructs from both OM and OM* cultures appeared 
physically dense and have an ivory coloration. These are also accompanied with 
positive alizarin red staining in the top section of OM static/perfusion constructs 
and both sections of the OM* static/perfusion constructs. Based on the 
histological staining of OM* constructs, there are no overlap between the alcian 
blue and alizarin red. Hence, calcium accumulation in these constructs are 
initiated by the cells and caused by spontaneous attachment of calcium ions with 
CSA in the scaffold. With further cultivation of respective scaffolds until 60 days, 
more distinctive differences in both physical appearances and histologic staining 
are observed among the constructs (Figure 54). These observations are 
summarised in Table 18. 
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Figure 52: Physical appearances and histological staining of cell-free scaffolds 
after 60 days. The physical appearances and histologic staining of each scaffold was 
recorded with a camera, as the microscope was unable to capture the entire cross-
section due to limited microscope field of view. Further, the bottom section of CMCM 
scaffolds was excluded due to severe shrinkage and no specimen could be retrieved 
from this part of the scaffold for further analysis. Scale bar = 1 mm. 
Figure 53: Physical appearances and histologic staining of hMSC-laded 
constructs cultivated in static and perfusion conditions for 30 days. The CM 
construct shown in this illustration is representative for both CMCM and CMOM 
constructs shown in Figure 56, since both of these constructs were cultivated in the 
same chondrogenic differentiation medium in the first 30 days. It should be noted that 
the aECM scaffolds (CM scaffold) applied to the OM* differentiation approach had 
contained 1 mg/mL CSA, which was not present in the OM scaffold applied in the OM 
differentiation approach. Scale bar = 1 mm. 
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Table 18: Summary on the differences in physical appearance and histological 
staining observed among the constructs after 60 days in culture. 
CMCM CMOM 
 Shrinkage is observed in static 
cultures, which are much shorter 
than the perfusion cultures. 
 Alizarin red is negative but alcian 
blue is evenly distributed in the top 
and bottom sections. 
 The static cultures shrunk significantly 
in size, while the structural integrity of 
perfusion cultures remained intact. 
 Alizarin red absent in static cultures, 
but is intensive in perfusion cultures. 
 Alcian blue is evenly distributed in the 
top and bottom sections of static 
cultures. Staining is less intensive in 
the perfusion cultures, especially the 
top sections. 
 A define contour was observed 
throughout the construct from static 
culture, especially at the bottom 
section. 
 The contour is positive for alcian blue 
(yellow arrow). 
Figure 54: Physical appearances and histological staining of hMSC-laded 
constructs cultivated in static and perfusion conditions for 60 days.  Generally, 
the CMCM, CMOM and OMOM static cultures had shown shrinkage in length; in 
comparison to corresponding perfusion cultures. However, this was the other way 
around for OMOM* constructs, which had more significant condensation in the 
perfusion culture. Further, define contour that is stained positive for alcian blue was 
observed only on the CMOM, OMOM and OMOM* static construct. This was 
denoted by the yellow arrows. Scale bar = 1 mm. 
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OMOM OMOM* 
 The static cultures shrunk in 
length, but less significant than the 
CMCM and CMOM constructs. 
 Alizarin red is positive throughout 
the entire construct from both 
static and perfusion cultures. 
 Alcian blue is evenly distributed 
throughout the static cultures. In 
contrast, only the top section of 
perfusion cultures is stained 
positive, but at a negligible level. 
 A define contour is also observed 
throughout the construct from 
static culture, especially at the 
bottom section. 
 The contour is positive for alcian 
blue (yellow arrow). 
 Condensation is most obvious in the 
perfusion cultures instead. 
 No significant differences in histological 
staining, except for the bottom 
sections. More alizarin red observed in 
the static cultures than the perfusion 
cultures. 
 Alcian blue staining is also less intense 
in the top section of constructs derived 
from the static and perfusion cultures. 
 A define contour is also observed 
throughout the construct from static 
culture, especially at the bottom 
section. 
 The contour is positive for alcian blue 
(yellow arrow). 
3.4.7     Analysis with µCT and estimating the concentration of mineralised 
deposits 
The extent of mineralisation in each specimen is further characterised with 
µCT after 60 days (Figure 55--57). Unlike the histological analyses, µCT is a 
non-destructive approach and elucidates more detailed information on the spatial 
distribution of calcium throughout a construct. Furthermore, the algorithm applied 
in this study is programmed to detect mineralised volumes with more than 
10 mg HA/cm³ and less dense calcium deposits are not visible to the detector. 
Hence, the concentration of mineralised deposits detected in the constructs can 
be estimated with the algorithm and correlated better to native bone tissues. In 
turn, better characterisations and comparisons are achieved among different 
constructs derived in this thesis. Shown in Figure 55, mineralised deposits are 
detected only in cell-free scaffolds exposed to osteogenic differentiation medium 
(OMOM, OMOM*, CMOM). However, the deposits are sparsely distributed 
mainly along the periphery of scaffolds (top-section). Based on the estimated 
values derived from the algorithm, the concentration of mineralised deposits 
found in each scaffolds are as follows: CMOM ≥ OMOM* > OMOM > CMCM. 
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The additional supplementation of CSA in OMOM* and CMOM scaffolds have 
resulted in slightly higher accumulation of mineralised deposits and in similar 
quantity. 
Similar to the cell-free scaffolds, mineralised deposits are only detectable in 
hMSC-laded constructs that are exposed to osteogenic medium. However, the 
concentration of mineralised deposits is significantly higher in the hMSC-laded 
constructs, specifically in the perfusion cultures. Interestingly, the effects of CSA 
on the overall accumulation of mineralised deposits are negligible in the      
hMSC-laded constructs. The observed trend for the static culture is instead 
OMOM > OMOM* > CMOM > CMCM, with mineralised deposits detected in both 
sections of the OMOM constructs (Figure 56) and only in the top section of 
constructs containing CSA. Nonetheless, Figure 57 had best illustrated the 
research motivations of this thesis and the advantages of bioreactor culture with 
consistent medium perfusion. Although some deposits are detected in the CMCM 
constructs, they are in negligible quantity. Shown in all the osteogenic 
differentiated constructs (OMOM, OMOM*, CMOM) from perfusion culture, 
mineralised deposits are found in both the top and bottom sections. Furthermore, 
these deposits are distributed throughout the constructs and distinct structural 
differences are observed on the 3D µCT images. Generally, the trend for 
mineralised deposits accumulation is OMOM > CMOM > OMOM* > CMCM. 
Although the OMOM perfusion constructs have accumulated the most deposits, 
the structural integrity is not retained and has collapsed to form a compact 
construct after fixation in 4% formaldehyde/DPBS. In contrast, the constructs that 
contained CSA have retained their cylindrical dimensions and this is most 
obvious in the CMOM perfusion constructs. However, this is also accompanied 
with a porous texture and a smooth mineralised construct surface is absent. 
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Figure 55: µCT of cell-free scaffolds and the estimated amount of calcium 
accumulated in each scaffold after 60 days. This is done to validate the potential 
for spontaneous accumulation of calcium in respective aECM scaffolds and whether 
they can be detected with µCT. Spontaneous calcium accumulation will occur only 
after osteogenic medium is applied and is most obvious in CM scaffolds with CSA. 
Scale bar: 1 mm. 
Figure 56: µCT of constructs cultivated at static condition and the estimated 
amount of calcium accumulated in each scaffold after 60 days. Mineralised 
deposits are only detected in the top section of OMOM* and CMOM static 
constructs. In contrast, OMOM static construct have accumulated the most deposits 
and these are distributed in both sections of the construct.  Scale bar: 1 mm. 
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3.4.8  Gene expression profiling 
The relative gene expression of respective constructs cultivated in static or 
perfusion conditions for 30 and 60 days are summarized in Figure 58–60. Briefly, 
the markers for stem cell (CD90, Sox2) and chondrocyte (Sox9, Col IIa) are 
summarised in Figure 58. The markers for hypertrophic chondrocyte (Col Xa) 
and osteoprogenitors/pre-osteoblasts (Runx2, ALP, Col Ia) are summarised in 
Figure 59, followed by markers for mature osteoblast (Sp7), osteocytes (Mepe, 
Dmp1, Sost) in Figure 60.  
Generally, a greater variance is observed among the static cultures than the 
perfusion cultures, especially the gene expression of mature cell lineages such 
as Col Xa, Sp7, Dmp1 and Sost. As a result, large standard deviations are 
documented. This is potentially attributed by the inconsistent and uncontrolled 
static cultivation niches being applied between different trials. In contrast, the 
consistent and controlled niches generated in the perfusion bioreactor have 
resulted significantly lesser variances and the donor effect is also negligible. 
Nonetheless, gene expressions in the top and bottom section of the same 
Figure 57: µCT of constructs cultivated in perfusion bioreactor and the 
estimated amount of calcium accumulated in each scaffold after 60 days. The 
constructs derived from each differentiation regime have shown significant 
differences in their mineralised deposits accumulation pattern. These differences 
are more distinct than the corresponding static culture. Scale bar: 1 mm. 
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construct are mostly similar, and are true for both static and perfusion cultures. 
Hence, both sections are interpreted together and the representative gene 
expression in respective specimens are summarised in Table 19.  
Table 19: The representative gene expression recorded in each construct 
after 30 and 60 days in culture. The underlined genes are up-regulated in both 
static and perfusion cultures, but these genes are significantly higher in the 
perfusion cultures than the static cultures. 
Specimens Static Perfusion 
CM 
30 days 
Sox9, Runx2, ALP, Sp7, 
Mepe, Dmp1, Sost 
Sox2, Col IIa, Runx2, ALP 
CMCM 
60 days 
Sox9, Col IIa, Runx2, Mepe Col IIa, Runx2, ALP 
CMOM 
60 days 
Sox9, Col IIa, Col Xa, Mepe, 
Sost 
CD90, Sox2, Col IIa, ALP, 
Sp7 
OM* 
30 days 
Sox2, Sox9, Col IIa, Col Xa, 
Runx2, ALP 
Sox2, Sox9, Col IIa, Col Xa, 
Runx2, ALP 
OMOM* 
60 days 
CD90, Sox9, Col IIa, Runx2 CD90, Sox2, Sox9, Col IIa, 
Runx2, Col Xa, ALP, Sp7 
OM 
30 days 
Sox9, Col IIa, Col Xa, 
Runx2, ALP, Sp7 
Sox2, Sox9, Col IIa, Col Xa, 
Runx2, ALP, Sp7 
OMOM 
60 days 
Sox9, Mepe, Sost CD90, Sox2, Sox9, Col IIa, 
Col Xa, Runx2, ALP, Sp7 
As mentioned in Chapter 3.4.5 and Figure 51, the calculated cell number in 
each construct did not meet the minimum threshold required to derive a hypoxic 
niche. Hence, it is deduced that pO2 distribution in the top and bottom sections of 
bone bioreactor is relatively homogeneous and oxygenated. Through the gene 
expression profile, this deduction is further strengthened, as there are also no 
significant differences detected between the top and bottom sections of all 
perfusion cultures. Furthermore, the expression of Sox9, a hypoxia-regulated 
gene, is suppressed in CM, CMCM and CMOM perfusion cultures. In contrast, 
Sox9 expression is elevated in corresponding static cultures that are typically 
assumed to be hypoxic; due to limited gas exchange potential via the passive 
diffusion mechanism. Without a hypoxic niche in the bioreactor, the effects of 
enhanced chondrogenic gene expression incurred by interplay of hypoxia, acidic 
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medium and CSA (Figure 45) observed in the mESC experiments are not 
repeated here. Instead, the mechanisms for hMSC renewal (elevated 
CD90/Sox2) and osteogenesis (elevated Runx2/ALP/Sp7) are promoted. 
Interestingly, Sox9 is also elevated in OM, OMOM, OM* and OMOM* perfusion 
culture and is always coupled with increased Col Xa and ALP expression. Similar 
to the mESC experiments, chondrocyte hypertrophy occurs in constructs with 
higher initial Sox9 and Col2a and is further enhanced by oxygenated osteogenic 
medium. Other than pO2 attributed effects, inclusion of CSA in osteogenic 
differentiated constructs (OM* and OMOM*) is found to accelerate construct 
development and osteogenesis. As shown in the gene expression profile, all 
osteogenic markers are elevated extensively after only 30 days in culture (OM*) 
and is most significant in perfusion cultures. In contrast, similar elevation in gene 
expression is only observed after 60 days in corresponding OM and OMOM 
constructs that do not contain CSA. Despite the elevated osteogenic markers 
described above, it should be highlighted that Col Ia expression is unanimously 
attenuated throughout the 60 days of cultivation; both static and perfusion 
cultures of hMSC-laded aECM scaffolds. 
In terms of the differences between static and perfusion cultures, it is not 
limited to the large standard deviation recorded in static cultures. Generally, it is 
observed that the static cultures of all differentiation approaches have a 
tendency to undergo terminal differentiation. From the list of representative gene 
expression of all 60 days samples (Table 19), it is a general trend for the hMSC 
to differentiate into mature osteocytes (elevated Mepe and Sost). Further, the 
markers for more naïve cell types (CD90, Sox2, Sox9, Runx2, ALP) will decline 
after 30 days. On the contrary, these markers for naïve cells are elevated at a 
significantly higher amount in the perfusion cultures, specifically the osteogenic 
differentiated constructs (CMOM, OMOM and OMOM*). Based on these 
observations, the perfusion bioreactor is shown to support self-renewal of hMSC 
and continual growth of engineered bone constructs in vitro over extended period 
of time. In contrast, the static culture is less vibrant and the pool of hMSC will 
deplete over time as they undergo terminal differentiation and become mature 
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cell types. Eventually, the growth of engineered bone constructs will become 
limited as a longer cultivation period;  essential for further maturation and gain-of-
function, is applied. 
 
Figure 58: Relative gene expression of hMSC and chondrocyte markers in all 
specimens. The stem cell and chondrogenic gene expression profiles of respective 
specimen after 30 days (left) and 60 days (right) of culture. The mean value from all 
three hMSC donors are used, with the static and perfusion are plotted side-by-side 
for comparison. n = 9, *p < 0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 59: Relative gene expression of hypertrophic chondrocyte and primary 
osteogenic lineage markers in all specimens. The gene expression profiles of 
respective specimen after 30 days (left) and 60 days (right) of culture. Col Xa 
represents hypertrophic chondrocytes and the other genes represent the 
osteoprogenitors and pre-osteoblast. The mean value from all three hMSC donors 
are used, with the static and perfusion are plotted side-by-side for comparison. n = 9, 
*p < 0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 60: Relative gene expression of osteoblast and osteocyte markers in all 
specimens. The gene expression profiles of respective specimen after 30 days (left) 
and 60 days (right) of culture. Sp7 represents the mature osteoblast, while Mepe, 
Dmp1 and Sost are presented in the sequence of osteocyte development. The mean 
value from all three hMSC donors are used, with the static and perfusion plotted for 
comparison. n = 9, *p < 0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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3.4.9  Discussion 
3.4.9a  Up-scaling undifferentiated hMSC expansion in spinner flask 
Similar to the efforts made by collaborators in Calgary (85,86), a large 
quantity of undifferentiated hMSC is achieved in this thesis with 250 mL spinner 
flasks. The quantity is at least 4-fold more than corresponding conventional cell 
culture vessels (T175 flask); after hMSC expansion is performed within the same 
time-frame of 12 days (Table 16). The overall results have demonstrated the 
superiority of spinner flasks over conventional cell culturing vessels for             
up-scaling hMSC expansion. Furthermore, the rapid expansion protocol has 
negligible effects on the multipotency and hMSC derived through this approach 
are similar to those expanded on T175 cell culture flasks. This is demonstrated 
by insignificant differences in expression of hMSC markers (Figure 32A) and the 
differentiation assays (Figure 32B) between both setups. Nonetheless, it should 
be noted that the slightly elevated Sox2 expression is a potential cause for 
shorter doubling time and higher output of hMSC in spinner flask culture (Table 
16), since Sox2 is a regulator for stem cell self-renewal (186,187). Hence, further 
exploitations with proteomic analytics by LC:MS/MS should be performed to 
elucidate the activated pathways responsible for higher cell proliferate rate, while 
maintaining the multipotency of the hMSC expanded in spinner flasks. With a 
clearer idea on the mode of mechanism, existing hMSC expansion approaches 
can be further adjusted to improve the quality and quantity of undifferentiated 
hMSC. Additionally, new insights on the deterioration of hMSC quality with 
increasing donor age will be gained. This knowledge will be critical for future 
applications in personalised medicine aimed to synthesize autologous implants 
for each individual and enhance patient outcome. 
It should also be highlighted that direct transfer of optimal specifications 
established in a smaller 125 mL spinner flask is shown less effective in a 250 mL 
spinner flask. The differences in medium volume and impeller will alter the Re 
and maximum shear stress exerted on the hMSC-laded microcarrier beads 
(Table 14). These are critical parameters that determine the spatial distribution of 
hMSC-laded beads in the larger spinner flask (Figure 28) and affect hMSC 
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proliferation in the setup. Hence, additional optimisations have to be conducted 
in spinner flasks of variable sizes; in order to attain the best outcome in             
up-scaling hMSC expansion. 
3.4.9b Establishing a consistent manufacturing process for tailored aECM 
scaffolds  
In this thesis, a manufacturing process that ensures consistent production of 
tailored aECM scaffolds with customised dimensions in large scale is designed 
and investigated. Due to the dynamic combinations of parameters applied to the 
bone bioreactor, it is vital to produce aECM scaffolds with consistent structural 
properties from different batches. This will establish a baseline that enable direct 
comparison between constructs derived from each set of parameters, and 
achieve more accurate assessments over the effects of these parameters on 
construct development and hMSC differentiation. Furthermore, the consistent 
aECM scaffolds will also elucidate the response of hMSC from different donor 
(donor effects) or tissue source and define the specificity of applied parameters 
to recapitulate physiological congruent events in the bone bioreactor. Other than 
keeping the quality of aECM scaffolds used in this thesis in check, the same 
principle is also applicable for commercial manufacturing of clinical grade 
personalised or generic bone substitutes and ensuring GMP is enforced. 
Generally, a mold and cast approach is used in this thesis to manufacture 
aECM scaffolds with consistent properties. Firstly, male molds with customised 
dimensions are designed on a computer and derived through 3D-printing. This 
method of approach is selected for its capability and flexibility to synthesize 
molds/products with irregular dimensions. The specification also supports rapid 
prototyping in the most cost-effective manner and enables future examinations 
on the effects of scaffold geometries over construct development in the bone 
bioreactor. Next, the 3D-printed male molds are casted in silicone to derive large 
quantities of uniform female molds, which are later applied in aECM scaffolds 
production. As shown in Figure 49, the standard deviation of COL I or CSA 
content between aECM scaffolds from different batches of production remained 
rather high. It indicated that the consistency procedures applied in this thesis is 
 
Results and Discussion 
166 | P a g e  
 
deficient and further optimisations are necessary. Nonetheless, these aECM 
scaffolds remained acceptable for this proof-of-concept study as the variance 
within the same batch is negligible. Also shown in Figure 49A, the average 
absolute collagen content in both CM and OM scaffolds is similar. Furthermore, 
there is also no significant variance between the top and bottom section of a 
single construct. Calibrated against the initial amount of COL I added to the 
female mold (2 mg), approximately 61.0% (1220.3 µg) is retained in the CM 
scaffold and 67.0% (1339.6 µg) in the OM scaffold. However, this is lesser than 
anticipated as a previous study had shown that approximately 95–98% of added 
collagen mix should be retained (188). Based on the bar chart (Figure 49A), 
major COL I loss is recorded at the top section of both CM and OM scaffolds, 
while the slender bottom section has retained most of the added COL I. Hence, it 
is concluded that the larger dimensions of the top section is the leading cause 
and the loss of COL I has most likely occurred during removal of lyophilised 
scaffolds from female molds and preparation for cross-linking. Due to the larger 
dimensions, the collagen fibrils will be more sparsely distributed and contribute to 
a more porous structure after lyophilisation. Consequently, the top section will 
have a higher tendency to break apart during extraction from the female molds. 
In contrast, the slender dimensions of the bottom section would have kept the 
collagen fibrils compact and result in more stable structure. Hence, further 
optimisations can be done either by direct application of cross-linking procedures 
to the lyophilized aECM scaffolds in the female molds or modifying the molds to 
allow easier extraction of aECM scaffolds after lyophilisation. Nonetheless the 
results have also highlighted the potential of synthesizing a structurally stable 
biphasic scaffold for articular cartilage replacement with this approach. This can 
be achieved by adding different concentrations of COL I to the female mold. 
Since it is lyophilised and synthesized as a whole, the biphasic scaffold should 
be structurally defined and stable, similar to the aECM scaffolds derived in this 
thesis (Figure 19). This will allow inoculation of different cell types to each layer 
and preventing separation of the biphasic scaffolds during cell culture; a critical 
specification that many previous literatures aimed to attain (189–191). 
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 Additionally, it is also noted that the absolute CSA content in the CM 
scaffolds is minute. In the top section, approximately 3.7% is retained (initial 
amount = 1300 µg) and about 5.3% in the bottom section (initial amount = 700 
µg). Nonetheless, the recorded CSA concentrations have corresponded to the 
collagen content in each section and remained relevant as a previous study from 
the Transregio67 showed that about 5--8% of CSA or glycosaminoglycan are 
typically retained in such aECM scaffolds (188). Taken together, the concept for 
large-scale manufacturing of aECM scaffolds in a consistent and rapid manner is 
demonstrated. However, additional optimisations are essential for reducing the 
variabilities from different batches of production. Furthermore, extra care should 
be taken when removing the scaffolds from the female mold, so as to reduce loss 
of collagen and CSA. Also the silicone mold can also be substituted with other 
materials to minimize adhesion of aECM scaffolds. 
3.4.9c  Lesser hMSC density resulted homogenous oxygenated niche in the 
bioreactor 
 Even though proficient hMSC inoculation in the customised apparatus is 
demonstrated and at least 70.9% of inoculated hMSC have adhered on 
respective scaffold after 24 h (Figure 50), the number of hMSC retained in each 
scaffold is significantly reduced after the first 30 days of cultivation (Figure 51). 
Nonetheless, this should be seen as a transitional period for the hMSC to adapt 
to respective aECM scaffolds, since cell proliferation is initiated between          
Day 30--60; specifically in the static culture. Furthermore, this is a local effect 
caused by the aECM scaffolds and not a result of bioreactor cultivation, as 
majority of the constructs (CM, OM, CMCM and OMOM) from both static and 
perfusion cultures shared similar number of hMSC. Based on previous 
preliminary studies (Chapter 3.4.2) and literatures (192–194), the cytotoxic 
effects of glutaraldehyde is negligible and can be eliminated as a potential causal 
factor. Hence, the lesser hMSC number is most likely attributed by the collagen 
content present (Figure 49 and 50); with each aECM scaffold containing 
approximately 1200 µg COL I in 0.57 cm3 (2105 µg/cm3). As shown by previous 
literatures, the collagen content will determine the structural properties and 
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porosity of a scaffold and these factors have direct influence over cell fate and 
cell proliferation (195–197). Generally, a loose and porous scaffold will increase 
cell proliferation, while a compact and less porous scaffold will limit cell 
proliferation and initiate remodelling (196, 197). Although the latter will explain 
the results in this thesis, there are no direct evidences to support this deduction 
and further aECM scaffold characterisations should be performed for validation. 
Another strong indicator that shows excessive COL I is applied in this thesis 
would be the consistently down-regulated Col Ia gene expression in all of the 
constructs over 60 days (Figure 59). This is further supported by previous 
literatures that showed high concentrations of COL I in engineered scaffolds will 
reduce Col Ia gene expression and cell proliferation (198, 200). Hence, further 
considerations should be made in future experiments to reduce the COL I 
concentrations, while ensuring that the structural stability of aECM scaffold is 
retained. Nevertheless, the similar COL I content in the top and bottom sections 
of aECM scaffolds have resulted consistent distribution of hMSC throughout the 
scaffold in this thesis. This has allowed more concise comparisons between the 
perfusion and static cultures. Through this setup, the effects contributed by 
differences in dimensions/volume of the top and bottom section is minimised and 
the different cultivation regimes applied would be the primary stimulant. 
Based on the cell numbers, further modelling (Chapter 2.2.3b) is done to 
estimate the pO2 distribution in the perfusion bioreactor. As indicated by the solid 
black line in Figure 51, the cell number in all perfusion culture did not meet the 
minimum threshold; required to generate a hypoxic niche (< 5 Torr). Instead, a 
relatively oxygenated niche between 30--85 Torr is estimated by the 
mathematical model. Unlike the mESC experiments that have 7.5 x 106 mESC 
inoculated directly into each cultivation platform in the bioreactor, only 3 x 106 
hMSC is applied. Furthermore, the hMSC inoculation procedure is performed in a 
separate apparatus, before hMSC-laded scaffolds are transferred into the 
bioreactor later. The two-step procedure may also reduce the number of hMSC 
further during the transfer. Consequently, a pO2 gradient is absent in the hMSC 
setup, due to shortage in local oxygen consumption and a relatively high medium 
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perfusion rate (5.5 mL/min) being applied. Nonetheless, the objective of this set 
of experiments is to compare the efficacy of static and perfusion culture to 
support construct development in vitro. Hence, the current hMSC setup remains 
an appropriate point-of-reference for comparisons. However, it should be 
highlighted that a pO2 gradient similar to the mESC experiments remains 
achievable in the hMSC setup. Firstly, the inoculating hMSC density should be 
increased to at least 5 x 106, and more importantly the hMSC should be 
inoculated directly into the cultivation platform to reduce the tendency of cell loss 
during transfer of cell-laded constructs. Additionally, the medium perfusion rate 
can be reduced to limit replenishment of fresh oxygen in the bioreactor. These 
should be done in future studies to elucidate the effects of hypoxic niches on 
hMSC differentiation and construct development in the bioreactor. 
3.4.9d  Spontaneous calcium accumulation is negligible 
From Figure 52 and Figure 55, it is shown that spontaneous calcium 
accumulation can occur in the aECM scaffolds. The calcium deposits are 
detectable by both alizarin red staining and µCT. They are also more significant 
in CM scaffolds, as the negatively-charged sulfate groups on CSA will increase 
the tendency for calcium cations in the cell culture medium to bind. However, two 
major criteria have to be fulfilled for spontaneous calcium accumulation to occur: 
1) osteogenic differentiation medium that is either neutral or slightly basic        
(pH 7.4–7.6) has to be applied, and 2) the scaffold has to contain low density or 
complete cell-free. These conclusions are drawn based on the observations 
made in both figures. Without any form of exposure to osteogenic medium, the 
CM and CMCM constructs are stained negative for alizarin red and no 
mineralised deposits are detected by µCT. This will apply to constructs from both 
static and perfusion cultures. Furthermore, the scaffolds will also have to contain 
little amount of cells or completely cell-free for spontaneous calcium 
accumulation to occur. As shown in CMOM static constructs, alizarin red staining 
is negative (Figure 54) and the µCT has detected negligible amount of 
mineralised deposits that are sparsely scattered in the construct (Figure 56). 
Should spontaneous calcium accumulation be a definite event, these CMOM 
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static constructs will be stained positive for alizarin red; but this is not the case. 
Additionally, it is also not a major concern that a false-positive is identified among 
the specimens. With legit occurrence of mineralisation in the constructs, the 
alizarin red staining will be more compact and dense. This should also be further 
supported with alcian blue staining, as both stains will overlap in the event of 
calcium accumulation induced by CSA. Nonetheless, the spontaneous binding of 
calcium cations on the CSA should not be seen as a negative occurrence. As 
shown in the mESC experiments (CMOM, Figure 46), osteogenic gene 
expression was enhanced and this can also potentially accelerate the 
developmental process of engineered constructs to become bone-like tissues. 
3.4.9e Perfusion culture will preserve the structural integrity and enhance 
mineralisation throughout the constructs 
Generally, the isolated niche created by the cultivation platform in the 
perfusion bioreactor have played two major roles in construct development:        
1) enhancing mineralisation with mechanical fluid shear, while protecting the 
constructs from excessive fluid shear caused by high medium perfusion          
(5.5 mL/min), and 2) maintaining the overall structural integrity of constructs over 
the course of cultivation. The effects are best observed after 60 days, with the 
static culture being more condensed and some have severe shrinkage (CMCM 
and CMOM); as compared to corresponding perfusion cultures (Figure 54). 
Furthermore, results from µCT analysis also emphasized the advantages of 
culturing constructs in bone bioreactor. Unlike the static cultures that only have 
mineralised deposits accumulated in the top section of osteogenic differentiated 
constructs (Figure 56), mineralised deposits are evenly distributed throughout the 
constructs from perfusion culture, which are also more consistent and organised 
(Figure 57). Interestingly, these observations are made despite intense alizarin 
red staining detected in the OMOM and OMOM* static culture. This indicates that 
mineralisation in the perfusion cultures are at a much advanced state and dense 
hydroxyapatite crystals are present in these constructs. In contrast, accumulation 
of calcium deposits from osteoprogenitors and osteoblasts will explain the 
intense alizarin red staining in OMOM and OMOM* static cultures. 
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3.4.9f  Defined contour in static culture is different from the mESC experiments 
As described in the mESC experiments, formation of cell nodules is induced 
after osteogenic differentiation medium is applied. Eventually leading to the 
formation of defined and mineralised contour on CMOM and OMOM perfusion 
constructs (Chapter 3.2, Figure 42 and 47). Similarly in the hMSC experiments, a 
consistent and defined contour is also observed throughout the osteogenic 
differentiated constructs after 60 days of cultivation (yellow arrows in CMOM, 
OMOM and OMOM* static, Figure 54). However, the phenotype is limited to the 
static cultures and does not apply to the perfusion culture in this case. Additional 
investigations at a higher magnification under the light microscope have 
indicated that cell nodules are absent in all these constructs. Hence, it is 
concluded that the defined contour observed in the hMSC constructs is different 
from those in the mESC experiment. Based on the condensed physical 
appearance of the static cultures and tendency for the phenomenon to occur 
only in these constructs, the defined contour is a result of collapsing aECM 
scaffolds. Furthermore, this is a response to the osteogenic differentiation media, 
as the defined contour is absent in the CMCM static constructs. Unlike the 
hydrogels applied in mESC experiments, structurally-stable lyophilised aECM 
scaffolds are applied in this hMSC experiments. Hence, the structural properties 
of aECM scaffolds should not permit extensive cellular remodelling and the 
collagen fibrils have likely piled on top of each other as the construct contracted. 
This deduction is further supported by the absence of defined contour in the 
perfusion cultures that are less condensed than the static cultures. 
3.4.9g  CSA in aECM scaffolds favoured osteogenesis in hMSC experiments 
Unlike the mESC experiments that had applied 10 mM β-GP to initiate 
fibrillisation of collagen fibrils in the hydrogel, 60 mM of phosphate derivatives 
are used to synthesize the aECM scaffolds for hMSC experiments. As a result, 
the potency of CSA to induce chondrogenesis described in the mESC 
experiments is not applicable here. As shown in CM 30 days constructs (Figure 
58 and Table 19), the expression of chondrogenic markers (Sox9, Col IIa) is 
similar to the OM 30 days constructs and this has persisted even with further 
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cultivation up to 60 days in the perfusion culture. The extra phosphate groups in 
the aECM scaffolds could have favored osteogenesis instead. Nonetheless, 
these observations are comparable to the results from the Transregio67 that also 
showed similar aECM scaffolds to drive hMSC towards osteogenesis, and 
increment in sulfation degree of glycosaminoglycan will enhance this effect 
(177,179,180). In this thesis, the sulfated CSA has also exhibited similar effects. 
Furthermore, similar conclusions are also drawn in other literatures (80,81). 
Alternatively, the early application of oxygenated niche to the CM constructs 
could have also primed the hMSC for osteogenic differentiation. Similar in the 
mESC (Figure 45) and hMSC (Figure 58) experiments, the interplay of 
oxygenation and CSA in the bone bioreactor will limit chondrogenic gene 
expression (Sox9 and Col IIa). Consequently, the hMSC are specified to become 
osteoprogenitors (elevated Runx2 and ALP in Figure 59) and osteogenesis is 
favoured after osteogenic differentiation medium is applied to the CM constructs 
after 30 days. Such influence of earlier priming on later cellular phenotype is also 
demonstrated in other literatures (201,202) and should be noted in future trials. 
Interestingly, the combination of acidic chondrogenic medium with CSA has 
further enhanced the osteogenic effect. Especially in the CM 30 days and CMCM 
60 days static cultures, the hMSC have terminally differentiated to become 
osteocytes (Mepe- and Sost-positive, Table19). Nevertheless, the constructs did 
not accumulate any mineralised deposits despite such strong elevation in 
osteogenic gene expression (Figure 59, 60). Furthermore, the alizarin red and 
µCT analysis are also negative for the CMCM constructs (Figure 54, 56). These 
results have coincided with the observations made in the mESC experiments, 
which further supported the potential of acidic medium to attenuate 
mineralisation at the post-transcriptional level. 
4.3.9h Retaining consistency in gene expression and construct development in 
the bone bioreactor 
Despite tabulating 3 different donors together, the donor effect is rather 
minute for the naïve genes markers of stem cell, chondrocytes and 
osteoprogenitors/pre-osteoblast. Greater variances are only observed in the 
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mature genes that are expressed further down the path of differentiation. These 
include markers of mature osteoblast, and osteocytes, as indicated by the larger 
standard deviation in the gene expression profiles (Figure 58–60). Furthermore, 
larger deviations are also observed in the static cultures as compared to the 
perfusion culture. This indicated the potential of the bioreactor to exert similar 
cultivation environment and attaining consistency among different hMSC donors. 
Only when such consistency is maintained, the variability observed in gene 
expression and construct development could be concluded as direct cellular 
effects. This would be critical for future experiments that aim to investigate the 
effects of cell-specific parameters, such as the age of hMSC, disease versus 
healthy state, genomic differences and the potential of hMSC derived from 
different sources (adipose, bone marrow or hair follicle).  
4.3.9i  Hypoxia is a critical factor for chondrogenesis and osteocyte formation 
This is exceptionally obvious for the chondrogenic differentiated constructs 
(CM and CMCM). As shown previously in the mESC experiments (Figure 45), 
chondrogenic differentiation is optimum when acidic medium, low pO2 and CSA 
are applied concurrently. However, this is not observed in the hMSC perfusion 
culture and the marker for chondrogenesis (Sox9) is down-regulated in both 
sections instead. Interestingly, the chondrogenic gene markers are elevated in 
corresponding static cultures. Since static conditions are often related to limited 
mass transfers and hypoxia, it is assumed in this case that the elevated 
chondrogenic gene expression is a result of low oxygen concentration in the 
static culture. Furthermore, the constructs cultured in static are submerged in 
170 mL differentiation medium and the culture flasks are incubated in standing 
position; similar to the medium reservoir applied in perfusion cultures       
(Chapter 2.5.3d). Being at the bottom of the flask at most of the time, the greater 
distance to the air-liquid interface would have further limited the exposure of the 
constructs in static culture to oxygen.  
Additionally, it is also noted that the chondrogenic markers are elevated in the 
osteogenic differentiated constructs. However, this is coupled with elevated ALP 
and Col Xa expression. In this case, hypoxia is induced locally by calcium 
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accumulated in the constructs (OM, OMOM, OM*, OMOM*), which in turn limits 
mass transfer through passive diffusion. Interestingly, this phenomenon is 
comparable to endochondral ossification during long bone development. 
Similarly, chondrogenic hypertrophy is initiated after the hyaline cartilage model 
is calcified and mass transfer by diffusion is reduced. This will then initiate 
infiltration of vasculatures and osteoblasts to continue with the bone-building 
processes (171). Concurrently, the chondroprogenitors that are not in the 
calcified region will differentiate into more chondrocytes and expand the hyaline 
cartilage model. Taken together, the inductive effect of hypoxia for 
chondrogenesis is indisputable and it is applicable for both mESC and hMSC.  
Another intriguing effect of hypoxia observed in this thesis is the complete 
attenuation of gene expression for osteocytes (Dmp1. Mepe, Sost) in the 
oxygenated perfusion culture. As described in previous literatures (203-205), the 
transition of osteoblasts to osteocytes is triggered by oxygen-regulated protein 
150 (ORP150), a hypoxia induced pathway that will initiation Mepe and Dmp1 
expression. Comparisons made against static cultures have indicated that the 
phenomenon is limited to the cultures in perfusion and the expression of 
osteocyte markers will be enhanced when a hypoxia is introduced (Figure 60 and 
Table 19). These results can also be correlated to the mESC experiments 
described in this thesis, which recorded higher expression of osteocyte markers 
in the hypoxic bottom section of CMCM and CMOM constructs after 60 days 
(Figure 46). Furthermore, gene expression profiles from the hMSC experiments 
have also indicated that this is a “window effect”. Specifically, the hypoxia-
induced transition from osteoblasts to osteocytes will only be triggered when 
hypoxia is introduced at the early stages of cultivation. As mentioned above, 
localised hypoxia will be induced when more calcium accumulates within the 
OMOM and OMOM* constructs over time. In turn the expression of Sox9 and Col 
IIa, another hypoxia-induced chondrogenic markers, was elevated in OMOM and 
OMOM* constructs. Hence, this should have also induced the expression of 
osteocyte markers to be elevated. Although this is phenomenon is observed in 
the mESC experiments (Figure 46), this is not shown in the hMSC experiments. 
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This is an exciting result that should be further exploited, since the exact 
mechanisms of osteoblasts to osteocytes transition are still poorly understood. 
By understanding the roles of hypoxia in osteocyte formation, greater insights on 
bone homeostasis and repair mechanisms will be better elucidated. Thus 
improving the existing therapeutic approaches for bone defects used in clinic.  
4.3.9j  Correlations between hMSC and mESC experiments 
Overall, many results derived from the mESC and hMSC experiments have 
overlapped and the differentiation regimes applied are mostly transferable from 
the mESC to the hMSC. The examples are listed below:  
1. Capacity of perfusion culture in bioreactor to support stem cell 
self-renewal (continual Sox2 expression.) 
2. Attenuating effects of acidic medium on mineralisation at post-
transcriptional level (CMOM perfusion) 
3. Competency of osteogenic differentiation media to support 
mineralisation of bone constructs (CMOM and OMOM 
perfusion). 
4. Expression of chondrogenic marker after extended cultivation in 
osteogenic medium for 60 days (OMOM and OMOM* perfusion, 
Table 19). 
5. Potential of differentiated chondrocytes to undergo hypertrophy 
(Col Xa-positive), after the osteogenic differentiation medium is 
applied, specifically in an oxygenated cultivation niche. 
6. Potency of CSA to induce chondrogenesis, but this is most 
significant in complementary with hypoxia and acidic medium in 
the bone bioreactor. Application of oxygenation will reduce the 
chondrogenic potency. 
7. Potential of CSA to retain the structural integrity of constructs 
and reduce severe condensation of constructs as mineralisation 
occurs. 
8. Potential for CMOM systematic differentiation approach to 
induce transition from chondrogenesis to osteogenesis and 
deriving structurally stable mineralised bone constructs in vitro. 
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In conclusion, the advantages of perfusion bioreactor for construct cultivation 
and development are emphasized in this part of the thesis. Furthermore, it is also 
shown that the cultivation parameters defined for the mESC are mostly 
transferable and are applicable to the hMSC. Although some improvements are 
still necessary, a working concept is established and can be utilized as a point-
of-reference for future studies. Most importantly, physiological congruent events 
for chronic acidosis, endochondral ossification and intramembranous ossification 
are recapitulated in the bone bioreactor with success. Their effects on construct 
development are prominent and should be further exploited to achieve bone 
constructs with physiological properties in future experiments. Furthermore, the 
developmental mechanisms that are currently not widely established in the field 
can also be elucidated through this bioreactor setup. These include the 
intermittent expression of COL IIa during intramembranous ossification, as well 
as the mechanisms for transition of osteoblasts to osteocytes to occur.   
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CHAPTER 4: Key-findings and Conclusions 
4.1  Deriving engineered blood vessels in bioreactor: A proof-of-concept 
 A tubular PCL template is derived through electrospinning technique and its 
elasticity is similar to a small artery.  
 Addition functionalisation with rat-tail COL I have enhanced HUVEC adhesion 
and propagation on the PCL tubing. 
 A flat and uniform surface is optimum for HUVEC adhesion, as the cells 
would detach from the porous PCL scaffold when active medium perfusion is 
applied. This is rectified with complete encapsulation of PCL tubing within 
agarose bedding in this thesis. 
 An intermittent perfusion protocol (1 day active perfusion, followed by 3 days 
in static) is shown most effective for HUVEC propagation in the bioreactor. 
Continuous medium perfusion is undesirable for the existing single cell 
construct, even at low perfusion rate. 
 The existing setup provided flexibilities for further exploitations to derive 
functional large blood vessels in vitro. Additional specifications can be applied 
on top of existing setup for improvements and these include: 1) laying smooth 
muscle layer and connective tissue layer on top of the PCL-HUVEC template, 
2) manipulating hydrodynamics through lumen by adjusting tension of PCL 
tubing or applying variable medium perfusion rate, 3) applying electrical 
stimuli for cell alignment and enhancing maturation of engineered vasculature. 
 4.2  Characterising biomimetic bone bioreactor with mESC 
 The bioreactor has support stable propagation of engineered constructs for 
up to 60 days in vitro. 
 Although lesser effect is observed on the gross physical appearance, pO2 
gradient established in the bioreactor has substantial influences over gene 
expression in the top oxygenated section and the bottom hypoxic section of a 
single construct. 
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 Compared to my previous publication (53), the slightly basic DMEM basal 
medium used for osteogenic differentiation in CMOM approach has further 
induced gene expression of hypertrophic chondrocytes (Col Xa) and 
osteoblasts (Sp7). 
 Formation of cell nodules and mineralised contour in CMOM and OMOM 
constructs are correlated to bone collar development, occurring at early 
stages of endochondral ossification in vivo. For the first time, this was 
demonstrated in an in vitro culture. 
 The OMOM differentiation regime has produced constructs with highest 
mechanical stiffness (2333 ± 220.7 Pa) among all tested regimes. However, 
severe condensation is observed and the entire construct is slender from top 
to bottom. Nonetheless, the differentiation medium and time of application are 
effective for inducing osteogenesis. 
 CMCM differentiation regime has produced constructs with impaired 
mineralisation mechanisms. Despite higher expression of osteogenic gene 
markers, cell nodules and mineralised contour are absent. Instead, the acidic 
medium has induced osteoclastogenesis and its overall effects are correlated 
to chronic acidosis in vivo. Hence, further exploitations can be made to derive 
a disease in vitro model with the cultivation conditions described. 
 CMOM differentiation regime has produced mineralised constructs that 
adopted the irregular dimensions of the cultivation platform. These constructs 
have also remained structurally stable, even after removal from the bioreactor. 
The subsequent application of OM medium has not only contributed to the 
increased structural integrity, but also has a significant influence at the 
genetic level. The developmental processes of CMOM constructs are closely 
related to the actual processes of endochondral ossification in vivo. 
Formation of chondrocytes, hypertrophic chondrocytes, followed by the 
osteoblasts and osteocytes has occurred in designated sequences. Hence 
making it the most ideal candidate for further exploitations to derive bone-like 
tissues in vitro. 
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4.3  Manufacturing consistent mineralised constructs with hMSC 
 The spinner flask is an effective apparatus for up-scaling hMSC expansion 
within a short time-frame. The hMSC achieved from this expansion approach 
have remained undifferentiated and are similar to the hMSC derived from 
conventional cell expansion approach. 
 The potential of the mold and cast approach for large-scale manufacturing of 
tailored aECM scaffolds is demonstrated. However, further optimisations are 
necessary to reduce variations among aECM scaffolds derived from different 
batches of production. 
 Consistent structurally defined tailored aECM scaffolds are generated through 
the mold and cast approach. The structural integrity of these scaffolds is 
further stabilised via cross-linking with 25% L-glutaraldehyde vapour. 
 The hMSC inoculation method applied in this thesis is highly effective. 
However, the lesser hMSC density in the scaffold has resulted in an 
oxygenated niche being generated throughout the bone bioreactor. However, 
this can be rectified either by increasing the inoculated hMSC density on 
aECM scaffolds or reducing the medium perfusion rate. 
 For the hMSC experiments, an oxygenated niche is implemented in the bone 
bioreactor, as it is a more relevant point-of-reference for the conventional 
static cultures. Furthermore, the collagen content and cell numbers in both 
top and bottom sections are similar. Hence, the variabilities in constructs 
development and hMSC differentiation are primarily attributed by the different 
differentiation regime applied on the bone bioreactor. 
 The capability of bone bioreactor to maintain consistent cultivation niches 
across different experiments is demonstrated by lesser variations in gene 
expression between all three hMSC donors used in this thesis. In contrast, 
greater variances are recorded among the static cultures; as indicated by the 
large standard deviations. 
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 The implementation of active perfusion has not only supported continual 
hMSC self-renewal to provide a stable pool of stem cells for extensive 
construct development and maturation, the distribution of mineralised 
deposits is also more homogeneous and in larger quantity than 
corresponding static cultures. 
 Spontaneous calcium accumulation is most significant in CM scaffolds and 
will only occur after osteogenic differentiation medium is applied. However, 
this is a negligible effect when hMSC are inoculated on the aECM scaffolds 
and the false-positive mineralised constructs can be detect via overlapping 
alcian blue and alizarin red staining. On the contrary, this effect can also be a 
beneficial specification that will enhance osteogenic differentiation; as shown 
in the mESC experiments (CMOM). 
 Similar effects of differentiation regimes observed in the mESC experiments 
are also demonstrated in the hMSC experiments. 
 The OMOM* differentiation regime is shown to accelerate the process of 
osteochondral differentiation and supporting continual hMSC proliferation. 
However, the construct will shrink in size over time and the estimated 
concentrations of mineralised deposits are lesser than construct derived from 
the CMOM or OMOM regimes.  
 The transition from chondrogenesis to osteogenesis is also demonstrated in 
CMOM constructs (perfusion) investigated in the hMSC experiments. This 
has contributed to more intense alizarin red staining than the OMOM 
constructs (perfusion).  
 Similar to the mESC experiments, CSA is shown to prevent severe construct 
condensation as mineralisation occurs. In turn, the structural integrity and 
tailor dimensions of CMOM constructs are retained. Further analysis with 
µCT has shown that mineralisation in CMOM constructs are initiated at 
specific “hot-spots” that are evenly distributed within the construct. 
 The parameters for cultivation (pO2, medium pH and differentiation regime) 
are transferable from mESC to hMSC. 
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CHAPTER 5: Research Outlook 
Based on the findings made in this thesis, in complementary with other 
recently published literatures, I have included some key areas that can 
potentially be exploited further. The following sections describe each concept in 
brief. 
5.1 Co-culturing HUVEC, HUASMC and hMSC to achieve blood vessel-like 
constructs in vitro 
After establishing the basic template with human umbilical vein endothelial 
cells (HUVEC) on the electrospun poly-ε-caprolactone (PCL) tubing, additional 
cell layers can be added to the HUVEC-PCL template using a layer-by-layer 
approach. Generally, the blood vessel contains two basement membrane layers 
composed of elastic fibers: 1) between endothelium and tunica media,                
2) between tunica media and tunica externa (Figure 61). Hence, the electrospun 
tubings composed of elastic PCL fibers make an ideal material to simulate both 
layers. Depending on the type of blood vessel to construct (artery versus vein), 
the thickness of tubing and orientation of PCL fibers can be manipulated to 
achieve higher resemblance to the native tissue (Figure 8A).  
 
 
Figure 61: The rationale and design for an engineered blood vessel. Fabricating 
an artificial artery construct through a layer-by-layer approach. This will enable 
different cell types to be derived separately and be put together at the end. 
 
Research Outlook 
 
182 | P a g e  
 
Additionally, the mechanics of blood flow occurring in physiology can be 
simulated by applying pulsatile medium perfusion through the lumen of the PCL 
tubing, and different perfusion rates can be investigated to determine the optimal 
conditions that will enhance the structural stability of engineered blood vessels. 
This will elucidate the effects of mechanical stimulants on blood vessel 
development and fill up the gap of knowledge in this field of study. Upon 
achieving a stable construct, the efficacy of the engineered blood vessel to 
undergo angiogenesis should be tested in animal models either through direct 
subcutaneous implantation or suturing the construct on a dissected artery. In 
both cases, cell-free PCL tubing should be used as a control. 
5.2  Larger-scale hMSC expansion and direct application of microcarriers 
for bone tissue engineering 
First of all, the dimensions of stir rod impeller can be further modified to 
achieve similar Reynolds number and maximum shear stress that are 
established for hMSC expansion in 125 mL spinner flask. Secondly, the 
beads:cell ratio during inoculation phase can be further optimised. In previous 
studies, a bead:cell ratio as little as 1:5 is shown efficient for subsequent hMSC 
expansion in a 125 mL spinner flask (85,86). However, the larger quantity of 
beads and higher volume of medium applied in the 250 mL flask have suggested 
otherwise. As shown in Chapter 3.1.2e, when a ratio of 1:10 is applied in this 
thesis and a higher cell density is achieved after 12 days. Furthermore, post-
cultivation analysis on microcarrier beads with DAPI has shown the presence of 
beads without any cells. Hence, more hMSC can still be inoculated, so as to 
attain more hMSC within a single passage phase. Alternatively, hMSC expansion 
can be carried out in two passage phases when the source of hMSC is limited. 
The first phase of expansion can be performed in smaller spinner flask            
(25–125 mL) to generate sufficient hMSC for subsequent expansion in 
single/multiple 250 mL spinner flasks.  
Other than increasing the yield of hMSC expansion, chondrogenic or 
osteogenic differentiation medium may also be applied directly to the hMSC-
laded beads after cell expansion. There are three advantages to this approach:   
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1) reduce loss of hMSC during trypsinization, 2) generating bone constructs with 
cell-laded microcarriers, and 3) enhancing chondrogenesis or osteogenesis with 
fluid shear stress. As shown in established literatures, spheroids derived from 
human stem cells are used as the basic building block to derive an engineered 
bone construct (206-208). By cultivating the spheroids in a compact space, they 
will fuse to form a larger construct. This is recently improved by co-cultivating 
stem cell spheroids with endothelial cell spheroids and an engineered bone 
construct with pre-vascular structures is achieved (209,210). Nonetheless, these 
studies faced a great challenge with batch-to-batch variation and are unable to 
generate large quantity of spheroids in a consistent and stable manner. This is 
detrimental for subsequent bench-to-clinic transfer, as the variations between 
different batches of engineered constructs and undifferentiated stem cells can 
potentially develop into cancerous cells or tumour after implantation in patients. 
However, similar work principles are applicable to the hMSC-laded beads 
generated in this thesis. Unlike the spheroids composed of only human stem 
cells, the microcarrier beads can be customised to accommodate different 
adherent cells. Furthermore, the quantity of stem cells required from the donor 
will also be reduced significantly. For example, at least 1 x 105 hMSC is required 
to synthesize a single spheroid over 5–7 days. In contrast, the same amount of 
hMSC can be inoculated on at least 20,000 beads (1–5 hMSC per bead) and 
expanded in the spinner flask to derive similar spherical structures as the 
spheroids after 12--15 days. Hence, direct application of hMSC-laded beads for 
subsequent tissue engineering will not only be cost- and labour-effective, 
consistent up-scaled production of hMSC that fulfils the GMP standards can also 
be ensured. 
5.3 Production of tailored constructs with 3D-printing technology 
As described in Chapter 2.5.2a, customised male molds with tailored 
dimensions are derived through 3D-printing in this thesis. Subsequently, female 
silicon molds are prepared to hold the COL I mix and derive a structured aECM 
scaffold after lyophilisation. However, these collagen scaffolds require further 
cross-linking with 25% glutaraldehyde vapour to attain structural stability. 
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Furthermore, these scaffolds can shrink in size in an unpredictable manner 
during the cross-linking procedures and the tailored dimensions may not be 
retained. This is undesirable for my aim to attain constructs for personalised 
medicine, as the tailored bone constructs are insufficient to meet the needs of 
the patient. Alternatively, structurally stable scaffolds composed of bioactive 
materials such as ceramics (211,212), calcium phosphate (213,214), or alginate 
(215,216) can be printed directly with the 3D-printer; and cultivated in the 
biomimetic perfusion bioreactor. Thus enhancing cell infiltration and facilitate 
construct maturation prior to implantation in patient. Since we have shown in this 
thesis, the potential of the bone bioreactor to support physiological congruent 
development processes in vitro, the additional cultivation step should allow the 
3D-printed scaffolds to gain anatomical and mechanical properties resembling 
the native bone tissues. Consequently, better integration of engineered 
constructs to the site-of-injury is facilitated and patient treatment outcome is 
enhanced. 
5.4  Implementing electrical field to the bone bioreactor 
Other than using biochemical stimulants to initiate osteogenesis and 
mineralisation of engineered constructs in vitro, additional stimulants can be 
applied to enforce the path of stem cell differentiation. Further, this also helps to 
establish a higher degree of biomimicry in the bone bioreactor, and more 
complex research questions on the interplay of biochemical and physical cues on 
bone development can be answered. 
As established in our lab by Heß et. al., the application of an intermittent 
electrical field up to 10 Hz in a cyclic manner was shown to enhance 
osteogenesis and mineralisation of hMSC-laded PCL scaffolds (217). Further, 
Thrivikraman et.al. also showed that osteogenesis by hMSC was further 
enhanced on conductive materials with electrical field applied (218). In 
physiology, piezoelectricity is generated through mechanical strain of bone 
during movement and the application of electrical field will simulate this 
phenomenon. Interestingly, electrical stimulation is also widely applied in clinics 
as a treatment plan to increase total bone mass in patients (219,220). Hence, it 
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will be beneficial to include this parameter in the specifications of the biomimetic 
bone bioreactor. Similar to the existing setup with a tissue culture chamber 
(Figure 62), a silicon tubing will be attached to the bone bioreactor, filled with cell 
culture medium and looped around the transformer core (221). Consistent 
electrical field is then applied throughout the bioreactor by the means of 
Transformer-like Coupling (TLC). Nonetheless, additional mathematical 
modelling and simulations are essential to define the electrical field generated 
within the bone bioreactor, as well as calculating the actual intensity of electrical 
field that the constructs will experience.  
 
  
Figure 62: Existing setup to apply electrical field through a cell culture 
chamber. Similar to this setup, the cell culture chamber will be replaced with the 
bone bioreactor, with one end attached to the inlet and the other at the outlet. 
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Appendix 2: murine embryonic fibroblasts (MEFs) isolation protocol 
1. At 13–14 days after the appearance of the copulation plug, harvest the 
embryos from female C57/BL6 mice. Generally, 6–10 embryos can be 
expected from each pregnant female, and should yield enough primary 
MEFs for several experiments. 
2. Euthanize the pregnant female by cervical dislocation on a sterile bench-top 
and soak the fur of the mouse thoroughly with 75% ethanol in dH2O. 
Transfer the mouse to a tissue culture hood and laid it down on its back on 
a petri dish. 
3. Make a cut in the skin with scissors and pull away with hand to expose the 
abdominal wall.  
4. Prepare three Petri dishes with one containing 10 mL of 0.25% trypsin-
EDTA and the other two with 20 mL PBS. 
5. With a new pair of scissors, cut through the abdominal wall and use a pair 
of forceps to lift up the uterine horns. Cut away the uterus with scissors and 
ensure no contact was made with the fur.  
6. Place the uterus in the Petri dish with PBS and separate the embryos by 
slicing through between each embryo. Squeeze the embryos out of the 
uterus with the forceps and removed any uterine tissues. Should the 
embryo is still in the yolk sac; pull the sac off gently with the forceps. 
7. Transfer the embryos to a new dish with PBS and swirl the dish to remove 
blood from the embryos. Aspirate the PBS and repeat the washing step with 
fresh PBS two more times. 
8. To isolate the MEFs, dissect and discard the head of the embryos that is 
above the eyes and tear out the red tissue (heart and liver) with two pair of 
forceps. Place the rest of the embryo in the Petri dish with 0.25% trypsin-
EDTA. 
9. After dissecting, chop up the embryos with a scalpel blade into tissue 
pieces of    1-2 mm. Using a 5 mL pipette, pipet up and down several times 
to break down the tissue further. Incubate the tissue at 37 °C in an 
incubator for 10 mins. 
10. Break down the tissue further with a 5 mL pipette again, before incubating 
at 37 °C for another 10 mins. 
11. Transfer the cell suspension to a 50 mL conical tube and add 20 mL MEF 
medium to inactivate the trypsin. The MEF medium is composed of DMEM 
high glucose medium with 15% FBS and 1% Pen-Strep. 
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12. Mix well and let the cell suspension sit for 5 mins to allow fragments of 
tissue to sink to the bottom of the conical tube. 
13. Divide the cell suspension equally and transfer with care to T75 flasks and 
avoid transferring the larger tissue fragments at the bottom to the flask. 
Each T75 flask should receive a volume of the cell suspension equivalent to 
two embryos.  
14. On top of the cell suspension, top up additional volume with MEF medium 
and the final volume in each T75 flask should be 15 mL.  
15. Next day, aspirate the old medium to remove dead cells and debris. Check 
the cell density in each flask. Should the cell culture reached 80% 
confluency, split the cells at 1:3 ratio and this will be passage phase 1. 
Otherwise, add 15 mL fresh MEF medium and maintain the cell culture until 
it is ready for passaging. 
16. Expand the MEFs until the desired quantity and freeze the cells in standard 
freezing medium (DMEM high glucose medium with 15% FBS, 1% Pen-
Strep and 10% DMSO) for subsequent use in the future. 
17. Ensure that the MEFs do not exceed passage phase 10, as the cells would 
undergo senescence at this point.  
